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 Acetate supplementation increases brain acetyl-CoA levels that influence 
inflammation, energy production, histone and non-histone protein acetylation, and 
purinergic signaling.  Interestingly, acetate significantly increases fatty acid content in 
lipopolysaccharide (LPS)-stimulated BV2 (immortalized murine cell line) microglia 
compared to control-treated LPS-stimulated cells.  This suggests that increasing brain 
acetyl-CoA metabolism may also influence lipid synthesis.  We wanted to determine if 
treatment with glyceryl triacetate alters central nervous system (CNS) lipid content in 
mice subjected to experimental autoimmune encephalomyelitis (EAE), an autoimmune 
multiple sclerosis model.  In addition, we performed experiments to determine whether 
treatment had an effect on disease progression, protein levels of enzymes involved in 
lipid metabolism, cytoskeletal structure, and myelin structure.  We found acetate 
supplementation attenuated the onset of clinical symptoms in EAE mice based on a 
clinical score and hang time test.  These experiments also showed treatment altered spinal 
cord phospholipid, fatty acid, cholesterol, and ganglioside content in mice subjected to 
EAE.  In addition, treatment significantly increased total brain phosphatidylserine and 
choline glycerophospholipid as well as GD3 ganglioside levels in EAE mice compared to 
control-treated EAE mice.  We also determined how treatment altered brain lipid levels 
within the myelin fraction, the membrane fraction lost in EAE.  Acetate supplementation 
significantly increased brain myelin phosphatidylinositol and GM1 ganglioside levels in 
EAE mice compared to control-treated EAE mice.  These data showed that increasing 
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acetyl-CoA metabolism altered CNS lipid content in mice subject to EAE to suggest that 
treatment may alter CNS lipid metabolism in this model.  To test this hypothesis, we used 
Western blot analysis to measure protein levels of enzymes involved in lipid synthesis 
and lipid breakdown.  EAE resulted in a significant increase of cytosolic phospholipase 
A2 protein levels, but treatment returned those levels back to control to suggest treatment 
may modulate cytosolic phospholipase A2-mediated lipid breakdown.  In addition, we 
found treatment significantly decreased phosphorylated acetyl-CoA carboxylase protein 
levels in EAE mice, an enzyme involved in fatty acid synthesis.  The phosphorylated 
acetyl-CoA carboxylase is the inactive form of the enzyme, which suggests acetate may 
shift this enzyme from the inactive to active form to promote fatty acid synthesis.   
 These data test the hypothesis that treatment may alter CNS lipid metabolism in 
mice subjected to EAE.  This is significant regarding the treatment of demyelinating 
diseases because developing a therapy to promote lipid synthesis and/or reduce lipid 
breakdown may prevent, possibly replace, the lipid loss found in EAE.  As well, we 
determined how acetate supplementation altered EAE-induced increases in cytoskeletal 
structure and myelin inhibiting protein levels.  We found EAE injury resulted in a 
significant increase in cytoskeletal associated proteins, β-actin and merlin, but treatment 
was unable to return these levels to control.  This suggests treatment may not alter all 
EAE disease pathologies.  In addition, there was a significant increase in oligodendrocyte 
myelin glycoprotein, a myelin inhibiting protein, and acetate supplementation returned 
this protein back to control levels.  This suggests treatment may alter myelin structure, 
and this was also shown in the FluoroMyelinTM staining.  Treatment slightly increased 
FluoroMyelinTM intensity in EAE compared to control-treated EAE mice but not to same 
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extent as control levels.  These studies demonstrate that acetate supplementation reduced 
disease progression, altered CNS and myelin lipid content, and influenced CNS and 






 Multiple sclerosis (MS) is an inflammatory demyelinating neurodegenerative 
disease (Cusick et al. 2013, Lassmann & van Horssen 2011, McQualter & Bernard 2007) 
affecting more than 2.3 million people worldwide (McQualter & Bernard 2007).  The 
inflammatory aspect of the disease involves a self-antigen T-cell attack on the central 
nervous system (CNS) (Cusick et al. 2013).  In MS, the permeability of the blood brain 
barrier (BBB) decreases allowing peripheral immune cell infiltration, consisting of T-cell 
lymphocytes, into the CNS (Lassmann & van Horssen 2011).  Antigen presenting cells 
like macrophages present an antigen to T cells, and as a result, T cells are activated to 
promote the release of pro-inflammatory cytokines and the recruitment of additional 
immune cells to target the foreign antigen (Cusick et al. 2013, Lassmann & van Horssen 
2011, McQualter & Bernard 2007).  With regards to MS autoimmunity, T-cells presented 
with a self-antigen against myelin promote the destruction of myelin via microglia and 
macrophage activation, pro-inflammatory cytokine release, and further peripheral 
immune cell infiltration.  These events lead to chronic CNS inflammation (Cusick et al. 
2013, Lassmann & van Horssen 2011, Nakahara et al. 2012, McQualter & Bernard 2007) 
and immune-mediated demyelination (Lassmann & van Horssen 2011).  There is another 
mechanism by which demyelination can occur in MS, oligodendrocyte-deficient 
demyelination (Nakahara et al. 2012).  This mechanism leads to demyelination either 
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through mature oligodendrocyte cell death or dysfunction in oligodendrocyte 
differentiation and/or function (Lucchinetti et al. 2000). 
 Oligodendrocytes are glial cells within the CNS that are important in myelination 
(Mitew et al. 2014, Boulanger & Messier 2014), and myelin promotes axonal insulation 
to assist in normal neuronal signal transduction (Mitew et al. 2014, Aggarwal et al. 2011, 
Chrast et al. 2011).  Oligodendrocyte progenitor cells (OPCs) are precursor cells that 
differentiate into mature oligodendrocytes.  OPCs undergo activation and recruitment to 
the site of demyelination initiated by a stimulus like inflammation or the presence of 
myelin debris.  A stimulus caused by inflammation promotes the release of particular 
growth factors, cytokines, and matrix metalloproteinases promoting oligodendrocyte 
development, inhibiting differentiation, activating proliferation, promoting survival, and 
increasing recruitment to the site of demyelination.  For example, a growth factor, 
platelet-derived growth factor (PDGF) forms a complex with platelet-derived growth 
factor receptor A (PDGFRα) and NG2 expressed on OPCs to promote proliferation but 
not differentiation.  Once OPCs are recruited to the site of demyelination, OPCs undergo 
differentiation to become mature oligodendrocytes.  Differentiation from OPCs to mature 
nonmyelinating oligodendrocytes is based on the release of the thyroid hormone 
triiodothyronine, the decrease of PDGF, and the release of other growth factors like IGF-
1 and TGF-β1.  At this point, mature oligodendrocytes attach to the axon becoming 
mature myelinating oligodendrocytes promoting myelination (Boulanger & Messier 
2014).  It is suggested that in MS pathology, early demyelination leads to remyelination 
recovery, but as the disease progresses, remyelination fails leading to significant 
demyelination (Boulanger & Messier 2014) shown by changes in CNS lipid in MS 
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(Alling et al. 1971, Cumings 1969, Cumings 1953, Cumings & Goodwin 1968, Davison 
& Wajda 1962, Gerstl et al. 1970, Gerstl et al. 1961).  These data suggest that there is a 
dysfunction in the oligodendrocytes that may be related to immune-mediated 
demyelination.  Both immune-mediated and oligodendrocyte-deficient demyelination are 
present in different MS lesion patterns. 
 There are four MS lesion patterns.  Types I and II relate to immune-mediated 
demyelination, and types III and IV relate to oligodendrocyte-deficient demyelination.  
T-cells and macrophages are present in Types I and II lesion patterns increasing 
inflammation contributing to demyelination.  Interestingly, distinguishing Type II from 
Type I is based on the presence of immunoglobulins in particular IgG and complement 
proteins.  Type III lesions show oligodendrocyte cell death suggesting no mature 
myelinating glial cells at the lesion site.  As a result, there is a decrease in myelination 
leading to demyelination.  On the other hand, Type IV lesion pattern is related to a 
dysfunction in the oligodendrocytes.  Although there is no oligodendrocyte cell death 
observed in Type IV lesions, these cells show no myelinating function (Lucchinetti et al. 
2000, McQualter & Bernard 2007), which in turn promotes demyelination.  The 
pathological characteristic found in MS suggests two mechanisms for demyelination: 
immune-mediated and oligodendrocyte-deficient demyelination, both of which results in 
the loss of myelin and may contribute differently to various MS diagnoses. 
 MS patients are diagnosed with either relapse-remitting, primary progressive, or 
secondary progressive (Cusick et al. 2013, Lublin & Reingold 1996, Lublin et al. 2014).  
Most patients, approximately 80%,  are diagnosed with relapsing-remitting (McQualter & 
Bernard 2007) who demonstrate symptoms for a period of time followed by periods of 
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recovery (Lublin & Reingold 1996).  Over time, 50% of patients with relapsing-remitting 
develop secondary progressive MS (Lublin & Reingold 1996) that results in a net 
decrease in the recovery period.  People who present with primary progressive MS show 
symptoms with no recovery period (Lublin & Reingold 1996).  Understanding the 
pathology of secondary progressive and primary progressive MS will provide insight as 
to how remyelination in chronic MS fails that leads to significant demyelination 
(Boulanger & Messier 2014).  Furthermore, demyelinating lesions within patients 
suffering from progressive MS may display more oligodendrocyte-deficient 
demyelination versus immune-mediated.  On the other hand, the pathology of relapse-
remitting MS may provide insight into the demyelination injury and remyelination 
recovery periods possibly related to both immune-mediated and oligodendrocyte-
deficient demyelination.  In short, MS is a complex disease with differing pathology and 
diagnoses.  Because of its complexity, different animal models have been developed to 
study the different aspects of MS disease pathology and to determine the effectiveness of 
treatments during different clinical courses. 
 
Animal Models of Multiple Sclerosis 
 Different MS animal models allows us to understand the various aspects of MS 
pathology, lesion patterns, and diagnoses.  These models include the experimental 
autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis (TMEV), 
cuprizone, and lyso-lecithin or also known as lyso-phosphatidylcholine.  These models 
can resemble either relapse-remitting, primary progressive, or secondary progressive MS 
and mimic types I and II lesion patterns or types III and IV (Denic et al. 2011, Simmons 
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et al. 2013, Basso et al. 2008, Batoulis et al. 2011, Hampton et al. 2008, Berard et al. 
2010, Palumbo & Bosetti 2013).  Furthermore, some of these systems allow us to 
understand mechanisms involved in the demyelination and remyelination process (Denic 
et al. 2011).  
 TMEV is a viral-induced autoimmune MS model and has insisted in 
understanding mechanisms involved in viral infections as risk factors for developing MS 
(Denic et al. 2011).  In particular, associations between infections of either human herpes 
virus-6 or Epstein-Barr virus to the later development of MS has been proposed (Berti et 
al. 2002, Kakalacheva et al. 2011, Virtanen & Jacobson 2012).  Regarding human herpes 
virus-6, 12 out of 13 MS patients compared to no controls showed human herpes virus-6 
expressing oligodendrocytes especially in regions of plaques (Challoner et al. 1995) 
suggesting viral-induced immune mediated demyelination.  In addition, the prevalence of 
human herpes virus-6 infection is higher in MS patients compared to other neurological 
diseases and controls (Chapenko et al. 2003).  As well, human herpes virus-6 positive 
cells in the brain were observed in 73% of MS patients within an area of active 
demyelination where only 2 out of 28 controls observed these cells.  Furthermore, 54% of 
MS versus 0% of control patients showed active human herpes virus-6 infection present 
in the blood (Knox et al. 2000), and the presence of brain human herpes virus-6 DNA 
was found more in MS (57.8%) compared to non-MS patients (15.9%) (Cermelli et al. 
2003).  Each of these observations suggest a possible association between human herpes 
virus-6 infection and later development of MS.   
 In addition to the human herpes virus-6, there is a suggested association between 
Epstein -Barr virus and later development of MS (Kakalacheva et al. 2011, Virtanen & 
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Jacobson 2012).  Epstein-Barr virus can become latent in B-cells during a person’s life 
suggesting that memory B-cells that recognize the antigen are active in an individual’s 
immune system (Kakalacheva et al. 2011, Virtanen & Jacobson 2012).  Based on studies 
observing the correlation between developing infectious mononucleosis, the disease 
caused by Epstein-Barr virus, in MS versus non-MS patients, there is approximately a 
twofold higher risk for someone who developed infectious mononucleosis to later 
develop MS (Handel et al. 2010, Thacker et al. 2006).  Epstein-Barr virus RNA and 
protein are found in plasma and B-cells in brains of MS patients, but it is not detected in 
patients with other inflammatory neurological diseases (Serafini et al. 2007).  This 
suggests a strong association between Epstein-Barr infection and MS development.  
TMEV model may be useful to help understand the pathology of viral-induced immune-
mediated demyelination.  The induction of the TMEV RNA virus promotes CNS 
inflammation resulting in immune-mediated demyelination, and as a result of the chronic 
CNS inflammation, this model stimulates the chronic progressive model (Denic et al. 
2011, Procaccini et al. 2015).  In this regard, TMEV would not be an appropriate model 
to mimic relapse-remitting MS but may help in the understanding of the potential risk of 
viral infections leading to autoimmune-induced demyelination (Procaccini et al. 2015).  
The TMEV model mimics immune-mediated demyelination induced by a previous viral 
infection, but another MS model, the cuprizone model, mimics oligodendrocyte-deficient 
demyelination. 
 Cuprizone, given in the diet, is a copper chelating agent suggested to induce 
mature oligodendrocyte death through a dysfunction in mitochondrial metabolism (Denic 
et al. 2011, Procaccini et al. 2015).  Cuprizone deactivates enzymes within the respiratory 
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chain leading to oxidative stress (Kipp et al. 2017).  Once administrated, the 
demyelination process begins (Procaccini et al. 2015) primarily within the corpus 
callosum and the white matter in the hippocampus (Ransohoff 2012) due to the loss of 
mature oligodendrocytes (Procaccini et al. 2015).  On the other hand, once cuprizone is 
removed from the diet, remyelination can occur through the differentiation of OPCs that 
were unaffected by the diet.  Differentiation of OPC to mature oligodendrocytes results in 
remyelination (Procaccini et al. 2015).  Cuprizone selectively targets mature 
oligodendrocytes but not neurons, astrocytes, microglia, and OPCs.  Cuprizone 
significantly decreases the number of mature oligodendrocytes whereas the number of 
OPCs remain unaffected suggesting a decrease in the myelinating function due to 
treatment (Benardais et al. 2013).  Cuprizone serves as a good model in understanding 
the mechanisms involved regarding oligodendrocyte function during the demyelination 
and remyelination process.  In addition, these data suggest the cuprizone model allows us 
to understand mechanisms involved not only in the development of lesion pattern III, but 
also oligodendrocyte-deficient demyelination versus immune-mediated demyelination 
(Simmons et al. 2013, Procaccini et al. 2015, Ransohoff 2012, Palumbo & Bosetti 2013).  
In addition to cuprizone, another toxin-induced demyelinating agent is lyso-lecthin. 
 The use of lyso-lecthin has helped to understand the demyelination and 
remyelination processes.  Lyso-lecthin, injected into spinal cord (Denic et al. 2011) of 
mice, induces direct demyelination within the white matter tracts (Procaccini et al. 2015, 
Ransohoff 2012) but has no association with immune-mediated demyelination 
(Procaccini et al. 2015).  Over time, remyelination can occur (Ransohoff 2012).  The big 
drawback to this model is that it does not truly mimic MS pathology with either immune-
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mediated or oligodendrocyte-deficient demyelination (Procaccini et al. 2015).  Another 
MS animal model widely used is the experimental autoimmune encephalomyelitis (EAE) 
model, and this model mimics immune-mediated demyelination. 
 EAE is an autoimmune MS model mimicking the self-antigen attack on the CNS 
resulting in immune-mediated demyelination (Simmons et al. 2013, Palumbo & Bosetti 
2013).  Depending on the protocol and mouse background, EAE can model different MS 
diagnoses: relapse-remitting, primary progressive, or secondary progressive.  EAE 
relapsing-remitting models include SJL/J mice inoculated with proteolipid protein (PLP) 
peptide (PLP139-151), (Batoulis et al. 2011, Simmons et al. 2013) and C57BL/6 mice 
inoculated with a low dose of myelin oligodendrocyte glycoprotein (MOG) peptide 
(Batoulis et al. 2011, Simmons et al. 2013, Berard et al. 2010).  A chronic progressive 
EAE model involves C57BL/6 mice inoculated with high dose of MOG peptide (MOG35-
55) (Batoulis et al. 2011, Simmons et al. 2013, Berard et al. 2010) and followed by an 
injection of pertussis toxin (Kipp et al. 2017, Procaccini et al. 2015). In addition, a 
secondary progressive EAE model has been developed (Basso et al. 2008, Hampton et al. 
2008, Simmons et al. 2013).  In all these models, EAE induction results in an 
autoimmune response via self-antigen attack of myelin components resulting in immune-
mediated demyelination (Denic et al. 2011, Simmons et al. 2013) through a Th1/Th17 
response based on the release of IFN-γ and IL-17 (Constantinescu et al. 2011, Murphy et 
al. 2010, Robinson et al. 2014).  IL-33 may also play a role in EAE pathogenesis as 
inhibition of IL-33 decreases IFN-γ and IL-17 and improves symptoms in EAE model.  
Inhibition of IL-33 in EAE results in a decrease of pro-inflammatory mediators such as a 
transcription factor promoting Th1 cell differentiation (T-bet) and RAR-related orphan 
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receptor gamma t.  Furthermore, inhibiting IL-33 increases anti-inflammatory cytokines 
such as IL-10 and TGFβ in the EAE spinal cord (Li et al. 2012). 
 EAE allows us to understand the autoimmune pathology of MS, but there are 
some drawbacks to this model.  MOG-induced C57BL/6 EAE is a chronic progressive 
model but does not lend itself to study the relapse-remitting form of MS.  The majority of 
individuals with MS are diagnosed with relapse-remitting while the other fraction is 
diagnosed with primary progressive (McQualter & Bernard 2007).  As mentioned 
previously, about 50% of relapse remitting patients will develop the secondary 
progressive form of MS (Lublin & Reingold 1996).  Chronic EAE models may assist in 
the developing a treatment strategy for progressive MS.  In addition, the EAE disease is 
primarily found in the spinal cord (Batoulis et al. 2011, Ransohoff 2012, Simmons et al. 
2013) whereas MS disease is significantly found within the brain (Procaccini et al. 2015).  
Therapies effective in EAE have led to clinical trials and FDA approval.  On the other 
hand, there are plenty of therapies showing promising results in EAE but failed in clinical 
trials (Denic et al. 2011, Kipp et al. 2017, Procaccini et al. 2015).  We decided to use the 
chronic EAE model for our studies because it represents an autoimmune progressive 
model to investigate mechanisms related to both immune-mediated and oligodendrocyte 
deficient demyelination.  This model may allow us to understand a potential dysfunction 
in lipid metabolism in MS.  We can determine how EAE injury results in changes in CNS 
lipid content and protein levels of enzymes and metabolites involved in lipid synthesis 
and breakdown.  Furthermore, there is only one FDA approved therapy for primary 
progressive MS (Dargahi et al. 2017), diagnosed in 20% of patients (McQualter & 
Bernard 2007), and current therapies seem ineffective in treating the secondary 
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progressive form (Dargahi et al. 2017).  In this model, we can determine the effectiveness 
of glyceryl triacetate in the progressive EAE course and determine a potential treatment 
strategy for progressive MS. 
 
Current Available Therapies for Multiple Sclerosis 
 Disease-modifying therapies (DMTs) are the current FDA approved MS 
medications that modulate the immune response either by inhibiting immune cell 
infiltration or by acting as anti-inflammatory agents (Lim & Constantinescu 2010).  First-
line medications include interferon-β and glatiramer acetate, and second-line medications 
include mitoxantrone, fingolimod, dimethyl fumarate, natalizumab, and alemtuzumab 
(Lim & Constantinescu 2010).  Each one has its own mechanism of action targeting 
components within the immune response to produce its immunosuppressive effect. 
 Interferon-β (IFN-β) was the first FDA approved drug for the treatment of 
patients with relapse-remitting MS (Dargahi et al. 2017) in 1993 (Delbue et al. 2017).  
This treatment inhibits T-cell activation and decreases BBB permeability that in turn 
decreases immune cell infiltration into the CNS (Lim & Constantinescu 2010).  This 
treatment also increases anti-inflammatory cytokines like IL-10 and IL-4 while 
decreasing pro-inflammatory cytokines such as IFN-γ, IL-17, and TNF-α (Dargahi et al. 
2017, Oh & O'Connor 2015).  In clinical trials, IFN-β decreases relapse rate, the severity 
of relapses, the number of lesions (Dargahi et al. 2017), and is safe in patients suffering 
from MS (Oh & O'Connor 2015).  The other first line treatment that is FDA approved is 
glatiramer acetate (Delbue et al. 2017). 
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 Glatiramer acetate resembles the structure of myelin basic protein (MBP) 
(Dargahi et al. 2017, Lim & Constantinescu 2010), and importantly, MBP is a protein 
found within myelin (Campagnoni & Campagnoni 2004, Eichberg & Iyer 1996).  
Glatiramer acetate decreases the number of autoreactive T-cells (Lim & Constantinescu 
2010) presented with a self-antigen against MBP.  By blocking the interaction between T-
cells and the self-MBP peptide (Dargahi et al. 2017), antigen presenting cells cannot 
present the self-antigen to T-cells to promote autoreactive T-cell activation and immune-
mediated demyelination.   In addition, this treatment decreases pro-inflammatory 
cytokines and increases anti-inflammatory cytokines (Dargahi et al. 2017) to decrease 
CNS inflammation.  In clinical trials, this treatment decreases the relapse rate by 30%, 
improves MRI scans, decreases new lesion formation (Dargahi et al. 2017, Lim & 
Constantinescu 2010), and is well-tolerated (Lim & Constantinescu 2010, Oh & 
O'Connor 2015).  IFN-β and glatiramer acetate are first-line, but there are numerous 
second line medications also effective in treating MS like natalizumab, mitoxantrone, and 
alemtuzumab. 
 Natalizumab is a monoclonal antibody treatment targeting α4 integrins such as 
α4β1 integrin (Dargahi et al. 2017, Delbue et al. 2017, Lim & Constantinescu 2010, Oh 
& O'Connor 2015).  The integrin, α4β1, is expressed on immune cells and interacts with 
vascular cell adhesion molecule 1 (VCAM-1) expressed on BBB endothelial cells 
(Dargahi et al. 2017, Lim & Constantinescu 2010).  Natalizumab blocks this interaction 
between α4β1 and VCAM-1 by binding to VCAM-1 resulting in the decrease of immune 
cell infiltration into the CNS (Dargahi et al. 2017, Delbue et al. 2017, Lim & 
Constantinescu 2010, Rice et al. 2005) decreasing CNS inflammation.  In particular, 
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peripheral T-cells are unable to cross the BBB and promote the self-antigen immune 
attack in the CNS contributing to immune-mediated demyelination.  In the EAE model, 
α4β1 integrins are essential in the trafficking of T-cells into the CNS to contribute to 
EAE pathogenesis (Bauer et al. 2009).  In the EAE model, targeting α4β1 integrins 
results in a decrease of immune cells within the CNS and the attenuation of clinical 
paralysis (Yednock et al. 1992).  Natalizumab decreases relapse rate by 68%, disability 
progression by 42%, number of lesions (Dargahi et al. 2017, Delbue et al. 2017, Polman 
et al. 2006), and clinically improves MRI scans (Delbue et al. 2017, Lim & 
Constantinescu 2010, Polman et al. 2006).  In addition, this treatment is well tolerated 
(Oh & O'Connor 2015), shows long term benefits, and increases the quality of life 
(Delbue et al. 2017) of patients suffering from MS.  This treatment is prescribed to 
patients with severe relapse-remitting MS (Lim & Constantinescu 2010) due to the 
increase risk of developing progressive multifocal leukoencephalopathy, a fatal 
demyelinating disease (Dargahi et al. 2017, Delbue et al. 2017).  This treatment was FDA 
approved (Dargahi et al. 2017, Delbue et al. 2017) until PML was detected in a few 
patients, and as a result, natalizumab was removed from the market until recently 
reinstated for special circumstances (Dargahi et al. 2017).   
 Mitoxantrone started as a cancer drug for patients with non-Hodgkin’s lymphoma, 
breast cancer, acute myeloid leukemia, and prostate cancer by targeting type II 
topoisomerase to prevent DNA synthesis and repair that leads to the inhibition of cancer 
cell division.  Now, this drug is FDA approved for the treatment of MS (Delbue et al. 
2017).  Using human MS peripheral blood mononuclear cells in vitro, mitoxantrone 
decreases immune cell proliferation, promotes immune cell death, and decreases dendritic 
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cell maturation (Neuhaus et al. 2005) suggesting this treatment modulates the immune 
response and possesses immunosuppressive properties (Dargahi et al. 2017) in MS.  As 
well, this treatment prevents T-cell activation and antigen presentation, decreases the 
proliferation of immune cells such as T-cells, B-cells, and macrophages (Lim & 
Constantinescu 2010), and decreases pro-inflammatory cytokines (Dargahi et al. 2017, 
Lim & Constantinescu 2010).  In preclinical studies, mitoxantrone attenuates clinical 
paralysis and disease onset in the EAE model (Lim & Constantinescu 2010, Ridge et al. 
1985), and in clinical trials, treatment decreases the number of relapses by 69% (Lim & 
Constantinescu 2010) and disability progression by 80%.  Due to serious side effects like 
cardiotoxicity and acute leukaemia (Lim & Constantinescu 2010), this treatment is not 
used often (Dargahi et al. 2017).    
 Alemtuzumab is a monoclonal antibody inhibiting CD52 expressed on 
lymphocytes and monocytes (Lim & Constantinescu 2010).  As a result, activated T and 
B-cells are eliminated, and there is switch from a pro-inflammatory to an anti-
inflammatory state (Dargahi et al. 2017).  Anti-CD52 improves clinical symptoms based 
on a decrease in clinical score between control-treated EAE mice and anti-CD52-treated 
EAE mice.  In addition, treatment decreases T-cell infiltration, pro-inflammatory 
cytokines, demyelination, and axonal loss (Turner et al. 2015).  In clinical trials, this 
treatment delays the onset of disability by 74% (Lim & Constantinescu 2010) and 
decreases the relapse rate (Dargahi et al. 2017).  Unfortunately, due to frequent and 
serious side effects, this drug is only prescribed when patients are unable to respond to 
other DMTs (Dargahi et al. 2017).  The second line agents, natalizumab, mitoxantrone, 
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and alemtuzumab, have serious side effect profiles and so, these better tolerated second 
line agents, fingolimod and dimethyl fumarate, are prescribed more often. 
 Fingolimod was the first oral FDA approved drug for the treatment of patients 
with relapse-remitting MS (Dargahi et al. 2017).  Fingolimod targets the sphingosine-1-
phosphate receptor that interacts with T-cells promoting inflammatory signaling (Lim & 
Constantinescu 2010).  As a result, this treatment decreases auto-reactive lymphocytes 
into the CNS (Dargahi et al. 2017).  Fingolimod was effective in MS animal models and 
moved onto clinical trials (Lim & Constantinescu 2010).  In the relapse-remitting EAE 
model, fingolimod significantly improves clinical symptoms showing an attenuation of 
relapses and an improvement in motor behavior.  Interestingly, treatment is not effective 
in the secondary progressive EAE model (Al-Izki et al. 2011) suggesting 
immunomodulatory therapies might not be sufficient in the treatment of progressive MS.  
In clinical trials, treatment with fingolimod decreases the relapse rate by about 50%, 
lesion number and volume (Lim & Constantinescu 2010, Dargahi et al. 2017), the 
number of relapses (Dargahi et al. 2017), and is well tolerated (Lim & Constantinescu 
2010). 
 Dimethyl fumarate is another oral FDA approved MS therapy (Dargahi et al. 
2017, Delbue et al. 2017).  Treatment shows neuroprotective properties through nuclear 
factor E2-related factor 2 activation decreasing oxidative stress in the CNS (Dargahi et al. 
2017, Lim & Constantinescu 2010, Oh & O'Connor 2015).  This treatment also displays 
anti-inflammatory properties by decreasing pro-inflammatory cytokines and cell adhesion 
molecules decreasing immune cell infiltration into the CNS (Dargahi et al. 2017, Lim & 
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Constantinescu 2010).  In clinical trials, treatment decreases the relapse rate (Dargahi et 
al. 2017) with moderate side effects and overall long-term safety (Oh & O'Connor 2015). 
 There are a few FDA approved DMTs on the market that also modulate the 
immune response.  Daclizumab binds to IL-2 receptor that decreases the activation of T-
cells overall decreasing inflammation (Dargahi et al. 2017, Lim & Constantinescu 2010).  
In clinical trials, treatment decreases relapse rate and lesion formation (Dargahi et al. 
2017).  Teriflunomide is a leflunomide metabolite (Dargahi et al. 2017, Lim & 
Constantinescu 2010) that inhibits dihyro-orotate dehydrogenase (Dargahi et al. 2017, 
Lim & Constantinescu 2010, Oh & O'Connor 2015) preventing the proliferation and 
differentiation of lymphocytes (Dargahi et al. 2017, Lim & Constantinescu 2010).  In 
clinical trials, treatment decreases relapse rate, lesion number, and disability progression 
(Dargahi et al. 2017, Oh & O'Connor 2015).  Interestingly, ocrelizumab is the first FDA 
approved drug for primary progressive MS (Dargahi et al. 2017) and targets CD20 
expressed on B-cells.  Treatment eliminates B-cells to suppress T-cell induced 
inflammation to inhibit the activation of CD4 T cells, cytokine release, and antibody 
release (Dargahi et al. 2017).  These therapies seem to be effective in relapse-remitting 
MS but not effective in treating secondary progressive (Dargahi et al. 2017).  This leads 
to the need for the development of new therapeutic strategies effective in treating 
progressive MS. 
 
Gaps in Knowledge 
 There are two mechanisms by which demyelination can occur in MS, immune-
mediated demyelination, Types I and II, and oligodendrocyte-deficient demyelination, 
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Types III and IV (Lucchinetti et al. 2000, Nakahara et al. 2012).  Current DMTs are 
immunomodulatory (Lim & Constantinescu 2010) targeting the immune-mediated 
demyelination but not the oligodendrocyte-deficient demyelination.  This suggests that 
current MS therapies do not treat the entire disease.  Developing therapies to promote the 
differentiation of OPCs, increase the myelination function of oligodendrocytes, increase 
the production of lipid, or decrease the breakdown of lipid are mechanisms that may be 
effective in treating all forms of demyelination.  Using different MS animal models may 
also lead to potential therapeutic targets leading to the recovery of myelin lipid and 
normal lipid turnover rates. 
 MS patients are diagnosed with either relapse-remitting, primary progressive, or 
secondary progressive course.  Current DMTs are effective in the treatment of relapse-
remitting (Dargahi et al. 2017, Lim & Constantinescu 2010) where there is only one FDA 
approved drug for primary progressive, and current DMTs seem to be ineffective for 
treating secondary progressive (Dargahi et al. 2017).  Therefore, this suggest that 
developing therapeutic strategies in the treatment of progressive versus relapse-remitting 
MS is definitely needed. 
 Immune-mediated demyelination involves both the increase in CNS inflammation 
and the loss of myelin (Cusick et al. 2013, Lassmann & van Horssen 2011, McQualter & 
Bernard 2007).  Understanding the inflammatory response in EAE and MS is fairly well-
known, but research still focuses on how to down-regulate the immune response 
therapeutically.  The understanding of the demyelination processes in EAE and MS and 
how to therapeutically promote the recovery of myelin is where research needs to switch 
its focus.  Altering spinal cord lipid in EAE may lead to a therapy that in turn increases 
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myelin lipid deposition to treat demyelinating diseases.  Our studies set out to determine 
how glyceryl triacetate alters CNS lipid content in mice subjected to EAE, an 
autoimmune progressive MS animal model.  If treatment alters CNS lipid content in this 
model, this will lead to determining how treatment alters lipid synthesis and/or 
breakdown to show that recovery of lipid lost due to injury.  
 
Lipid Synthesis, Lipid Breakdown, and Myelin Lipid Composition 
 Lipids are essential in membrane structure and stability (Schmitt et al. 2015, 
Zhang & Liu 2015, Morell 1984), signaling regulation (Glade & Smith 2015, Kim et al. 
2014), inflammation (Schmitt et al. 2015, Shimizu 2009), and normal cognitive function 
(Glade & Smith 2015, Kim et al. 2014, Zhang & Liu 2015).  For example, 
phosphatidylserine is important in maintaining normal nerve membrane and myelin 
structure, regulating neurotransmitter metabolism, and regulating phospholipase 
C/protein kinase C signaling (Glade & Smith 2015).  In addition, phosphatidylserine 
supplementation improves learning and memory in the elderly showing various levels of 
dementia suggesting lipids contribute to normal cognitive function (Glade & Smith 2015, 
Kim et al. 2014).  Also, gangliosides, cholesterol, and plasmalogens promote myelin 
stability (Saher et al. 2005, Schmitt et al. 2015), and plasmalogens contribute to 
phospholipase A2-mediated inflammation (Schmitt et al. 2015).  Very importantly, lipids 
are essential in membrane structure for example myelin structure, comprised mostly of 
lipid compared to protein (Morell 1984).  In order for lipids to incorporate into the myelin 
structure, lipids are produced through the precursor, acetyl-CoA (Jaworski et al. 2016).  
Acetyl-CoA is the precursor to fatty acid, cholesterol, and ceramide synthesis. Acetate is 
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converted to acetyl- CoA by acyl-CoA synthetase enzyme (Jaworski et al. 2016, Shimazu 
et al. 2010) and has been shown to incorporate into phospholipid (Smith 1964, Mehta & 
Namboodiri 1995), fatty acid (D'Adamo & Yatsu 1966), and cholesterol (Chakraborty et 
al. 2001). 
 Fatty acids are long-chain carboxylic acids that can be saturated, with no double 
bonds, or unsaturated, with one or more double bonds.  First, malonyl-CoA is produced 
by the introduction of a carboxyl group to acetyl-CoA catalyzed by acetyl-CoA 
carboxylase, and the condensation of malonyl-CoA with another acetyl-CoA results in 
the formation of β-ketoacyl-CoA.  From this point, elongation by two carbons per 
reaction results in fatty acids with 12 or more carbons.  In addition, desaturase enzymes 
catalyze the insertion of a double bond into fatty acids to form unsaturated fatty acids.  
Overall, fatty acids are formed either by de novo synthesis with the acetyl-CoA precursor 
or through the elongations and desaturation of essential fatty acids from the diet including 
linoleic (18:2n6) or alpha-linolenic (18:3n3) acids (Barcelo-Coblijn & Murphy 2009, 
Cinti et al. 1992, Jaworski et al. 2016, Baenke et al. 2013, Benjamins et al. 2012).  Once 
the appropriate fatty acids are formed, two fatty acids are incorporated into phospholipid 
at the sn-1 and sn-2 positions (Baenke et al. 2013). 
 Phospholipid contains a glycerol-3-phosphate backbone with fatty acids located at 
the sn-1 and sn-2 position indicated by X and R shown in Figure 1.  Phosphatidic acid 
(PtdOH) is the precursor to the production of phospholipids.  First, dihydroxyacetone 
phosphate (DHAP) is acylated to form acyl-DHAP, the precursor to ether lipids like 
plasmalogen (PlsEtn and PlsCho) and plasmanyl (PakEtn and PakCho) fractions of 
ethanolamine and choline glycerophospholipid (EtnGpl and ChoGpl).  Additional 
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acylation results in the production of PtdOH to give rise to phosphatidylinositol (PtdIns) 
or diacylglycerol (DAG).  From there, DAG forms phosphatidylethanolamine (PtdEtn) 
and phosphatidylcholine (PtdCho).  Interestingly, PtdCho can be formed from PtdEtn 
through methylation of the side group at the sn-3 position shown by letter Y in Figure 1.  
Phosphatidylserine (PtdSer) can be formed from PtdEtn through the addition of a 
carboxyl group at the sn-3 position (Baenke et al. 2013, Benjamins et al. 2012, 
Braverman & Moser 2012, Brites et al. 2004, Hajra 1995, Kennedy 1986, Magnusson & 
Haraldsson 2011, Kim et al. 2014). 
 
Figure 1: General structure of phospholipids.  Sn-1, sn-2, and sn-3 positions are 
indicated by the arrows.  X and R is the locations of a fatty acid, and Y is the location of 
the phospholipid side group. 
 
 
 Acetyl-CoA is also the precursor to cholesterol synthesis.  The condensation of 
three acetyl-CoAs result in the production of β-hydroxy-β-methylglutaryl (HMG)-CoA, 
and further, HMG-CoA is reduced to mevalonic acid catalyzed by HMG-CoA reductase.  
After the production of mevalonic acid, there is a series of reactions that results in the 
production of cholesterol and cholesteryl esters, a cholesterol metabolite (Baenke et al. 
2013, Benjamins et al. 2012, Saher et al. 2011, Jaworski et al. 2016).  The synthesis of 
cholesterol occurs primarily in the brain because cholesterol does not cross the blood 
brain barrier (Morell & Jurevics 1996).  
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 Sphingolipid synthesis requires the production of palmitoyl-CoA, a fatty acid-
CoA and through a series of reactions results in the production of ceramide, the precursor 
to sphingolipids.  Ceramide is the precursor to the production of sphingomyelin 
(CerPCho), sulfatides or galactocerebrosides, and gangliosides (Benjamins et al. 2012).  
Gangliosides also require the addition of mono- or polysaccharides and sialic acid (N-
acetyl-neuraminic acid, NANA) to ceramide (Schnaar et al. 2014, Yu et al. 2011). 
 There is a natural turnover of lipid (Rosenberger et al. 2002, Ando et al. 2003, 
Moser et al. 1999) that requires a synthesis of lipid in conjugation with a breakdown of 
lipid involving phospholipase activity such as cytosolic phospholipase A2 and 
phospholipase C.  Phospholipases hydrolyze membrane phospholipids to promote 
inflammatory and signaling cascades.  Cytosolic phospholipase A2 (cPLA2) releases 
arachidonic acid from membrane phospholipids at the sn-2 position shown in Figure 2.  
Arachidonic acid is used to form inflammatory eicosanoids like prostaglandins and 
thromboxanes catalyzed by cyclooxygenases or leukotrienes catalyzed by 5-
lipoxygenase.  In addition, cPLA2 can hydrolyze membrane ether phospholipids to 
release arachidonic acid and inactive lyso-platelet-activating factor (lyso-PAF).  PAF  
 
 
Figure 2:The phospholipase targets on phospholipids.  Abbreviations include cPLA2 
(cytosolic phospholipase A2) and PLC (phospholipase C). 
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becomes active after the acetylation of lyso-PAF, which then promotes inflammation 
(Shimizu 2009, Benjamins et al. 2012).  In addition to cPLA2, phospholipase C (PLC) 
cleaves the bond indicated in Figure 2 at the sn-3 position of phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) releasing DAG and inositol-1,4,5-trisphosphate (I(1,4,5)P3).  
Important to note, PtdIns(4,5)P2 is formed through the phosphorylation of PtdIns.  DAG 
activates protein kinase C, an important signaling molecule, and I(1,4,5)P3 increases 
calcium release from the endoplasmic reticulum (Suh et al. 2008, Benjamins et al. 2012).  
Cytosolic PLA2 is important in promoting pro-inflammatory lipid signaling, and PLC is 
important in regulating signal transduction.  
 Regarding the EAE model and MS, there are changes in lipid content and 
phospholipase levels (Kalyvas & David 2004, Soliman et al. 2013b, Cumings 1969, 
Cumings 1953, Cumings & Goodwin 1968, Gerstl et al. 1970, Gerstl et al. 1961).  MS is 
considered in part, an autoimmune disease, and cPLA2 promotes inflammation 
contributing to immune-mediated demyelination.  Cytosolic PLA2 is associated with an 
increase in immune cells in EAE lesions, and the inhibition of cPLA2 results in the 
improvement of symptoms in this model.  This suggests that an increase in cPLA2 levels 
contribute to immune-mediated demyelination (Kalyvas & David 2004) in EAE.  In 
addition, MS and EAE have been associated with changes in myelin lipid content (Alling 
et al. 1971, Cumings 1969, Cumings & Goodwin 1968, Gerstl et al. 1970, Salvati et al. 
1990).  Myelin is an electrical insulator to assist in directing the electrical current along 
the axon (Aggarwal et al. 2011, Chrast et al. 2011).  Myelin composition (Morell 1984) is 
primarily composed of lipid (80%) where the other fraction is composed of protein 
(20%).  The lipid portion is composed of cholesterol (28%), galactolipid (28%), and 
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phospholipid (43%).  Within myelin galactolipid, galactocerebrosides occupy 23%, and 
sulfatides occupy 4%.  Myelin phospholipid portion is composed of PtdEtn (16%), 
PtdCho (11%), CerPCho (8%), PtdSer (5%), PtdIns (0.6%), and ethanolamine 
plasmalogen (PlsEtn, 12%).  The protein fraction is composed of proteins primarily MBP 
(Campagnoni & Campagnoni 2004, Eichberg & Iyer 1996) and PLP (Greer & Lees 2002, 
Hudson 2004).  Other myelin proteins include 2’:3’-cyclic nucleotide 3’ 
phosphodiesterase (Eichberg & Iyer 1996), myelin-associated glycoprotein (MAG) 
(Eichberg & Iyer 1996, Georgiou et al. 2004), MOG (Pham-Dinh et al. 2004), and 
oligodendrocyte-myelin glycoprotein (OMgp) (Mikol et al. 1993, Mikol & Stefansson 
1988).  In the EAE model, injury decreases spinal cord phospholipid (Revina et al. 2011, 
Taranova 1985) in particular PtdEtn, PtdCho, and PtdSer (Revina et al. 2011), spinal cord 
and brain cerebrosides (Roth et al. 1982, Taranova 1985), spinal cord and brain sulfatides 
(Maggio et al. 1972), and spinal cord gangliosides (Maggio et al. 1972).  Regarding 
myelin brain lipid, EAE injury decreases phospholipid content in particular CerPCho, 
PtdSer + PtdIns, and PtdEtn (Salvati et al. 1990).  EAE injury results in significant 
decreases in CNS lipid that is comparable to lipid changes shown in MS.  Regarding 
white matter in MS patients, there are decreases in sphingomyelin (Davison & Wajda 
1962), plasmalogen (Cumings 1969, Davison & Wajda 1962), phospholipid (Cumings 
1953, Cumings & Goodwin 1968, Gerstl et al. 1970, Gerstl et al. 1961, Alling et al. 1971, 
Cumings 1969), cerebrosides (Cumings 1969, Cumings 1953), sulfatides (Alling et al. 
1971), gangliosides (Kishimoto et al. 1967), and cholesterol (Cumings 1953).  There is a 
decrease in lipid content and an increase in phospholipase activity to suggest an increase 
in pro-inflammatory lipid signaling or possibly a metabolic issue resulting in a 
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dysfunction of lipid metabolism.  A therapy to promote lipid synthesis and/or decrease 
lipid breakdown within the CNS may be a potential remyelination therapy to treat 
patients suffering from demyelinating diseases like MS.  In this regard, increasing acetyl-




 Glyceryl triacetate currently approved as a food additive (Tsen et al. 2014) 
metabolizes into acetate and glycerol when administered orally (Arun et al. 2010a, Long 
et al. 2013, Tsen et al. 2014).  From there, acetate is available to enter the CNS to form 
active acetyl-CoA utilized in energy production, acetylation, and lipid synthesis (Bhatt et 
al. 2013, Bhatt & Rosenberger 2014, Soliman & Rosenberger 2011, Soliman et al. 
2012b).  Acetate, a two carbon monocarboxylic acid, which is the shortest fatty acid and 
again, is converted to the active form acetyl-CoA by acyl-CoA synthetase (Jaworski et al. 
2016).  After a single dose of glyceryl triacetate given to control Sprague-Dawley rats, 
brain acetyl-CoA increases 2.2 fold 30 minutes to 4 hours post treatment (Reisenauer et 
al. 2011).  By increasing brain acetyl-CoA metabolism, treatment can alter inflammation, 
histone acetylation, purinergic signaling, and energy stores. 
 It is suggested glyceryl triacetate is anti-inflammatory in animal models of 
neuroinflammation and neuroborreliosis.  In a LPS-induced neuroinflammation rat 
model, acetate supplementation reduces microglia activation, reactive astrocytes 
(Reisenauer et al. 2011), and decreases IL-1β protein and mRNA levels (Soliman et al. 
2012b).  In addition, in the rat model of neuroborreliosis, treatment decreases microglia 
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activation and brain IL-1β levels suggesting a decrease in the pro-inflammatory response 
(Brissette et al. 2012).  Acetate shows anti-inflammatory effects in vitro as well as in 
vivo.  In primary astrocytes, acetate treatment attenuated TNFα and IL-1β levels (Soliman 
et al. 2013a), and similarly in BV2 microglia, acetate treatment attenuated pro-
inflammatory cytokine levels like IL-1β, TNFα, and IL-6 (Soliman et al. 2012a).  Acetate 
also alters pro-inflammatory lipid signaling in vitro.  In LPS-stimulated BV2 microglia 
cultures, treatment returned PLCβ1 levels to controls.  However, in LPS-stimulated 
primary astrocytes, treatment significantly decreases phosphorylated cPLA2 and PLCβ1 
levels compared to sodium chloride-treated LPS-stimulated primary astrocytes.  In LPS-
stimulated BV2 and primary astrocytes, treatment significantly decreases 
cyclooxygenase-1 (COX-1) and COX-2 levels, but interestingly, only in LPS-stimulated 
astrocytes, acetate significantly decreases prostaglandin E2 levels compared to sodium 
chloride-treated LPS-stimulated cells (Soliman et al. 2013b).  Acetate reduces pro-
inflammatory lipid signaling in vitro and in vivo to suggest treatment displays anti-
inflammatory effects.  This shift from a pro-inflammatory to an anti-inflammatory state 
may be a result of changes in histone acetylation shifting gene and protein expression to 
increase anti-inflammatory compounds versus pro-inflammatory ones.   
 In a LPS-induced neuroinflammation model, acetate supplementation 
significantly increases histone acetylation and decreases histone deacetylase levels and 
activity compared to control-treated LPS-induced rats (Soliman et al. 2013a, Soliman et 
al. 2013b, Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b).  
Treatment reverses the effects of MK-801, a drug which induces histone hypoacetylation, 
in mice to correlate with cognitive improvements shown by an increase in performance in 
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the elevated plus maze and novel object recognition tests (Singh et al. 2016).  Acetate 
supplementation reduces inflammation that may correlate to changes in histone 
acetylation and levels of histone deacetylase, but treatment also alters purinergic 
signaling in vivo.   
 In a LPS-induced neuroinflammation model, LPS exposure decreases brain CD73 
levels and increases brain adenosine A2A receptor, and acetate supplementation returns 
these levels back to control (Smith et al. 2014).  These data suggest that treatment alters 
purinergic signaling in the neuroinflammation model.  As well, treatment increases brain 
phosphocreatine levels suggesting treatment alters energy stores in the CNS (Bhatt et al. 
2013).  In addition, acetate regulated MAPK and NF-κB signaling in primary astrocytes 
(Soliman et al. 2013a) and MAPK and JNK pathway in BV2 microglia (Soliman et al. 
2012a).  Acetate alters inflammation, acetylation state, purinergic signaling, energy 
stores, and MAPK regulation. 
 Acetate supplementation is effective in rat models of neuroinflammation and 
neuroborreliosis, but it is also effective in treating cancer, Canavan disease, and traumatic 
brain injury.  Canavan disease is an autosomal recessive demyelinating disease where 
people suffering from this disease show a mutation in the gene that encodes for 
aspartoacylase (ASPA) that releases acetate from N-acetylaspartate (NAA).  Due to this 
mutation, there is an increase in NAA and a decrease in acetate in the brain.  As a result, 
there is hypomyelination due to acetate unable to incorporate into myelin (Namboodiri et 
al. 2006b, Namboodiri et al. 2006a).  Acetate supplementation alters brain acetate levels 
but not brain NAA levels (Mathew et al. 2005).  Increasing brain acetate bypasses the 
mutation, and acetate is utilized to produce myelin lipid in Canavan disease.  In tremor 
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rats, a model for Canavan disease, treatment significantly increases motor performance 
through the rotarod and increases myelin galactocerebroside compared to untreated 
tremor rats (Arun et al. 2010b).  Glyceryl triacetate is safe and tolerable at both low and 
high doses in tremor rats and infants suffering with Canavan disease (Madhavarao et al. 
2009, Segel et al. 2011).  These data that suggest acetate supplementation is beneficial in 
the treatment of Canavan disease.  Treatment prevented cell growth in glioma-derived 
tumor cells (Long et al. 2015, Long et al. 2013, Tsen et al. 2014) and significantly 
increases motor performance in a rat model for traumatic brain injury (Arun et al. 2010a).  
Acetate supplementation is effective in the treatment of rat models of neuroinflammation, 
neuroborreliosis, Canavan disease, and traumatic brain injury.  In particular, treatment 
has been shown to be effective in tremor rats and infants suffering from Canavan disease, 
a demyelinating disease, to suggest treatment may be beneficial in other demyelinating 
diseases like MS.  Understanding acetate’s role to promote lipid synthesis may treat 
demyelination and lead to the development of a remyelination therapy to recover the lipid 
lost due to demyelination.  Acetate supplementation may be an avenue to address this, 
and interestingly, acetate significantly increases fatty acid content in LPS-stimulated BV2 
microglia cultures (Bhatt & Rosenberger 2014).  With the knowledge from this previous 
study, we wanted to investigate acetate’s role in altering lipid metabolism in an injury 
state. 
 
Overview of Dissertation 
 We propose that acetate supplementation alters CNS lipid content in mice 
subjected to EAE.  To test this hypothesis, spinal cord and brain lipid levels were 
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determined in control and EAE mice treated with either water or glyceryl triacetate.  We 
also determined how treatment alters disease progression, spinal cord protein levels of 
enzymes involved in lipid metabolism, cytoskeletal structure, and myelin structure.  We 
found that acetate supplementation attenuated the onset of clinical symptoms in EAE 
mice.  In addition, the treatment altered spinal cord phospholipid, fatty acid, cholesterol, 
and ganglioside content in these animals.  Acetate supplementation altered total brain and 
myelin brain phospholipid and ganglioside content in EAE mice.  These data suggest that 
treatment alters CNS lipid content in mice subjected to EAE.  EAE injury results in a 
significant increase in cPLA2 levels, but treatment returned cPLA2 levels to control levels 
to suggest a role in modulating the pro-inflammatory lipid signaling.  In addition, 
treatment returned OMgp, a myelin protein, back to control levels, and acetate 
supplementation slightly increased FluoroMyelinTM intensity, a myelin lipid-affiliated 
stain, in the EAE mice compared to control-treated EAE mice.  These data suggest that 
treatment may alter myelin structure in this model.  On the other hand, treatment did not 
alter cytoskeletal structure changes due to the EAE injury suggesting acetate may not 
have a role in reversing all EAE pathology.  Acetate supplementation attenuated disease 
progression, altered CNS and myelin lipid content, and influenced CNS and myelin 







 Reagents, reagent grade solvents, and resorcinol reagent were from EMD 
(Gibbstown, NJ, USA), Macron Fine Chemicals (Radnor, PA, USA), Sigma (St. Louis, 
MO, USA), Calbiochem (Billerica, Massachusetts, USA), and Mallinckrodt Chemicals 
(St. Louis, MO, USA).  Thin layer chromatography plates (silica gel 60) were purchased 
from EMD (Gibbstown, NJ, US) and 1,2,3-triheptadecanoin, used as an internal standard 
for fatty acid analysis, was from Nu-Chek Prep (Elysian, MN, USA).  Myelin 
oligodendrocyte glycoprotein (MOG35-55) was purchased from AnaSpec (Fremont, CA, 
USA), and pertussis toxin was purchased from List Biological Laboratories (St. 
Campbell, CA, USA).  A SuperSignal West Femto chemiluminescent substrate was 
purchased from Thermo (Waltham, MA USA), and a femtoLUCENTTM PLUS HRP kit 
was purchased from Biosciences (Cat # 786-056, San Jose, CA, USA).  Materials and 
reagents needed for Western blot analysis were purchased from BioRad (Hercules, CA, 
USA).  Antibodies were purchased from Cell signaling (Beverly, MA, USA), Santa Cruz 
(Dallas, TX, USA), or Sigma (St. Louis, MO, USA).  Paraformaldehyde was purchased 
from Alfa Aesar (Haverhill, MA, USA), and microscope slides and coverslips were 
purchased from VWR (Chicago, IL, USA) and Brain Research Laboratories (Waban, 
MA, USA) respectively.  PolyFreeze was purchased from Sigma (St. Louis, MO, USA),
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 Triton X-100 was purchased from VWR (Chicago, IL, USA), and sucrose was purchased 
from EMD (Gibbstown, NJ, USA). 
 
Induction of EAE and Treatment 
 All animal procedures were performed under an approved UND animal protocol 
based on the National Institutes of Health Guidelines for the Care and Use of Laboratory 
Animals.  C57BL/6 female mice (Charles River Laboratories, Portage, MI, USA) were 
divided into groups of four mice per cage by our animal facility personnel.  After a one-
week acclimation period, the individual cages were assigned to 1 of 4 non-blinded 
treatment groups: EAE mice treated with water, EAE mice treated with glyceryl 
triacetate, control mice treated with water, and control mice treated with glyceryl 
triacetate in that order until all groups were represented.  These groups were arbitrarily 
assigned and not randomized.  In the morning of first experimental day within the animal 
facility, mice were treated with either water or glyceryl triacetate (4.0 g/kg body weight, 
once daily) by oral gavage.  Ten minutes after the initial treatment, EAE was induced 
with a subcutaneous injection of MOG35-55 (50 µg/mouse) dissolved in complete Freund’s 
adjuvant (Sigma, St Louis, MO, USA).  Two days after the inoculation, EAE mice 
received a second injection of pertussis toxin (200 ng, i.p.) (Kalyvas & David 2004).  
Control mice were treated with either glyceryl triacetate or water on the first 
experimental day however these mice did not receive the subcutaneous injection of 
complete Freund’s adjuvant or pertussis toxin.  These groups of mice were included to 
determine if changes in lipid content was due to treatment alone.  There are limitations in 
using control mice instead of sham-treated mice in that the immunization procedure with 
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adjuvant followed by pertussis toxin may introduce potential complicating effects.  All 
mice were treated at the same time daily with an oral gavage of either water or glyceryl 
triacetate (GTA, 4 g/kg body weight) until the end of the experimental timeframe.  To 
insure access to food, all mice subjected to EAE were given moistened food in petri 
dishes on the day the first animal demonstrated tail weakness and/or paralysis.  The 
moistened food was replaced daily until the end of the treatment period.  At the end of the 
treatment period, mice were anesthetized with pentobarbital (50 mg/kg, i.p., Virbac, Fort 
Worth, TX, USA) and euthanized by cardiac perfusion using heparinized (Baxter, 
Deerfield, IL, USA) phosphate buffered saline (PBS: 137mM NaCl, 2.7 mM KCl, and 
10mM phosphate (Na2HPO4/KH2PO4) at pH 7.4).  Mice used for histochemical analysis 
were subsequently perfused with 4% paraformaldehyde to fix the spinal cord for myelin 
staining.  The spinal cords and brains used for chemical analysis were dissected out of the 
animals, flash frozen in liquid nitrogen, and then stored at -80°C until use.  Spinal cords 
fixed with paraformaldehyde were stored in a 4% paraformaldehyde solution at 4⁰C until 
analysis.   
 
Myelin Staining 
 Before sectioning, spinal cords of control mice (n = 5), EAE mice treated with 
water (n = 4), and EAE mice treated with GTA (n = 5) were equilibrated overnight in 
30% sucrose dissolved in PBS.  20µm sections of the lumbar region of the spinal cord 
were made using an IEC cryostat, and a myelin stain was performed using 
FluoroMyelin™ Green (1:300, Molecular Probes, Eugene, OR, USA) based on 
manufacturer’s instructions.  Images were collected using an Olympus BX50 fluorescent 
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microscope equipped with Spot Advanced Imaging software (Version 3.4.5).  Values of 
the spinocerebellar and fasciculus length were reported as means ± SD for each group in 
units of mm. 
 
Behavioral Testing 
 During the treatment period, mice were evaluated daily for signs of paralysis and 
assigned a clinical score.  The assigned scores correspond to: 0; no symptoms, 1; flaccid 
tail, 2; mild hind limb weakness, 3; severe hind limb weakness, 4; hind limb paralysis, 
and 5; hind limb and forelimb paralysis (Kalyvas & David 2004).  All mice were 
acclimated to the hanging wire test on days 3-5 post-inoculation then tested at 4-5 day 
intervals up to day 36 to determine the impact treatment had on motor strength, balance, 
and grip strength.  The hanging wire test involves recording the duration (up to 60 sec) 
that an animal is able to hold onto to a wire mesh while being inverted approximately 15 
cm above a cushioned mat (Sango et al. 1996).  The sample size, described in Figure 3, 
was the total number of mice used for this analysis (n = 24).  In Figure 3, values were 
reported as means ± SD for each group per testing day.   
 
Total Spinal Cord and Brain Lipid Extraction 
 Frozen spinal cord and brain samples of control (n = 6, per treatment) and EAE 
mice (n = 8, per treatment) treated either water or GTA were weighed and then extracted 
in a glass Tenbroeck homogenizer using n-hexane: 2-propanol (3: 2 by volume) as 
described (Radin 1981, Bhatt & Rosenberger 2014).  The lipid extracts were collected 




Myelin Brain Lipid Extraction 
 Frozen brains of control (n=8), EAE mice treated with water (n=3), and EAE 
mice treated with GTA (n=8) were weighed and placed in large Wheaton homogenizers 
using a Telfon pestle.  After allowing the tissue to thaw to avoid freeze artifacts, 5mL of 
0.3M sucrose was added to homogenize tissue using Eberback Model 7265 ConTorque 
Tissue Homogenizer (Ann Arbor, MI).  Using 0.83M sucrose, 15mL was added to 
Beckman (Indianapolis, IN, USA) polycarbonate centrifuge tubes (Lot A60327, 
Indianapolis, IN, USA).  Then, the homogenized sample was slowly added to the 
centrifuge tubes with a 0.3M sucrose wash.  Similar weighted tubes was placed in a 
Beckman L8-60M ultracentrifuge (Indianapolis, IN, USA) at a speed of 30,000rpm at 
4⁰C for 30 minutes.  Before that, a ghost run was performed to bring the chamber to the 
appropriate temperature to avoid warming the samples.  Once the run was complete, the 
cloudy interface was removed and placed in a new Beckman centrifuge tube, and in these 
tubes, distilled water was added to wash out the sucrose.  Tubes were weighted and 
accurately balanced with a corresponding tube by adding distilled water.  Tubes were 
centrifuged at 30,000rpm at 4⁰C for 15 minutes, and supernatant fluid was discarded 
leaving the crude myelin pellet (Norton & Poduslo 1973, Autilio et al. 1964).  2mL of 
20mM Tris HCl at pH 7.45 at 4⁰C was added to the tubes to dissolve the pellet, and the 
sample was transferred to 16mm screw top test tubes to perform a Folch lipid extraction 
as previously described (Folch et al. 1957).  Lipid extracts were stored in hexane: 2-




Thin Layer Chromatography 
 Spinal cord and brain phospholipids were isolated using thin layer 
chromatography (20 x 20 cm, Merck silica gel 60 plates, EMD, Gibbstown, NJ) using a 
solvent system of chloroform/ methanol/ glacial acetic acid/ water (50: 37.5: 3: 2 by 
volume).  A second series of two-dimensional separations were performed to isolate the 
ethanolamine and choline plasmalogen from their parent glycerophospholipid fractions.  
This separation was performed on 10 x 10 cm thin layer chromatography plate using the 
solvent system described above in the first direction and chloroform/ methanol/ 
ammonium hydroxide (65: 25: 4, by volume) system in the second direction.  Between 
dimensions, the plates were exposed to hydrochloric acid fumes to hydrolyze the vinyl 
ether linkage found in the plasmalogen fractions.  Bands corresponding to 1-O-alkenyl-2-
acyl-sn-glycero-3-phosphoethanolamine (ethanolamine plasmalogen or PlsEtn), 1,2-
diacyl-sn-glycero-3-phosphoethanolamine  and 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine  (PtdEtn + PakEtn or phosphatidylethanolamine + 
plasmanylethanolamine), 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine (choline 
plasmalogen or PlsCho), 1,2-diacyl-sn-glycero-3-phosphocholine  and 1-O-alkyl-2-acyl-
sn-glycero-3-phosphocholine (PtdCho + PakCho or phosphatidylcholine + 
plasmanylcholine), 1,2-diacyl-sn-glycero-3-phosphoinositiol (PtdIns or 
phosphatidylinositol), 1,2-diacyl-sn-glycero-3-phosphoserine (PtdSer or 
phosphatidylserine), and sphingomyelin (CerPCho) were scraped from the plate and used 
to quantify either esterified fatty acid content or phospholipid content (Bhatt & 
Rosenberger 2014).  Neutral lipids were isolated using a solvent system of heptane/ 
isopropyl ether/ glacial acetic acid (60: 40: 4 by volume) on 20 x 20 cm silica gel 60 
34 
 
plates.  Bands corresponding to cholesterol and cholesteryl esters were scraped from the 
plates and used to quantify content (Breckenridge & Kuksis 1968).  Gangliosides were 
isolated on 20 x 20 cm silica gel 60 plates using a solvent system of chloroform/ 
methanol/ water (55:45:10 by volume).  Bands corresponding to standards were 
visualized with a resorcinol-HCl reagent following a heating step where plates were 
covered with a 20 x 20 cm glass plate and then heated to 105°C for 30 minutes (Ueno et 
al. 1978, Svennerholm 1957).   
 
Quantifying Phospholipid Content 
 The individual phospholipid bands were visualized with iodine vapor, scraped 
from the plate, and were quantified using a colorimetric lipid phosphorus assay (Rouser 
et al. 1969).  Sample and standard absorbance was measured on a DU 530 UV/VIS 
spectrophotometer (Beckman/Coulter) at 797 nm.  Sample concentration was assigned 
based on an external standard curve (3.125 to 400 nmol) and reported as the means ± SD 
in units of µmol/g wet weight.   
 
Quantifying Ganglioside Content 
 Individual ganglioside bands were scraped from the thin layer chromatography 
plates and transferred to screw top test tubes. Ganglioside content was quantified based 
on a resorcinol assay as previously described (Svennerholm 1957).  Absorbance was 
measured on a DU 530 UV/VIS spectrophotometer (Beckman/Coulter) at 450nm.  
Sample concentration was established based on an external standard curve of fructose 
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ranging in concentration from 14 to 1800nmol.  Results are reported as the means ± SD 
in units of µmol/g wet weight. 
 
Quantifying Esterified Fatty Acid Content 
 Esterified fatty acid content from individual phospholipid bands were visualized 
using 6-p-toluidino naphthalene sulfonic acid (62.6 mg in 200 mL 50 mM Tris, pH 7.4) 
under UV light.  Bands were transferred into screw top test tubes and then methylated 
using 2% sulfuric acid in toluene/ methanol (1: 1, by volume) for 120 minutes at 65°C 
using triheptadecanoin as an internal standard (Bhatt & Rosenberger 2014).  Fatty acids 
were extracted in n-hexane and quantified on a gas liquid chromatograph (Shimadzu) 
equipped with a flame ionization detector and a SP-2330 capillary column (Supelco, 
Bellefonte, PA, USA).  Peak area analysis of individual fatty acids was used to quantify 
fatty acid concentration using Simadzu EZStart software (build 14, version 7.2.1 SP1, 
Kyoto, Japan).  Values are reported as the means ± SD in units of µmol/g wet weight.   
 
Quantifying Cholesterol and Cholesteryl Ester Content 
 Individual cholesterol and cholesteryl ester bands were visualized using iodine 
vapor, were scraped from the plate, and were transferred into screw top test tubs.  
Cholesterol content was quantified using an iron binding colorimetric assay (Bowman & 
Wolf 1962).  Absorbance was measured on a DU 530 UV/VIS spectrophotometer 
(Beckman/Coulter) at 550 nm, and content was calculated based on an external standard 
curve (582-2.27µg to determine spinal cord lipid and 558.4-1.09 µg to determine brain 




 Frozen spinal cord samples of control mice (n = 8), EAE mice treated with water 
(n = 5), and EAE mice treated with GTA (n = 8) were transferred into small plastic vials 
containing ice-cold 50 mM Tris buffer pH = 8.0 containing 150 mM sodium chloride, 
1.0% Triton X-100, 0.5 % sodium deoxycholate, and 0.1 % sodium dodecyl sulfate with 
protease inhibitors (complete EDTA-free, Roche, Mannheim, Germany).  The samples 
were homogenized using a polytron, allowed to incubate for 2 h at 4°C, and centrifuged 
at 12,500 x g for 20 min at 4°C using a microfuge 22R centrifuge (Beckman Coulter, 
Indianapolis, IN, USA).  The supernatant was collected, divided into equal aliquots, and 
then stored at -80°C until use.   
 
Total Protein Determination 
 Protein concentration was determined based on a micro-Bradford assay (Bradford 
1976).  The absorbance was measured using Labsystem Multiskan Plus plate reader from 
Fisher Scientific at 595 nm, and protein concentration was determined based on an 
external standard curve (0.375 µg to 6 µg, bovine serum albumin). 
 
Western Blot Analysis 
 Phospholipase, β-actin, merlin (moesin-, ezrin-, radixin-like protein), 
oligodendrocyte myelin glycoprotein (OMgp), and lipid synthesis enzyme levels were 
measured using Western blot analysis (Soliman et al. 2013a, Soliman et al. 2013b, 
Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b). The lipid 
synthesis enzyme protein levels analyzed were alkylglycerone phosphate synthase 
37 
 
(AGPS), acyl-CoA synthetase (AceCS1, cytoplasmic & AceCS2, mitochondrial), and 
phosphorylated acetyl-CoA carboxylase (p-ACC).  Samples were separated on 7.5, 10, or 
12% SDS-PAGE gels using 25 µg of protein suspended in 6x loading buffer (10 % 2-
mercptoenthanol, 250mM Tris at pH6.3, 60 % glycerol, 6 % SDS, and 0.02 % 
bromophenol blue) at 100V for 2 h and then transferred to nitrocellulose membranes at 
100V for 1.5-2 h on ice.  To analyze OMgp protein, 100µg of protein was loaded onto a 
10% gel using the same procedure as described above.  A solution of 5 % defatted milk 
(MP Biomedicals, Solon, OH, USA) in TTBS (Tween Tris Base Solution, 20mM Tris, 
150mM NaCl, 0.05% Tween-20, pH 7.5) was used to block the membrane and during the 
incubation of primary antibodies targeting PLC β1, PLC δ1, β-actin, AGPS, AceCS1, 
AceCS2, merlin, OMgp, and p-ACC (overnight at 4oC).  Antibodies targeting cPLA2 and 
pcPLA2, membranes were incubated in 5% BSA in TTBS containing the primary 
antibody (overnight at 4⁰C).  The primary antibodies used were pcPLA2 (Cell signaling 
2832, rabbit IgG, 1:1000), cPLA2 (Cell signaling 2831, rabbit IgG, 1:1000), PLC β1 
(sc9050, rabbit IgG, 1: 500), PLC δ1 (sc30062, rabbit IgG, 1: 1,000), β-actin (A2228, 
mouse IgG2a, 1: 2,000), AGPS (sc374201, mouse 1gG, 1:1000), AceCS1 (sc85258, rabbit 
IgG, 1:2000), AceCS2 (sc85256, 1:1000, rabbit IgG), merlin (sc331, rabbit IgG, 1:1000), 
OMgp (sc271704, mouse IgG, 1:500), and p-ACC (Millipore 07-303, rabbit IgG, 
1:1000).  Membranes were washed with TTBS and then incubated with the secondary 
antibody for 2 hr at room temperature.  The secondary antibodies used were goat anti-
rabbit IgG HRP for phospholipase (sc2004, 1: 10,000), goat anti-mouse IgG2a HRP for β-
actin (sc2061, 1: 20,000), goat anti-mouse IgG HRP for AGPS (1:10,000) and OMgp 
(1:5000) (sc2005), goat anti-rabbit IgG HRP for AceCS2, merlin, and p-ACC (BioRad 
38 
 
170-5046, 1:10,000), and goat anti-rabbit IgG HRP for AceCS1 (BioRad 170-5046, 
1:5,000).  Chemiluminescent protein bands were visualized with a femto substrate 
(Thermo, Biosciences) using an Omega Lum G gel imaging station (Aplegen, San 
Francisco, CA, USA), and protein bands were quantified using UltraQuant software 
(Aplegen, Version 14.05.15).  The band intensity of all protein bands was normalized to a 
GAPDH loading control and reported as the mean ± SD (GAPDH: primary sc25778, 
rabbit IgG, 1:500 or 1:1000; secondary sc2004 or BioRad 170-5046, goat anti-rabbit IgG 
HRP, 1: 10,000) (Liu et al. 2015, Markoullis et al. 2012, Schiffmann et al. 2012). 
 
Statistical Analysis 
 A One-way ANOVA with a Tukey-Kramer multiple comparison posttest was 
used to calculate statistical differences (p ≤ 0.05) between the mean ± SD values of 
multiple groups.  Student’s t-test was used to quantify statistical difference between the 
mean ± SD values of intraday behavioral testing group.  All statistical analysis was 
performed using GraphPad InStat software (Ver. 3.0 for Windows, San Diego CA, USA) 
with statistical significance set at p ≤ 0.05.  To determine sample size for the experiments 






Increasing Acetyl-CoA Metabolism Attenuates Injury and Alters  
Spinal Cord Lipid Content in Mice Subjected to Experimental  
Autoimmune Encephalomyelitis 
 
Acetate Supplementation Attenuates Clinical Symptoms in Mice Subjected to EAE 
 Prior to and during the 40 day treatment period each mouse was assigned a daily 
clinical score based on the level of paralysis displayed (Kalyvas & David 2004) and 
weighed (Figure 3).  Mice were also subjected to a hanging wire test during the treatment 
period to test motor strength, coordination, and grip strength (Figure 3B).  We found that 
control-treated EAE mice developed tail paralysis on day 13 post-inoculation, 
experienced ascending paralysis that peaked on day 26, and remained consistent through 
the end of the treatment period having an averaged clinical score of 3.5 (severe hind limb 
weakness to hind limb paralysis) (Figure 3A).  Several of the glyceryl triacetate-treated 
EAE mice demonstrated tail paralysis on day 15, however as a group, none progressed 
beyond this stage of injury.  Of the glyceryl triacetate-treated EAE mice that 
demonstrated tail paralysis only one failed to regain full movement by the end of the 
treatment period.  On day 20 through the end of the treatment period, glyceryl triacetate-
treated EAE mice showed significantly less signs of injury and performed the hanging 
wire test significantly better than control-treated EAE mice (Figure 3B).  On days 20 




Figure 3: Behavioral analysis of mice subjected to EAE and treated with either water 
(H2O) or glyceryl triacetate (GTA) (4 g/kg).  Panel A shows the averaged effect treatment 
had on daily clinical scores, panel B shows the averaged effect treatment had on hanging 
wire test, and panel C shows the averaged changes in body weight measured throughout 
the treatment period.  Clinical score criteria described in panel A represents: 0, no 
paralysis, 1, flaccid tail, 2, mild hind limb weakness, 3, severe hind limb weakness, 4, 
hind limb paralysis, and 5, hind limb and forelimb paralysis.  All values report the means 
± SD and the asterisks represents a statistical difference (p ≤ 0.05) comparing water-
treated to glyceryl triacetate-treated EAE mice (n = 24, total).
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to support their body weight up-side-down for an average of 25 sec compared to 1-2 sec 
for control-treated EAE mice.  In addition, there was a significant reduction in the body 
weight between days 20 to 34 post-inoculation comparing control-treated to glyceryl 
triacetate-treated EAE mice (Figure 3C).  None of the control animals demonstrated 
changes in clinical symptoms associated with EAE (data not shown).  Therefore, these 
animals were not subjected to the hanging wire test and their body weights were not 
averaged into that data found in Figure 3C.  This body weight shift in EAE mice treated 
with water paralleled the increase in clinical score and reduction in hang-time.  As a 
whole, these data suggest acetate supplementation prevented the onset of clinical 
symptoms in mice subjected to EAE. 
 
EAE Results in a Reduction of Spinal Cord Phospholipid That Was Not Found in 
EAE Mice Treated With Glyceryl Triacetate 
 
 To investigate the impact treatment had  spinal cord lipid, we quantified 
phospholipid content in whole spinal cords from control and EAE mice treated with 
either water or glyceryl triacetate.  Table 1 shows the spinal cord phospholipid levels 
(µmol/g wet weight) of the primary phospholipid groups: EtnGpl, PtdIns, PtdSer, 
ChoGpl, and CerPCho.  Mice subjected to EAE and given a control treatment showed a 
30% reduction in the levels of EtnGpl, ChoGpl, and CerPCho compared to control mice 
treated with water or glyceryl triacetate.  Further, EAE resulted in a 24% reduction in 
PtdSer compared to control mice given glyceryl triacetate (Table 1A).  More importantly, 
the phospholipid levels in mice subjected to EAE and treated with glyceryl triacetate did 
not differ compared to either group of control mice.  The levels of EtnGpl, PtdSer, and
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Table 1: Spinal cord phospholipid content of control and EAE mice treated with either 
water or glyceryl triacetate. 
A Control (n=6) EAE (n=8) 
Phospholipid H2O-treated GTA-treated H2O-treated GTA-treated 
  
 µmol/g wet weight 
EtnGpl 15.9 ± 1.1 15.7 ± 2.3 a11.9 ± 1.7 c16.1 ± 3.9 
PtdIns 3.6 ± 0.7 3.9 ± 0.8 2.9 ± 0.5 3.5 ± 0.7 
PtdSer 10.7 ± 1.1 11.9 ± 0.8 b9.1 ± 0.7 c12.2 ± 1.7 
ChoGpl 20.3 ± 1.2 20.6 ± 1.9 a,b13.5 ± 2.0 c18.1 ± 3.9 
CerPCho 8.6 ± 1.1 8.1 ± 0.9 a,b6.3 ± 1.2 7.1 ± 1.0 
     
B µmol/g wet weight 
PtdEtn+PakEtn 7.4 ± 0.6 7.1 ± 1.0 a5.4 ± 0.6 a,b,c10.3 ± 2.0 
PlsEtn 8.5 ± 1.2 8.6 ± 1.4 6.5 ± 1.6 a,b5.8 ± 2.2 
PtdCho+PakCho 14.8 ± 0.8 14.8 ± 1.9 a,b10.8 ± 1.8 c15.5 ± 3.7 
PlsCho 5.5 ± 1.5 5.8 ± 0.8 a,b2.7 ± 0.7 a,b2.6 ± 0.6 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, EtnGpl, ethanolamine glycerophospholipid, PtdEtn + PakEtn, 
1,2-diacyl-sn-glycero-3-phosphoethanolamine  and 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine or phosphatidylethanolamine and plasmanylethanolamine, PlsEtn, 
1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine or ethanolamine plasmalogen, 
PtdIns, phosphatidylinositol, PtdSer, phosphatidylserine, ChoGpl, choline 
glycerophospholipid, PtdCho + PakCho, 1,2-diacyl-sn-glycero-3-phosphocholine  and 1-
O-alkyl-2-acyl-sn-glycero-3-phosphocholine or phosphatidylcholine and 
plasmanylcholine, PlsCho, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine or choline 
plasmalogen, and CerPCho, sphingomyelin.  The letters indicate statistical significance 
(p ≤ 0.05) where “a” represent comparisons made to water-treated control mice, “b” 
represent comparisons made to glyceryl triacetate-treated control mice, and “c” represent 
comparisons made to water-treated EAE mice.  
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ChoGpl in the EAE-glyceryl triacetate group were significantly higher compared to mice 
subjected to EAE and treated with water (Table 1A).  Analysis was performed to isolate 
the plasmalogen fractions from EtnGpl and ChoGpl.  Treatment significantly increased 
the levels of PtdEtn + PakEtn compared to all groups and returned PtdCho + PakCho 
fraction to control levels (Table 1B).  Treatment did not result in the recovery of the 
PlsEtn and PlsCho fractions to control levels.  These data suggest that increasing CNS 
acetyl-CoA metabolism may either prevent or reverse the loss of spinal cord phospholipid 
in mice subjected to EAE. 
 
Acetate Supplementation Modulates Spinal Cord Fatty Acid Content in Mice 
Subjected to EAE 
 
 To determine if increasing acetyl-CoA metabolism altered fatty acid metabolism, 
we measured esterified fatty acid content in control and EAE mice treated with either 
water or glyceryl triacetate.  Similar to that found in vitro (Bhatt & Rosenberger 2014), 
acetate supplementation did not alter the esterified fatty acid content in control mice 
(Tables 2 and 3).  However, EAE resulted in a significant reduction in the content of 
palmitic (16:0), stearic (18:0), oleic (18:1n-9 + n-7), arachidonic (20:4n-6), and 
docosatetraenoic (22:4n-6) acids in the EtnGpl and ChoGpl fractions (Table 2).  
Treatment with glyceryl triacetate however prevented the decrease in these fatty acids, 
returning their levels to that found in control mice.  Interestingly in mice subjected to 
EAE, esterified fatty acid content in PtdSer demonstrated only reductions in palmitic 
(16:0) and arachidonic (20:4n-6) acids with a significant increase in docosatetraenoic 
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Table 2: Spinal cord esterified fatty acid content in ethanolamine and choline 
glycerophospholipid from control and EAE mice treated with either water or glyceryl 
triacetate.  
 Control (n=6) EAE (n=8) 
Fatty acid H2O-treated GTA-treated H2O-treated GTA-treated 
  
EtnGpl µmol/g wet weight 
16:0 1.3 ± 0.1 1.3 ± 0.2 a,b0.7 ± 0.08 c1.2 ± 0.2 
18:0 4.2 ± 0.3 4.2 ± 0.4 a,b2.9 ± 0.4 c4.2 ± 0.7 
18:1n-9 + n-7 9.5 ± 0.6 10.1 ± 1.1 a,b6.3 ± 0.8 c9.2 ± 1.5 
20:1n-9 3.7 ± 0.6 3.8 ± 0.5 3.0 ± 0.6 c4.8 ± 1.0 
20:4n-6 2.2 ± 0.1 2.2 ± 0.2 a,b1.7 ± 0.2 c2.3 ± 0.4 
22:4n-6 1.7 ± 0.1 1.6 ± 0.1 a,b1.2 ± 0.2 c1.8 ± 0.4 
22:6n-3 3.2 ± 0.2 3.0 ± 0.4 2.3 ± 0.4 c3.4 ± 0.9 
Total 31.3 ± 2.0 31.9 ± 3.2 a,b20.9 ± 2.6 c31.0 ± 5.2 
     
ChoGpl µmol/g wet weight 
16:0 5.0 ± 1.7 5.1 ± 1.6 a,b3.1 ± 0.3 4.6 ± 0.8 
18:0 4.1 ± 0.4 4.3 ± 0.7 a,b3.0 ± 0.3 c4.4 ± 0.8 
18:1n-9 + n-7 9.2 ± 0.5 9.6 ± 1.1 a,b6.6 ± 0.5 c9.8 ± 1.5 
20:1n-9 0.9 ± 0.1 1.0 ± 0.3 0.7 ± 0.1 c1.2 ± 0.03 
20:4n-6 0.6 ± 0.1 0.6 ± 0.09 0.6 ± 0.04 0.6 ± 0.13 
22:4n-6 0.1 ± 0.1 0.09 ± 0.02 0.08 ± 0.007 0.1 ± 0.03 
22:6n-3 1.0 ± 0.2 1.0 ± 0.2 0.8 ± 0.07 c1.1 ± 0.2 
Total 22.9 ± 1.2 24.2 ± 2.2 a,b16.1 ± 1.1 c23.8 ± 3.3 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, EtnGpl, ethanolamine glycerophospholipid and ChoGpl, 
choline glycerophospholipid.  The letters indicate statistical significance (p ≤ 0.05) where 
“a” represent comparisons made to water-treated control mice, “b” represent comparisons 




Table 3: Spinal cord esterified fatty acid content in phosphatidylserine and 
sphingomyelin from control and EAE mice treated with either water or glyceryl 
triacetate. 
 Control (n=6) EAE (n=8) 
Fatty acid H2O-treated GTA-treated H2O-treated GTA-treated 
  
PtdSer µmol/g wet weight 
16:0 0.2 ± 0.04 0.2 ± 0.06 a,b0.04 ± 0.01 a,b0.08 ± 0.03 
18:0 5.7 ± 0.7 5.8 ± 1.0 6.5 ± 0.4 a,b,c8.4 ± 1.5 
18:1n-9 + n-7 4.0 ± 0.5 4.4 ± 0.7 4.0 ± 0.4 a,c5.5 ± 1.0 
20:1n-9 1.2 ± 0.2 1.3 ± 0.4 1.9 ± 0.4 a,b,c2.8 ± 0.7 
20:4n-6 0.2 ± 0.04 0.2 ± 0.04 a,b0.04 ± 0.06 a,b0.4 ± 0.07 
22:4n-6 0.3 ± 0.08 0.3 ± 0.08 a0.4 ± 0.07 a,b0.5 ± 0.1 
22:6n-3 0.8 ± 0.2 0.7 ± 0.2 0.9 ± 0.2 a,b1.2 ± 0.3 
Total 15.7 ± 3.0 16.2 ± 2.3 17.7 ± 1.6 a,b,c22.9 ± 4.7 
     
CerPCho µmol/g wet weight 
16:0 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.4 ± 0.2 
18:0 0.9 ± 0.1 1.0 ± 0.2 a,b0.4 ± 0.06 a,b0.6 ± 0.07 
18:1n-9 + n-7 0.4 ± 0.1 0.4 ± 0.07 0.3 ± 0.07 0.4 ± 0.2 
24:0 0.4 ± 0.2 0.5 ± 0.1 a,b0.1 ± 0.03 a,b0.2 ± 0.03 
24:1n-9 0.8 ± 0.3 1.0 ± 0.3 a,b0.3 ± 0.06 a,b0.5 ± 0.08 
Total 4.5 ± 1.0 5.0 ± 1.1 a,b2.1 ± 0.3 a,b3.0 ± 0.6 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, PtdSer, phosphatidylserine and CerPCho, sphingomyelin.  The 
letter indicates statistical significance (p ≤ 0.05) where “a” represent comparisons made 
to water-treated control mice, “b” represent comparisons made to glyceryl triacetate-
treated control mice, and “c” represent comparisons made to water-treated EAE mice.
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(22:4n-6) acid (Table 3).  Moreover, treatment with glyceryl triacetate resulted in a 
significant 15% increase in all fatty acids reported with the exception of palmitic acid 
which remained significantly decreased compared to control mice.  With regard to 
CerPCho, EAE resulted in the significant reduction in stearic (18:0), lignoceric (24:0), 
and nervonic (24:1n-9) acids compared to control mice.  The content of these fatty acids 
remained significantly lower in EAE mice treated with glyceryl triacetate (Table 3), 
suggesting an increase in acetyl-CoA metabolism did not alter the incorporation or 
turnover of N-acyl derived fatty acids associated with ceramide synthesis.  Overall, these 
data suggest EAE resulted in a significant decrease in lipid and fatty acid content which 
parallels injury severity.  Treatment with glyceryl triacetate however returned the 
esterified fatty acid content in EtnGpl and ChoGpl to control levels, significantly 
increased content of fatty acids in PtdSer, but had no effect on fatty acid content found in 
CerPCho in EAE mice.  All of which suggests increasing acetyl-CoA metabolism in mice 
subjected to EAE may result in an increase in acetyl-CoA being utilized for the synthesis 
of esterified fatty acid that may possibly offset that lost to injury. 
 
Acetate Supplementation Prevents the Loss of Cholesterol in EAE Mice but Does 
Not Alter the EAE-Induced Decrease in Cholesteryl Esters 
 
 Similar to that found with measuring spinal cord phospholipid content, EAE 
significantly decreased the content of spinal cord cholesterol (Figure  4A) and cholesteryl 
esters (Figure 4B) compared to control mice treated with either water or glyceryl 
triacetate.  Treatment with glyceryl triacetate significantly increased the content of 
cholesterol in mice subjected to EAE compared to EAE mice treated with water but was 




Figure 4: Spinal cord cholesterol and cholesteryl ester content in control mice (n=6, per 
treatment) and EAE (n=8, per treatment) mice treated with either water (H2O) or glyceryl 
triacetate (GTA) (4g/kg).  Panel A shows spinal cord content of cholesterol, and panel B 
shows spinal cord content of cholesteryl ester.  Significant differences (p ≤ 0.05) are 
indicated with a letter where “a” represent comparisons made to control mice treated with 
water, “b” represent comparisons made to control mice treated with glyceryl triacetate, 
and “c” represent comparisons made to EAE mice treated with water.
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groups of mice subjected to EAE and treated with either water or glyceryl triacetate 
demonstrated a significant reduction in cholesteryl ester levels compared to control mice 
treated with either water or glyceryl triacetate.  These data suggest, similar to the 
esterified fatty acid content studies, increasing acetyl-CoA metabolism may act to restore 
spinal cord cholesterol content to control levels but had no effect on cholesteryl ester 
content. 
 
Acetate Supplementation Alters Spinal Cord Ganglioside Content in Mice Subjected 
to EAE 
 
 Figure 5 shows spinal cord ganglioside content in control and EAE mice treated 
with either water or glyceryl triacetate.  GD3 content was significantly decreased in 
response to EAE when compared to control mice (Figure 5A).  Acetate supplementation 
on the other hand resulted in a significant increase in GD3 content when compared to 
control mice treated with glyceryl triacetate and EAE mice treated with water.  Further, 
GD1a content was significantly decreased in animals subjected to EAE when compared 
to control animals (Figure 5B).  Acetate supplementation significantly increased GD1a 
levels in EAE mice compared to mice subjected to EAE and treated with water, but this 
increase was significantly less than that found in control animals.  GM1 levels were 
significantly decreased in both EAE groups (Figure 5C).  In addition, there were 
significant decreases in GT1a, GD2, GD1b, and GQ1b levels in mice subjected to EAE 
that remained decreased with treatment (Figure 5D).  Overall, acetate supplementation 





Figure 5: Spinal cord ganglioside content in control (n=6, per treatment) and EAE (n=8, 
per treatment) mice treated with either water (H2O) or glyceryl triacetate (GTA) (4g/kg).  
Panel A shows the spinal cord content of GD3, panel B shows the spinal cord content of 
GD1a, panel C shows spinal cord content of GM1, and panel D shows the spinal cord 
content of GT1a, GD2, GD1b, and GQ1b.  Significant differences (p ≤ 0.05) are 
indicated with a letter where “a” represent comparisons made to control mice treated with 
water, “b” represent comparisons made to control mice treated with glyceryl triacetate, 
and “c” represent comparisons made to EAE mice treated with water.
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Acetate Supplementation Returns Cytosolic Phospholipase A2 (cPLA2) to Baseline 
but EAE and Treatment Did Not Alter Phospholipase C (PLC) Levels 
 
 In peripheral nerve cell cultures, an alteration in actin polymerization is associated 
with myelin fragmentation (Jung et al. 2011) and is increased in Lewis rats subjected to 
EAE during the chronic injury phase (Smerjac & Bizzozero 2008).  To determine the 
impact injury and treatment had on β-actin in the mouse, we measured its levels in spinal 
cord of control and EAE mice treated with either water or glyceryl triacetate.  We found 
mice subjected to EAE and treated with water resulted in a significant 2-fold increase in 
β-actin levels when normalized to GAPDH (Figure 6F) consistent with the demyelinating 
injury.  In EAE animals treated with glyceryl triacetate, we found a slight decrease in β-
actin levels that was not significantly different from control or EAE mice treated with 
water.  These data, as expected, suggest EAE in the mouse increases β-actin levels (Jung 
et al. 2011, Smerjac & Bizzozero 2008).  However, the decrease in β-actin in the glyceryl 
triacetate-treated EAE mice suggests that treatment may not completely reverse all 
aspects of injury associated with EAE despite the clear reduction in the onset of clinical 
signs in this model.  β-actin alone is not a direct measure of neuronal injury, and future 
experiments will understand changes in other structural proteins like Cofilin 1 (Tilve et 
al. 2015) in this model.   
 Figure 6A-E shows spinal cord phospholipase protein levels in control mice and 
mice subjected to EAE treated with either water or glyceryl triacetate.  These data show 
that in control-treated EAE mice, there was a significant increase in phosphorylated 
(pcPLA2) and non-phosphorylated cPLA2 when normalized to GAPDH (Figure 6A and 
6B).  Similar to that found in cell culture (Soliman et al. 2013b), acetate supplementation 





Figure 6: Changes in spinal cord phospholipase and β-actin levels normalized to GAPDH 
in control and EAE mice.  Panel A shows changes in spinal cord phosphorylated cytosolic 
phospholipase A2 (pcPLA2) levels, panel B shows changes in cPLA2 levels, panel C 
shows the ratio of pcPLA2 to total cPLA2, panel D shows changes in phospholipase C 
(PLC) β levels, panel E shows changes in PLC δ levels, and panel F shows changes in β-
actin levels.  Sample size is n=8 for control, n=5 for EAE mice treated with water (H2O), 
and n=8 for EAE mice treated with glyceryl triacetate (GTA).  Significance differences (p 
≤ 0.05) are indicated by a letter where “a” represent comparisons made to control mice 
and “b” represent comparisons made to EAE mice treated with water.
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control animals.  In addition, the ratio of pcPLA2 to total cPLA2, did not change between 
the three groups analyzed suggesting at 40 days post-inoculation the phosphorylation 
state of cPLA2 was not increased (Figure 6C).  Because the ratio of pcPLA2/cPLA2 was 
not changed in those samples measured, the physiological significance regarding total 
PLA2 enzymatic activity and cellular localization within the spinal cord remains to be 
determined and a subject for future studies.  Further, neither EAE nor treatment altered 
spinal cord protein levels of phospholipase C (PLC) β and PLC δ when normalized to 
GAPDH as shown in Figures 6D and E, respectively.  These results suggest, similar to 
that reported (Kalyvas & David 2004), cPLA2 may play a greater role in EAE-mediated 
demyelination compared to PLC and that acetate supplementation with glyceryl triacetate 
may attenuate PLA2-mediated lipid signaling.  
 
Acetate Supplementation Slightly Increases FluoroMyelinTM Intensity in Mice 
Subjected to EAE 
 
 A histochemical analysis was performed using FluoroMyelin™ green to visualize 
changes in myelin content from lumbar regions of the spinal cord in control, EAE, and 
EAE mice treated with glyceryl triacetate.  Low magnification (40x) results show very 
distinct FluoroMyelin™ staining along the outer edges of the spinal cord in the 
spinocerebellar and fasciculus regions that was decreased in intensity in samples taken 
from mice subjected to EAE (Figure 7A-C).  High magnification (400X) analysis of 
control samples show that fluorescent staining is confined within a tight band along the 
outer surface on the spinal cord (ventral spinocerebellar track) with distinct vertical 
striations (Figure 7D).  The intensity of fluorescent staining was reduced in animals 
subjected to EAE in this region having a diffuse outer band with no apparent vertical 
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striations (Figure 7E).  EAE animals treated with glyceryl triacetate demonstrated 
fluorescent intensity similar to that found in control animals having an outer band with 
some vertical striations (Figure 7F).  Figure 7G shows the average length measured of the 
spinocerebellar and fasciculus region of control, EAE mice, and EAE mice treated with 
glyceryl triacetate.  These data show a decrease in the spinocerebellar/fasciculus length 
comparing control to EAE mice that had an insignificant recovery with glyceryl triacetate 
treatment.  These data suggest glyceryl triacetate may be positively influencing myelin 




Figure 7: FluoroMyelin™ stain of 20 µM lumbar spinal cord sections taken from control 
(Panels A & D), EAE mice (Panels B & E), and EAE mice treated with glyceryl triacetate 
(GTA, Panels C & F).  In Panel A, the bar indicates a length of 0.1mm at 40x 
magnification that is applicable to panels A-C.  In panel D, the bar indicates a length of 
0.1mm at 400x magnification (panels D-F).  Panel G shows the average length of the 
spinocerebellar and fasciculus region in control (n = 5), EAE mice (n = 4), and EAE mice 






Increasing Acetyl-CoA Metabolism Alters Spinal Cord Phosphatidylinositol 
Palmitic and Oleic Acid Levels in Mice Subjected to Experimental Autoimmune 
Encephalomyelitis 
 
Acetate Supplementation Alters Esterified Fatty Acid Content in 
Phosphatidylinositol of EAE Mice 
 
 Acetate supplementation altered spinal cord saturated and unsaturated fatty acid 
content in EtnGpl, ChoGpl, and PtdSer in EAE mice (Chevalier & Rosenberger 2017) 
(Tables 2 and 3).  Table 4 shows spinal cord esterified fatty acid content in PtdIns from 
control and EAE mice treated with either water or glyceryl triacetate.  Treatment with 
glyceryl triacetate showed a significant increase in palmitic acid (16:0) in EAE mice 
compared to control mice treated with water (102%), control mice treated with glyceryl 
triacetate (34%), and EAE mice treated with water (36%).  In addition, treatment showed 
a significant 47% increase in oleic acid (18:1n-9) in EAE mice compared to EAE mice 
treated with water. The EAE injury resulted in a significant decrease in stearic acid (18:0) 
compared to control mice treated with water (59%) and glyceryl triacetate (54%).  
However, treatment was not able to recover levels back to that found in controls.  
Furthermore, there was a significant 55-58% decrease in total fatty acid content due to 
the EAE injury, which again was not returned to control levels following treatment.  
Overall, these data suggest acetate supplementation alters PtdIns palmitic and oleic acid
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 content in mice subjected to EAE suggesting that treatment alters spinal cord fatty acid 
content in mice subjected to EAE. 
 
Table 4: Spinal cord esterified fatty acid content in phosphatidylinositol from control and 
EAE mice treated with either water or glyceryl triacetate. 
 Control (n=6) EAE (n=8) 
Fatty acid H2O-treated GTA-treated H2O-treated GTA-treated 
  
PtdIns µmol/g wet weight 
16:0 0.08 ± 0.02 0.1 ± 0.03 0.1 ± 0.02 a,b,c0.2 ± 0.04 
18:0 1.7 ± 0.2 1.5 ± 0.2 a,b0.7 ± 0.1 a,b0.9 ± 0.1 
18:1n-9 + n-7 0.4 ± 0.1 0.5 ± 0.1 b0.3 ± 0.05 c0.5 ± 0.1 
20:1n-9 0.1 ± 0.01 a0.04 ± 0.03 a0.02 ± 0.003 a0.03 ± 0.008 
20:4n-6 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.1 0.6 ± 0.1 
22:4n-6 0.05 ± 0.01 0.05 ± 0.02 0.04 ± 0.009 0.05 ± 0.009 
22:6n-3 0.3 ± 0.1 0.2 ± 0.1 0.2 ± 0.03 0.2 ± 0.04 
Total 6.2 ± 1.1 5.8 ± 1.6 a,b2.6 ± 0.3 a,b3.5 ± 0.5 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, and PtdIns, phosphatidylinositol.  The letter indicates statistical 
significance (p ≤ 0.05) where “a” represent comparisons made to water-treated control 
mice, “b” represent comparisons made to glyceryl triacetate-treated control mice, and “c” 






Increasing Acetyl-CoA Metabolism Increases Total Brain and  
Brain Myelin Lipid Content in Mice Subjected to Experimental  
Autoimmune Encephalomyelitis 
 
Acetate Supplementation Increases Total Brain Phospholipid Levels in Mice 
Subjected to EAE 
 
 Table 5 shows total brain phospholipid in control (n=6) and EAE mice (n=8) 
treated with either water or glyceryl triacetate.  There was no significant difference in 
EtnGpl, PtdSer, ChoGpl, and CerPCho content between the two control groups, also 
shown in the EAE spinal cord phospholipid data (Chevalier & Rosenberger 2017) (Table 
1).  There was no significant decrease in these phospholipid levels due to the EAE injury.  
Regarding total brain PtdIns, there was a significant decrease in phospholipid content in 
EAE mice treated with water and control mice treated with glyceryl triacetate compared 
to control mice treated with water, but treatment was unable to significantly alter PtdIns 
content between the two EAE groups.  We did not expect to show significant changes in 
brain lipid content due to the EAE injury because this injury is considered a spinal cord 
disease (Batoulis et al. 2011, Ransohoff 2012, Simmons et al. 2013).  Regarding 
CerPCho content (Table 5A), there was no significant differences between all groups.  
EAE resulted in a significant decrease in PtdIns compared to water- treated control mice, 
but treatment was unable to increase lipid levels (Table 5A).  Interestingly, acetate 
supplementation significantly increased PtdSer in EAE mice compared to EAE mice 
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Table 5: Total brain phospholipid content of control and EAE mice treated with either 
water or glyceryl triacetate. 
A Control (n=6) EAE (n=8) 
Phospholipid H2O-treated GTA-treated H2O-treated GTA-treated 
  
 µmol/g wet weight 
EtnGpl 15.3 ± 1.4 15.3 ± 1.6 15.6 ± 1.3 16.9 ± 1.0 
PtdIns 2.0 ± 0.1 a1.7 ± 0.2 a1.7 ± 0.2 1.9 ± 0.1 
PtdSer 5.8 ± 0.4 5.7 ± 0.7 5.6 ± 0.3 c6.3 ± 0.3 
ChoGpl 16.3 ± 1.0 16.3 ± 1.5 16.7 ± 1.2 a,b,c18.2 ± 0.5 
CerPCho 3.4 ± 0.6 2.7 ± 0.7 2.9 ± 0.6 3.3 ± 0.45 
     
B µmol/g wet weight 
PtdEtn+PakEtn 7.1 ± 0.7 7.3 ± 0.7 7.1 ± 0.5 7.9 ± 0.5 
PlsEtn 8.2 ± 0.8 8.0 ± 1.0 8.5 ± 0.9 8.9 ± 0.6 
PtdCho+PakCho 14.4 ± 0.7 14.6 ± 1.3 14.8 ± 0.9 a,b,c16.5 ± 0.5 
PlsCho 1.9 ± 0.9 1.7 ± 0.3 1.9 ± 0.4 1.7 ± 0.2 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, EtnGpl, ethanolamine glycerophospholipid, PtdEtn + PakEtn, 
1,2-diacyl-sn-glycero-3-phosphoethanolamine  and 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine or phosphatidylethanolamine and plasmanylethanolamine, PlsEtn, 
1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine or ethanolamine plasmalogen, 
PtdIns, phosphatidylinositol, PtdSer, phosphatidylserine, ChoGpl, choline 
glycerophospholipid, PtdCho + PakCho, 1,2-diacyl-sn-glycero-3-phosphocholine  and 1-
O-alkyl-2-acyl-sn-glycero-3-phosphocholine or phosphatidylcholine and 
plasmanylcholine, PlsCho, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine or choline 
plasmalogen, and CerPCho, sphingomyelin.  Statistical significance (p ≤ 0.05) is 
indicated by a letter:  “a” significant to water-treated control mice, “b” significant to 
glyceryl triacetate-treated control mice, and “c” significant to water-treated EAE mice.
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treated with water (Table 5A).  There was no significant difference in EtnGpl, PtdEtn + 
PakEtn, and PlsEtn between all control and EAE animals.  However, treatment with 
glyceryl triacetate resulted in a significant increase in ChoGpl levels in EAE mice.  
Regarding subgroups of ChoGpl, treatment significantly increasedPtdCho + PakCho 
levels in mice subjected to EAE but had no effect on PlsCho (Table 5A and 5B) similar 
to the spinal cord data (Chevalier & Rosenberger 2017) (Table 1).  Acetate 
supplementation increased total brain PtdSer and ChoGpl in particular PtdCho + PakCho 
content in mice subjected to EAE.  
 
Acetate Supplementation Increases Brain Myelin Phosphatidylinositol in Mice 
Subjected to EAE 
 
 Table 6 shows myelin brain phospholipid in control mice (n=8), EAE mice treated 
with water (n=3), and EAE mice treated with glyceryl triacetate (n=8).  There was no 
significant difference between all groups in PtdSer and CerPCho (Table 6A).  Treatment 
with glyceryl triacetate significantly increased PtdIns in EAE mice compared to water-
treated EAE mice.  EAE injury resulted in a significant decrease in PlsEtn and ChoGpl in 
particular the PtdCho + PakCho fraction, but treatment was unable to significantly 
increase lipid levels (Table 6A and 6B).  EAE injury resulted in a significant decrease in 
particular brain lipids (Table 6B) even though EAE is considered a spinal cord disease 
(Batoulis et al. 2011, Ransohoff 2012, Simmons et al. 2013).  One possible explanation is 
that PlsEtn is prominently found in myelin (Morell 1984), and we would expect the EAE 
injury would result in a decrease in myelin lipid.  Acetate supplementation increased 
brain myelin PtdIns in mice subjected to EAE.  
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Table 6: Myelin brain phospholipid content of control, EAE mice treated with water, and 
EAE mice treated with glyceryl triacetate. 
A  
Phospholipid H2O-treated Control H2O-treated EAE 
GTA-treated 
EAE 
 µmol/g wet weight 
EtnGpl 5.6 ± 0.8 4.0 ± 0.3 5.0 ± 1.0 
PtdIns 0.4 ± 0.1 0.3 ± 0.1 b0.5 ± 0.1 
PtdSer 1.7 ± 0.2 1.2 ± 0.1 1.7 ± 0.4 
ChoGpl 5.2 ± 0.9 a3.5 ± 0.2 4.3 ± 0.8 
CerPCho 0.8 ± 0.1 0.6 ± 0.1 0.8 ± 0.2 
B µmol/g wet weight 
PtdEtn + PakEtn 1.8 ± 0.3 1.3 ± 0.01 1.7 ± 0.5 
PlsEtn 3.8 ± 0.6 a2.7 ± 0.3 3.3 ± 0.6 
PtdCho + PakCho 4.1 ± 0.7 a2.7 ± 0.1 3.4 ± 0.8 
PlsCho 1.1 ± 0.3 8.4 ± 0.08 8.8 ± 0.2 
 
Values represent the means ± SD in units of µmol/g wet weight.  Abbreviations are: 
GTA, glyceryl triacetate, EtnGpl, ethanolamine glycerophospholipid, PtdEtn + PakEtn, 
1,2-diacyl-sn-glycero-3-phosphoethanolamine  and 1-O-alkyl-2-acyl-sn-glycero-3-
phosphoethanolamine or phosphatidylethanolamine and plasmanylethanolamine, PlsEtn, 
1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine or plasmalogen ethanolamine, 
PtdIns, phosphatidylinositol, PtdSer, phosphatidylserine, ChoGpl, choline 
glycerophospholipid, PtdCho + PakCho, 1,2-diacyl-sn-glycero-3-phosphocholine  and 1-
O-alkyl-2-acyl-sn-glycero-3-phosphocholine or phosphatidylcholine and 
plasmanylcholine, PlsCho, 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine or 
plasmalogen choline, and CerPCho, sphingomyelin.  Statistical significance (p ≤ 0.05) is 




Acetate Supplementation Had No Effect on Brain Cholesterol and Cholesteryl  Ester 
Content in Mice Subjected to EAE 
 
 Figure 8 shows brain myelin cholesterol and cholesteryl esters in control mice 
(n=8), EAE mice treated with water (n=3), and EAE mice treated with glyceryl triacetate 
(n=8).  This figure also shows total brain cholesterol and cholesteryl esters in control 
(n=6) and EAE (n=8) mice treated with either water or glyceryl triacetate.  There was no 
significant difference in myelin cholesterol and cholesteryl esters between all groups 
(Figure 8A & 8C).  In addition, there was no significant difference in total brain 
cholesteryl esters between all groups (Figure 8D).  There was a significant increase in 
total brain cholesterol in the EAE groups compared to water-treated control mice, but 
treatment did not alter total brain cholesterol between the two EAE groups (Figure 8B).  
Acetate supplementation did not alter brain cholesterol and cholesteryl ester levels in 
mice subjected to EAE. 
 
Acetate Supplementation Increases Total Brain GD3 Ganglioside and Brain Myelin 
GM1 Ganglioside Content in Mice Subjected to EAE 
 
 Figure 9 shows total brain ganglioside content in control (n=6) and EAE (n=8) 
mice treated with either water or glyceryl triacetate.  There was no significant difference 
in GM1, GD1a, and the remaining fraction (GT1a, GD2, GD1b, and GQ1b) between all 
groups (Figure 9B-D).  Treatment with glyceryl triacetate significantly increased total 
brain GD3 ganglioside content in EAE mice compared to control-treated EAE mice 
(Figure 9A).  Figure 10 shows myelin brain ganglioside content in control mice (n=8), 





Figure 8: Brain myelin (A and C) and total brain (B and D) cholesterol (A and B) and 
cholesteryl ester (C and D) content in control and EAE mice.  Sample number for panels 
A and C are n=8 for control mice, n=3 for EAE mice treated with water (H2O), and n=8 
for EAE mice treated with glyceryl triacetate (GTA) (4g/kg).  Sample number for panels 
B and D are n=6 for each control group and n=8 for each EAE group.  Regarding panels 
A and C, significance (p≤0.05) is indicated by a letter: “a” significant to control mice 
treated with water and “b” significant to EAE mice treated with water.  Regarding panels 
B and D, significance (p≤0.05) is indicated by a letter: “a” significant to control mice 
treated with water, “b” significant to control mice treated with glyceryl triacetate, and “c” 





Figure 9: Total brain ganglioside content in control (n=6, per treatment) and EAE (n=8, 
per treatment) mice treated with water (H2O) and glyceryl triacetate (GTA) (4g/kg).  
Panel A shows GD3, panel B shows GM1, panel C shows GD1a, and panel D shows the 
remaining fraction (combination of GT1a, GD2, GD1b, and GQ1b).  Significance 
(p≤0.05) is indicated by a letter: “a” significant to control mice treated with water, “b” 
significant to control mice treated with glyceryl triacetate, and “c” significant to EAE 





Figure 10: Brain myelin ganglioside content in control mice (n=8), EAE mice treated 
with water (n=3, H2O), and EAE mice treated with glyceryl triacetate (GTA, n=8) 
(4g/kg).  Panel A shows GM1, panel B shows GD3, panel C shows GD1a, and panel D 
shows the remaining fraction (combination of GT1a, GD2, GD1b, and GQ1b).  
Significance (p≤0.05) is indicated by a letter: “a” significant to control mice treated with 
water and “b” significant to EAE mice treated with water.
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There was no significant difference in GD3, GD1a, and the remaining fraction between 
all groups (Figure 10B-D).  Treatment with glyceryl triacetate significantly increased 
myelin brain GM1 ganglioside content in EAE mice compared to control-treated EAE 
mice (Figure 10A).  Overall, acetate supplementation significantly increased total 
brainGD3 and brain myelin GM1 ganglioside content in EAE mice. 
 
Acetate Supplementation Alters Spinal Cord Oligodendrocyte Myelin Glycoprotein 
and Phosphorylated Acetyl-CoA Carboxylase Protein Levels in Mice Subjected to 
EAE but Had No Effect on Alkylglycerone Phosphate Synthase and Acyl-CoA 
Synthetase 
 
 Figure 11 shows the protein levels of alkylglycerone phosphate synthase (AGPS), 
acyl-CoA synthetase (AceCS1 & AceCS2), merlin (moesin-, ezrin-, radixin-like protein), 
oligodendrocyte myelin glycoprotein (OMgp), and phosphorylated acetyl-CoA 
carboxylase (p-ACC) in control mice (n=7), EAE mice treated with water (n=5), and 
EAE mice treated with glyceryl triacetate (n=8).  AGPS is the enzyme important in ether 
phospholipid biosynthesis meaning the production of the plasmanyl and plasmalogen 
fractions (Braverman & Moser 2012, Rosenberger et al. 2002, Schmitt et al. 2015).  
There was no significant difference between control and EAE animals (Figure 11A).  
AceCS1, the cytoplasmic enzyme, and AceCS2, the mitochondrial enzyme, convert 
acetate into acetyl-CoA (Jaworski et al. 2016, Shimazu et al. 2010).  Similar to AGPS 
protein levels (Figure 11A), there was no significant difference between control and EAE 




Figure 11:  Spinal cord protein levels of alkylglycerone phosphate synthase (AGPS), 
acyl-CoA synthetase (AceCS1,cytoplasmic & AceCS2, mitochondrial), merlin (moesin-, 
ezrin-, radixin-like protein), oligodendrocyte myelin glycoprotein (OMgp), and 
phosphorylated acetyl-CoA carboxylase (p-ACC) in control mice (n=7), EAE mice 
treated with water (n=5, H2O), and EAE mice treated with glyceryl triacetate (n=8), 
GTA) (4g/kg).  Significance (p≤0.05) is indicated based on a letter: “a” significant to 
control mice treated with water and “b” significant to EAE mice treated with water.
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 We showed no significant differences in AGPS, AceCS1, and AceCS2 protein 
levels (Figure 11A-C) between control and EAE animals.  At 40 days post inoculation 
and treatment, we showed treatment prevented the loss of spinal cord lipid components in 
EAE mice (Chevalier & Rosenberger 2017).  Since we showed this recovery of lipid at 
this time point, we may need to determine protein levels of these enzymes early in the 
injury and treatment period.  AGPS is an enzyme at the beginning of ether phospholipid 
biosynthesis (Braverman & Moser 2012, Robinson et al. 2014, Schmitt et al. 2015), and 
AceCS1/2 catalyzes the conversion of acetate to acetyl-CoA (Jaworski et al. 2016) 
preceding the production of fatty acid and cholesterol.  All these data suggest that protein 
levels of these enzymes need to be analyzed earlier in the injury where acetate converts 
into acetyl-CoA and pushes that pool into the production of lipid. 
 Merlin is a cytoskeleton-associated protein that interacts with β-actin, for 
example, to link it to the plasma membrane (Hovens & Kaye 2001, Pecina-Slaus 2013).  
In the EAE model, there is a significant increase in β-actin (Jung et al. 2011, Smerjac & 
Bizzozero 2008), and in addition, we showed a significant increase in protein levels in 
EAE compared to control animals (Chevalier & Rosenberger 2017) (Figure 6).  We 
would expect an increase in merlin as well due to EAE injury.  EAE injury resulted in a 
significant increase in merlin protein levels when compared to control (Figure 11D).  
Treatment with glyceryl triacetate significantly decreased protein levels in EAE 
compared to control-treated EAE but was unable to completely return to control levels 
(Figure 11D) suggesting treatment does not alter cytoskeleton structure in EAE injury.   
 OMgp is a myelin inhibitor protein (Kan et al. 2016) that is suggested to inhibit 
remyelination and axonal growth (Cafferty et al. 2010, Huang et al. 2005, Kan et al. 
67 
 
2016, Vourc'h & Andres 2004, Wang et al. 2002, Mikol & Stefansson 1988).  OMgp 
along with NogoA and MAG bind to receptors such as NgR1, p75 neurotrophin receptor 
(p75NTR), and LINGO-1 to activate RhoA/ROCK pathway promoting the inhibition of 
remyelination and axonal growth (Kan et al. 2016).  Spinal cord mRNA levels of NogoA, 
NgR, p75NTR, LINGO-1, RhoA, and ROCK increases in rats subjected to EAE (Kan et 
al. 2016), and OMgp is suggested to be involved in this pathway as well (Cafferty et al. 
2010, Kan et al. 2016, Vourc'h & Andres 2004, Wang et al. 2002).  We expect OMgp 
significantly increases due to the EAE injury, and in fact, the EAE injury resulted in a 
significant increase in OMgp protein levels compared to control.  Interestingly, treatment 
with glyceryl triacetate returned OMgp protein levels back to control levels (Figure 11E).  
Acetate supplementation returned OMgp protein in EAE back to control levels to suggest 
treatment may alter myelin protein structure. 
 Phosphorylated ACC is the enzyme that converts acetyl-CoA to malonyl-CoA, 
the first step in the production of fatty acid (Baenke et al. 2013), and the phosphorylated 
form is inactive.  Protein levels of p-ACC significantly decreased in EAE mice treated 
with glyceryl triacetate compared to EAE mice treated with water (Figure 11F).  The next 
step is to determine protein levels of the non-phosphorylated form of ACC to determine if 
acetate is shifting ACC from the inactive to active form promoting fatty acid synthesis. 
Treatment decreased p-ACC protein levels in EAE mice to suggest a potential shift from 
an inactive to active form of the enzyme to promote fatty acid synthesis.  In Figure 11, 
acetate supplementation returned OMgp protein back to control levels and significantly 






Overall Conclusion of Dissertation 
 Acetate supplementation reduced disease progression, altered CNS and myelin 
lipid content, and influenced CNS and myelin protein content in mice subjected to EAE.  
We tested the hypothesis that acetate supplementation alters CNS lipid metabolism in 
mice subjected to EAE.  Treatment with glyceryl triacetate altered spinal cord 
phospholipid, fatty acid, cholesterol, and ganglioside content in EAE, and acetate 
supplementation altered brain phospholipid and ganglioside levels in these animals.  In 
addition, treatment attenuated the onset of clinical symptoms and returned cPLA2 levels 
back to control levels in EAE mice.  We also determined protein levels of enzymes 
involved in lipid synthesis, for example the inactive form of phosphorylated acetyl-CoA 
carboxylase.  This enzyme was significantly decreased in glyceryl triacetate-treated EAE 
mice compared to control-treated EAE mice.  These data suggest acetate may shift this 
enzyme from the inactive to active form to promote fatty acid synthesis.  Furthermore, 
OMgp, a myelin inhibitor protein, significantly increased due to the EAE injury, but 
treatment returned protein levels back to control levels suggesting acetate may alter 
myelin structure.  In addition, we found treatment slightly increased FluoroMyelinTM 
intensity in EAE mice compared to control-treated EAE mice, but the intensity level did 
not compare to control animals.  These data suggest treatment may alter myelin structure 
but not to the extent compared to control animals.  Acetate supplementation may alter 
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CNS lipid metabolism and myelin structure in mice subjected to EAE, and this is 
significant regarding the development of future treatments for demyelinating diseases like 
MS. 
 
Multiple Sclerosis May Be a Metabolic Disorder 
 MS may not be an autoimmune disorder but rather a metabolic disorder, a 
dysfunction in  lipid metabolism (Corthals 2011).  To support this idea, MS pathology 
includes both autoimmunity and oligodendrogliopathy (Nakahara et al. 2012) which is 
recognized through lesion patterns showing immune-mediated or oligodendrocyte-
deficient demyelination (Lucchinetti et al. 2000).  This suggest that MS may have an 
underlying metabolic dysfunction in lipid metabolism resulting in both types of 
demyelination.   
 MS is largely considered an inflammatory disease in which autoreactive T cells 
enter the CNS and destroy myelin resulting in the loss of myelin, chronic inflammation, 
and neuronal damage (Cusick et al. 2013, Zindler & Zipp 2010).  As a result, current 
therapeutic strategies for the treatment of MS work to inhibit peripheral immune cell 
infiltration and to down regulate the CNS immune response (Lim & Constantinescu 
2010, Minagar 2013).  However, another factor involved in MS, as well as other 
demyelinating diseases, is the dysfunction in mature oligodendrocyte maturation and 
function (de Castro et al. 2013, Lucchinetti et al. 2000, Wolswijk 2000).  Furthermore, in 
MS there is a significant decrease in overall lipid content within the white matter tracks 
and a significant increase in activity of the enzymes that metabolize membrane lipid 
(Cumings 1969, Kalyvas & David 2004, Alling et al. 1971, Cumings 1953, Cumings & 
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Goodwin 1968, Davison & Wajda 1962, Gerstl et al. 1970, Gerstl et al. 1961, Kishimoto 
et al. 1967).  Also, changes in energy metabolism in MS lesions may contribute to 
changes in myelin pathology (Rone et al. 2016).  The hypothesis MS may also be a 
metabolic disorder (Corthals 2011) may help explain the overall decrease in lipid content, 
which may be a result of a decrease in the rate of lipid synthesis.  It is well known that 
phospholipid, cholesterol, plasmalogen, and cerebroside levels are decreased in patients 
who suffer from MS (Cumings 1953, Cumings & Goodwin 1968, Alling et al. 1971, 
Cumings 1969, Davison & Wajda 1962, Gerstl et al. 1970, Gerstl et al. 1961).  While in 
the EAE model, there is a decrease in white matter PtdSer, PtdIns, EtnGpl, and CerPCho 
(Salvati et al. 1990).  The question remains whether this loss in lipid content is a result of 
a metabolic dysfunction or the result of immune-targeted degradation of myelin 
membranes. In this regard, the MOG35-55-induced EAE model effectively models the self-
antigen attack within the spinal cord resulting in demyelination, but this model may also 
be useful in quantifying the impact lipid metabolism has on injury progression.  We 
postulate that a metabolic dysfunction in lipid metabolism may contribute to myelin loss 
in patients who suffer from MS. 
 There are a number of demyelinating disorders associated with a dysfunction in 
lipid metabolism such as Canavan disease, peroxisomal disorders, and disorders of fatty 
acid metabolism.  Canavan disease results from a mutation in the gene that encodes for 
the enzyme ASPA, which releases acetate from NAA (Namboodiri et al. 2006b).  The 
lack of NAA-degrading enzyme activity leads to excess accumulation of NAA in the 
brain and in turn a deficiency in acetate necessary for myelin lipid synthesis.  This results 
in oligodendrocyte dysfunction, spongiform changes, and the absence of myelin 
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(Namboodiri et al. 2006b, Kumar et al. 2006, Gordon 2000, Namboodiri et al. 2006a).  
Currently, no treatment or cure is available for patients with this disease, but however, 
acetate supplementation is clinically beneficial and safe in clinical and preclinical studies 
for Canavan disease (Madhavarao et al. 2009, Segel et al. 2011).  Infants with this disease 
were given a low dose of glyceryl triacetate, which was found to be tolerable and safe in 
these patients (Madhavarao et al. 2009).  Acetate supplementation may be beneficial in 
treating demyelinating and metabolic disorders and in turn may be beneficial in the 
treatment of MS.  
  Peroxisomal disorders, Zellweger syndrome and X-linked adrenoleukodystrophy, 
show peroxisomal dysfunction in fatty acid metabolism.  This results in a decrease in 
plasmalogen content that contributes to a decrease in myelin lipid synthesis (Steinberg et 
al. 2004, Steinberg et al. 2006, Wanders & Waterham 2006).  Fatty acid supplementation 
like acetate supplementation is not a new concept in the treatment of demyelinating and 
metabolic disorders. Oleic acid supplementation is effective in patients who suffer from 
adrenoleukodystrophy, a disease characterized as having a decrease in very-long chain 
fatty acid (VLCFA) uptake into the peroxisome (Chrast et al. 2011) and an increase in 
plasma VLCFA levels (Chrast et al. 2011, Moser et al. 1981, Poll-The & Gartner 2012).  
The inability of VLCFA to be transported into peroxisomes results in a dysfunction in 
fatty acid metabolism resulting in a loss of short chain fatty acids, a disruption in 
membrane dynamics, and a decrease in fatty acid oxidation (Steinberg et al. 2004, 
Steinberg et al. 2006, Wanders et al. 2010, Wanders & Waterham 2006, Weller et al. 
2003, Kihara 2012).  Thus, it is important to maintain fatty acid homeostasis to maintain 
normal brain function (Kihara 2012).  Oleic acid is an eighteen carbon monounsaturated 
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fatty acid which inhibits the elongation of VLCFA (Moser et al. 1987, Rizzo et al. 1987).  
Oleic acid supplementation, given to adrenoleukodystrophy patients as glyceryl trioleate, 
decreases plasma VLCFA, improves clinical symptoms (Moser et al. 1987), and 
potentially normalizes fatty acid ratios within the CNS (Deon et al. 2008).  Alternative 
experimental therapies also include a combination of different triglycerides; glyceryl 
trioleate and glyceryl trierucate (4:1, by Vol., Lorenzo’s oil) that may be more clinically 
beneficial in lowering VLCFA.  In fact, Lorenzo’s oil lowers plasma VLCFA, increases 
peroxisomal function (Moser et al. 1999, Deon et al. 2008, Moser et al. 2007), and 
improves peroxisomal fatty acid oxidation (Wanders et al. 2010, Wanders & Waterham 
2006).  Lorenzo’s oil treatment inhibits ELOVL 1, an enzyme involved in VLCFA 
synthesis, (Sassa et al. 2014) suggesting a potential mechanism of action that may lead to 
an improvement in lipid metabolism in this disease.  Fatty acid supplementation may 
provide the necessary components to compensate for the metabolic dysfunction.   
 In addition to the dysfunction in fatty acid metabolism, patients with 
adrenoleukodystrophy show an increase in the production of leukotrienes within the CNS 
(Mayatepek et al. 1993, Mayatepek & Tiepelmann 1996).  Immune-mediated 
demyelination is present (Mayatepek et al. 1993, Mayatepek & Tiepelmann 1996), but 
there is also a dysfunction in fatty acid metabolism suggesting a similar trend to that in 
MS and EAE.  Both may contribute to changes in lipid content, and in patients suffering 
with MS, there are changes in CNS lipid content (Cumings 1969, Cumings 1953, 
Cumings & Goodwin 1968, Gerstl et al. 1970, Gerstl et al. 1961).  All this suggests MS 
may also have an underlying metabolic dysfunction in lipid metabolism on top of the 
immune-mediated demyelination.   
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 Another fatty acid treatment, docosahexaenoic acid (DHA) supplementation, 
shows therapeutic promise in patients who suffer from another peroxisomal disorder, 
Zellweger syndrome.  Zellweger syndrome results in a dysfunction in fatty acid oxidation 
that contributes to an accumulation of fatty acids, a decrease in plasmalogen levels, and 
hypomyelination (Chrast et al. 2011, Weller et al. 2003, Ferdinandusse et al. 2001, Poll-
The & Gartner 2012).  DHA supplementation improves neuronal function related to 
vision and muscle movement in young children and infants (Martinez 1996, Martinez et 
al. 1993, Martinez 2001, Martinez et al. 2000), returns plasma DHA and plasmalogen to 
normal (Martinez et al. 2000), and improves myelination shown in MRI scans of patients 
(Martinez & Vazquez 1998, Martinez et al. 2000).  Fatty acid supplementation shows 
promise in the treatment of demyelinating and metabolic disorders, and acetate 
supplementation may be the ideal fatty acid treatment because acetate is the simplest fatty 
acid and can be utilized for fatty acid (D'Adamo & Yatsu 1966), phospholipid (Smith 
1964, Mehta & Namboodiri 1995), and cholesterol (Chakraborty et al. 2001) synthesis. 
 In addition to Canavan disease and peroxisomal disorders, there are numerous 
disorders of fatty acid metabolism.  For example, rhizomelic chondrodysplasia punctata 
results from AGPS deficiency contributing to a decrease in myelin shown in MRI scans 
of patients.  The decrease in myelin is a result from a decrease in plasmalogen due to the 
AGPS deficiency (Sztriha et al. 1997), an enzyme important in ether phospholipid 
biosynthesis (Sztriha et al. 1997, Braverman & Moser 2012, Rosenberger et al. 2002).  
Sjogren-Larsson disease results from an increase in long-chain fatty alcohols, and 
Resfum disease shows a dysfunction in α-oxidation.  Also, Niemann-Pick disease results 
in a glycosphingolipid accumulation.  All of these diseases result in a disruption in 
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myelin stability, assembly, and compactness (Chrast et al. 2011) that in turn alters axonal 
function, axon-glia interactions, and disrupts lipid-mediated signaling (Chrast et al. 2011, 
Schmitt et al. 2015).  These metabolic disorders show changes in lipid content and 
metabolism, and MS and EAE also show changes in lipid content and metabolism 
(Cumings 1969, Cumings 1953, Cumings & Goodwin 1968, Gerstl et al. 1970, Gerstl et 
al. 1961, Kalyvas & David 2004) further suggesting MS may be a metabolic disorder 
rather than or on top of an autoimmune disorder (Corthals 2011). 
 Smith-Lemli-Opitz syndrome displays a dysfunction in cholesterol metabolism 
due to a mutation in the enzyme involved in the final step of cholesterol synthesis 
resulting in an increase in cholesterol metabolites but an overall decrease in cholesterol 
(Chrast et al. 2011).  In this disease, it is suggested that the inability to incorporate 
cholesterol into myelin results in the loss of myelin.  Interestingly, treatment involving 
cholesterol supplementation in combination with HMG-CoA reductase inhibitors shows 
an increase in plasma cholesterol and a decrease in its metabolites (Chan et al. 2009, 
Haas et al. 2007), and cholesterol supplementation alone is clinically beneficial for 
Smith-Lemli-Opitz disease (Elias et al. 1997, Irons et al. 1997).  This suggests there is a 
potential change in the rate of lipid deposition by supplying the system with dietary 
cholesterol.  Similarly, lovastatin, a HMG-CoA reductase inhibitor, significantly 
increases spinal cord myelin lipid levels and augments the survival and differentiation of 
OPCs in Lewis rats subjected to EAE (Paintlia et al. 2005).  All of which support the 
premise that a change in the rate of lipid deposition leads to injury, and treatment needs 
to focus on increasing the rate to reverse or prevent further injury.  As well, these 
diseases show changes in CNS lipid composition (Chrast et al. 2011) like MS (Cumings 
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1969, Cumings 1953, Cumings & Goodwin 1968, Gerstl et al. 1970, Gerstl et al. 1961, 
Alling et al. 1971, Davison & Wajda 1962, Kishimoto et al. 1967) to further suggest MS 
may have a dysfunction in lipid metabolism. 
 In addition to fatty acid supplementation, steroid administration in a MS animal 
model is anti-inflammatory and may promote steroid synthesis.  Cholesterol, an 
important myelin lipid (Morell 1984), is also important in the production of neurosteroids 
like pregnenolone, dehydroepiandrosterone (DHEA), progesterone, and androstenedione.  
In MS white matter, DHEA is significantly lower compared to non-MS white matter but 
no difference in pregnenolone levels is observed suggesting a dysfunction in the 
conversion of pregnenolone to DHEA.  MS white matter shows significantly lower 
mRNA levels of the enzyme that converts pregnenolone to DHEA to further support the 
idea that MS may be a metabolic disorder.  In this same study, EAE results in a 
significant decrease in DHEA and may be a result of a decrease in cholesterol 
availability.  Once these animals were administered DHEA, spinal cord inflammation 
decreased, and spinal cord mRNA levels of enzymes involved in the production of 
DHEA returned to control levels (Boghozian et al. 2017).  These data further suggest an 
underlying metabolic disorder, a dysfunction in lipid metabolism, may be present in MS 
and EAE. 
  In our studies, acetate supplementation prevented the loss of particular spinal cord 
lipid components in mice subjected to EAE.  If treatment is primarily anti-inflammatory, 
we would expect all lipid components would be recovered with treatment.  Treatment 
altered particular spinal cord lipid components suggesting EAE may have a metabolic 
dysfunction in lipid metabolism.  Therefore since EAE is a mouse model for MS, it may 
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suggest that MS is also a metabolic disorder.  Thus a potential effective strategy to 
prevent or slow demyelination may involve promoting myelin lipid synthesis.  Acetate 
within the central nervous system is readily converted into its CoA derivative suggesting 
acetate supplementation may be a potential therapy to promote lipid synthesis, and within 
the central nervous system acetate and acetyl-CoA are important precursors in the 
synthesis of fatty acid (D'Adamo & Yatsu 1966), phospholipid (Chakraborty et al. 2001, 
Smith 1964, Mehta & Namboodiri 1995), and cholesterol (Chakraborty et al. 2001). 
 
An Inflammatory Stimulus May Be Necessary to Shift the Acetyl-CoA Pool into 
Producing Lipid 
 
 Acetate treatment results in a significant increase in fatty acid content in LPS-
stimulated BV2 microglia compared to control-treated LPS-stimulated cells.  However, in 
the non-LPS stimulated cells, there was no significant difference in fatty acid content 
between the two control groups (Bhatt & Rosenberger 2014).  This suggests treatment 
may require a stimulus, like inflammation, to result in changes in lipid content between 
control-treated and acetate-treated injury groups.  To further support this hypothesis, we 
determined spinal and brain lipid content in both control and EAE animals.  The control 
group determined whether treatment alone altered CNS lipid content in vivo without the 
presence of an inflammatory stimulus.  Again, these animals were not injected with the 
MOG peptide and pertussis toxin to result in the spinal cord immune-mediated 
demyelination (Palumbo & Bosetti 2013).  The EAE group determined if treatment needs 
a stimulus, like EAE inflammation, to result in changes in lipid content similar to 
previous literature (Bhatt & Rosenberger 2014).  We found that in control mice, there 
was no significant difference in spinal cord and brain lipid content between the two 
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groups similar to previous in vitro work (Bhatt & Rosenberger 2014).  However, we 
found significant differences in spinal cord lipid content between the two EAE treatment 
groups.  Treatment significantly increased spinal cord lipid content in EAE mice 
compared to control-treated EAE mice, but again, there was no significant difference in 
lipid levels between the two control groups.  This supports the hypothesis that treatment 
may require a stimulus, such as LPS-stimulated microglia or EAE, to result in significant 
changes in lipid content.  Due to the presence of the inflammatory stimulus within the 
CNS, we hypothesized that treatment would alter brain lipid content even though EAE is 
a spinal cord injury (Batoulis et al. 2011, Ransohoff 2012, Simmons et al. 2013), and in 
fact, we found acetate supplementation increased brain phospholipid and ganglioside 
content in EAE compared to control-treated EAE mice.  Since there were changes in 
brain lipid content due to EAE and treatment, this suggests an inflammatory stimulus is 
important to result in changes in CNS lipid content and for the acetyl-CoA to be 
predominantly utilized in lipid synthesis. 
 The above data on lipid levels in EAE mice also provides insight into a 
mechanism of action for glyceryl triacetate in normal and EAE states.  In control healthy 
animals, there is a natural lipid turnover (Ando et al. 2003, Rosenberger et al. 2002, 
Moser et al. 1999) where the amount of lipid produced equals the amount of lipid broken 
down (Figure 12).  During the EAE injury, the amount of lipid broken down is 
significantly higher compared to the amount of lipid produced (Figure 12) due to chronic 
immune-mediated demyelination through the cPLA2 pathway (Kalyvas & David 2004).  
When EAE mice are treated with glyceryl triacetate, we suggest treatment either 
decreases lipid breakdown through the cPLA2 pathway, promotes lipid synthesis, or does 
78 
 
a combination of both to return the lipid turnover rate to control levels.  This then 
recovers the lipid lost due to injury (Figure 12).  Acetate supplementation recovered the 
EAE-induced spinal cord lipid loss and returned cPLA2 levels back to control to suggest 
treatment may promote lipid synthesis and/or reduces breakdown. 
 
 
Figure 12: Our bucket theory regarding lipid turnover rate in control, EAE, and EAE 
mice treated with glyceryl triacetate.  Abbreviations include EAE (experimental 
autoimmune encephalomyelitis) and GTA (glyceryl triacetate).  The arrows indicating 
deposition rate refer to the amount of lipid produced, and the arrows indicating turnover 
rate refer to the amount of lipid broken down.  Blue level indicates the level of lipid 
found within the spinal cord of these mice, and red level refers to the recovery of lipid 
due to treatment. 
 
 Acetate can be utilized in energy production, histone and non-histone protein 
acetylation, and lipid synthesis (Bhatt et al. 2013, Bhatt & Rosenberger 2014, Soliman & 
Rosenberger 2011, Soliman et al. 2012b).  In a normal control state, acetate may be 
utilized for the natural lipid turnover (Ando et al. 2003, Rosenberger et al. 2002, Moser et 
al. 1999) to promote the production of lipid to compensate for lipid being broken down, 
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but there is no metabolic demand for the entirety of the acetyl-CoA pool to be used for 
lipid synthesis.  The remaining pool may also be used to increase energy production 
(Bhatt et al. 2013).  A single dose of glyceryl triacetate was administered to control rats.  
Four hours later, treatment significantly increases brain phosphocreatine levels to suggest 
acetate supplementation promotes energy production in control rats (Bhatt et al. 2013).  
In addition to acetate being utilized for energy production, acetate may alter histone and 
non-histone protein acetylation.  Acetylation, which was shown when male Sprague-
Dawley rats were administered a single dose of glyceryl triacetate, and four hours post 
treatment, histone acetylation increases and histone deacetylase activity decreases 
(Soliman & Rosenberger 2011) to suggest treatment alters histone acetylation in control 
rats.  In a normal healthy state, acetate supplementation may alter lipid content to 
maintain the natural turnover (Ando et al. 2003, Rosenberger et al. 2002, Moser et al. 
1999) but may have a greater effect on energy production (Bhatt et al. 2013) and histone 
acetylation (Soliman & Rosenberger 2011, Soliman et al. 2012b).  Although in an injury 
state, like EAE or LPS-stimulated inflammation, we suggest acetate may be 
predominately utilized for lipid synthesis. 
 In an injury state like EAE, increasing the amount of available acetyl-CoA may 
push the pool to be predominantly utilized in the production of lipid.  Treatment with 
glyceryl triacetate significantly increased spinal cord phospholipid, fatty acid, cholesterol, 
and ganglioside content in EAE mice compared to control-treated EAE mice.  These data 
suggest that the acetyl-Co pool is being utilized to recover the lipid lost due to injury.  
This idea was supported by work completed by Bhatt and Rosenberger in LPS-stimulated 
BV2 microglia (Bhatt & Rosenberger 2014).  Acetate increases fatty acid content in LPS-
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stimulated microglia compared to control-treated LPS stimulated cells.  In addition, we 
found treatment with glyceryl triacetate significantly increased brain phospholipid and 
ganglioside content in EAE mice compared to control-treated EAE mice.  Again, we 
showed changes in brain lipid content between the two EAE treatment groups.  The EAE 
inflammatory stimulus is present within the CNS even though EAE is a spinal cord injury 
(Batoulis et al. 2011, Ransohoff 2012, Simmons et al. 2013).  Therefore, acetate is being 
utilized in the production of brain and spinal cord lipid in the presence of the EAE injury.   
 Oligodendrocytes treated with radiolabeled acetate results in radiolabeled acetyl-
CoA, which was not overly incorporated into TCA metabolites compared to cells treated 
with radiolabeled glucose.  This suggests in a myelinating cell, acetate is essential in the 
production of myelin lipid rather than energy production (Amaral et al. 2016).  This is 
not an obscure thought based on data from another study.  Increasing acetyl-CoA 
metabolism through pyruvate or glycolysis pathway is not necessary for myelin stability 
in myelinating glia cells (Della-Flora Nunes et al. 2017).  This suggests acetate may be 
predominantly utilized in lipid synthesis where there is that metabolic demand.  In an 
injury state, acetate is predominantly utilized to increase acetyl-CoA metabolism for lipid 
synthesis, but there may also be a secondary pathway where acetate is important in 
promoting histone acetylation.  
 Acetate promotes histone and non-histone protein acetylation in an injury state to 
alter inflammation and also may change the expression of enzymes involved in lipid 
metabolism.  In a neuroinflammation rat model, treatment with glyceryl triacetate results 
in an increase in histone acetylation and an increase in histone acetyltransferase activity 
to correlate with a decrease in IL-1β cytokine levels (Soliman et al. 2012b).  Treatment is 
81 
 
anti-inflammatory by down regulating the expression of pro-inflammatory cytokines.  In 
addition, acetate increases histone acetylation and decreases IL-1β and TNF-α protein 
levels in LPS-stimulated primary astrocytes (Soliman et al. 2013a) to suggest changes in 
histone acetylation may down-regulate the expression of pro-inflammatory cytokines 
both in vivo and in vitro.  Down-regulating the pro-inflammatory response does not 
contradict the hypothesis that an inflammatory stimulus needs to be present to show 
changes in lipid content.  When an inflammatory stimulus is present, acetate 
supplementation promotes histone acetylation to down-regulate inflammation (Soliman & 
Rosenberger 2011, Soliman et al. 2012b) but at the same time, alters lipid metabolism 
recovering the lipid lost due to injury (Bhatt & Rosenberger 2014, Chevalier & 
Rosenberger 2017).  Acetate significantly increases fatty acid content in LPS-stimulated 
BV2 microglia, and in the same study, acetate increases histone acetylation in these cells 
(Bhatt & Rosenberger 2014) suggesting histone acetylation may promote the expression 
of enzymes involved in fatty acid synthesis.  Furthermore, histone acetylation induced by 
treatment with glyceryl triacetate may down regulate the expression of enzymes involved 
in lipid synthesis and breakdown. 
 
Therapeutic Window Where Glyceryl Triacetate May Benefit Demyelinating and 
Metabolic Disorders 
 
 Based on previous literature and current studies, there may be a therapeutic 
window where glyceryl triacetate may be clinically beneficial in demyelination and 
metabolic disorders.  For example in patients with Canavan disease, acetate 
supplementation did not significantly improve or worsen clinical symptoms (Madhavarao 
et al. 2009).  In preliminary studies, we administered glyceryl triacetate to EAE mice 
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after they exhibited hind limb paralysis, and acetate supplementation did not improve 
onset of paralysis but also did not worsen symptoms (data not shown).  Comparing 
previous literature, preliminary results, and those outlined in these studies suggests there 
may be a therapeutic window where treatment may be effective in offsetting the loss of 
lipid due to injury.  In these studies, some animals experienced tail paralysis that was 
reversed to full mobility due to treatment with glyceryl triacetate.  In addition to acetate 
supplementation in Canavan disease and EAE, DHA supplementation in patients with 
Zellweger syndrome need to be treated early in development (Martinez 2001, Martinez et 
al. 2000) for treatment to be effective.  One theory for this idea is once disease has 
progressed to the extent where mature oligodendrocytes and OPCs remain unviable, 
acetate supplementation may not be effective in preventing or reversing disease 
progression alone to promote myelin lipid deposition.  OPCs differentiate into mature 
oligodendrocytes, and mature oligodendrocyte promote myelin and increase myelin lipid.  
When disease progresses to the point where there is a decrease in the number and/or 
functionality of OPCs and mature oligodendrocyte, fatty acid supplementation may not 
be effective in promoting myelination and reversing or preventing clinical onset in 
demyelinating diseases. 
 
Acetate’s Role in Oligodendrocyte Maturation, Differentiation, and Function 
 ASPA, the enzyme that releases acetate and aspartate from NAA (Namboodiri et 
al. 2006b), is found in both the cytosol and nucleus of oligodendrocytes (Baslow et al. 
1999, Bhakoo et al. 2001, Kirmani et al. 2003, Madhavarao et al. 2002, Kirmani et al. 
2002, Moffett et al. 2011).  It has been suggested ASPA expression promotes acetate 
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utilization into lipid synthesis (Kirmani et al. 2003, Kirmani et al. 2002), and aspartate is 
used for energy production in oligodendrocytes especially during differentiation (Amaral 
et al. 2016, Amaral et al. 2017).  In primary rat oligodendrocytes, NAA treatment 
increases ASPA and MBP protein suggesting that ASPA releases acetate into 
oligodendrocytes contributing to myelination.  Furthermore, NAA treatment significantly 
increases mRNA levels of Tcf712, Olig2, Ugt8, and Sgms1 in primary oligodendrocytes.  
Tcf712 and Olig 2 are markers associated with oligodendrocyte differentiation, and the 
remaining are markers associated with lipid synthesis (Singhal et al. 2017).  All these 
data suggest NAA contributes to ASPA releasing acetate, and acetate promotes 
myelination and oligodendrocyte differentiation.  In this regard, acetate may alter lipid 
content in oligodendrocytes by promoting oligodendrocyte differentiation and myelin 
lipid synthesis. 
 Radiolabeled acetate incorporates into the lipid portion of primary pig 
oligodendrocytes.  Radiolabeled acetate incorporates into 58.9% of the neural lipid 
fraction consisting of cholesterol and triglycerides, and the remaining portion consists of 
phospholipids like PtdCho (17.5%), EtnGpl (6.0%), PtdIns (3.2%), PtdSer (3.1%), and 
CerPCho (1.7%) (Burgisser et al. 1988).  Within EtnGpl, radiolabeled acetate 
incorporates primarily within the plasmalogen fraction (71.6%) while the remaining 
28.4% is PtdEtn + PakEtn (Burgisser et al. 1988).  This is not surprising because 
oligodendrocytes promote myelination in the CNS (Boulanger & Messier 2014, Mitew et 
al. 2014), and PlsEtn is predominately found in myelin (Morell 1984).  In addition, 
radiolabeled acetate incorporates into fatty acid and cholesterol (Warringa et al. 1987) in 
oligodendrocytes.  The expression of AceCS1 and AceCS2 in oligodendrocytes provides 
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further support to the idea that acetate’s role in oligodendrocytes is to promote lipid 
synthesis.  AceCS1, localized in the cytoplasm and nucleus, is expressed in 
oligodendrocytes while AceCS2, localized in the mitochondria, is expressed in 
astrocytes.  AceCS1 is associated with increasing histone acetylation in the nucleus and 
lipid synthesis in the cytosol where AceCS2 is associated with energy production in the 
mitochondria (Cahoy et al. 2008, Moffett et al. 2011, Moffett et al. 2013).  To further 
support the hypothesis that acetate is predominately utilized for lipid synthesis over 
energy production within oligodendrocytes, it has been shown that radiolabeled acetate 
incorporates into TCA cycle metabolites at much lower rate compared to cells treated 
with radiolabeled glucose (Amaral et al. 2016).  Also, acetyl-CoA produced through the 
glycolysis/TCA pathway is not essential for myelin maintenance (Della-Flora Nunes et 
al. 2017).  Acetate incorporates into oligodendrocyte lipid content, and lipids, in general, 
promote oligodendrocyte development and function.  In primary oligodendrocytes, 
cholesterol treatment is correlated with promoting oligodendrocyte differentiation 
(Berghoff et al. 2017), and DHA treatment promotes oligodendrocyte viability and 
protection from microglia activated-induced inflammation (Pu et al. 2013).  Increasing 
acetyl-CoA metabolism to alter lipid content in oligodendrocytes may a result from 
promoting myelination and oligodendrocyte development and function. 
 Even though acetate may promote myelin lipid synthesis in oligodendrocytes, a 
small amount of acetate may be making its way to energy production for proper 
oligodendrocyte development and function leading to myelin lipid production.  Myelin 
biosynthesis requires energy production in the form of ATP production and regulation of 
the glycolysis pathway.  It is suggested that mature oligodendrocytes are less 
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metabolically active than OPCs, and both cell types require glycolysis to produce ATP as 
an energy source.  Under injury-like conditions, mature oligodendrocytes decrease 
glycolysis and ATP metabolic processes to inhibit cell death, but this negatively affects 
the myelinating function.  Reducing myelin production results in the preservation of 
energy for cell survival.  There is no change in these processes in OPCs leading to cell 
death, and by decreasing the number of OPCs leads to a decrease in the differentiation to 
mature myelination oligodendrocytes.  This results in the ability for oligodendrocyte to 
produce myelin lipid (Rone et al. 2016).  Proper energy metabolism in oligodendrocytes 
leads to the production of lipid and normal function.  Acetate may promote myelination 
and normal development and function in oligodendrocytes. 
 
The Significance of CNS Lipid Changes Due to EAE and Treatment Related to 
Myelin Structure, Function, and Stability 
 
 Myelin composition is primarily comprised of lipid (80%) consisting of 
cholesterol (28%) and phospholipid (43%) while the remaining fraction is protein (20%) 
(Morell 1984).  In these studies, we found treatment with glyceryl triacetate significantly 
increased spinal cord phospholipid and cholesterol in mice subjected to EAE compared to 
control-treated EAE mice, and treatment resulted in the levels of these lipids in EAE 
mice equivalent to that found in control mice.  This suggests acetate supplementation 
may recover myelin lipid lost due to the demyelinating injury of EAE.  Major myelin 
phospholipids include PtdEtn (16%), PtdCho (11%), and PtdSer (5%) (Morell 1984).  We 
found acetate supplementation significantly increased spinal cord EtnGpl, ChoGpl, and 
PtdSer in EAE mice compared to control-treated EAE mice.  Regarding the EtnGpl and 
ChoGpl groups, treatment altered PtdEtn + PakEtn and PtdCho + PakCho rather than the 
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plasmalogen fractions.  All these data suggest treatment may alter myelin lipid content in 
mice subjected to EAE.  PtdIns occupies 0.6% of the myelin phospholipid fraction 
(Morell 1984), and treatment with glyceryl triacetate significantly increased brain myelin 
PtdIns in EAE mice compared to control-treated EAE mice to further suggest treatment 
may alter myelin lipid content in EAE mice.  Treatment may promote myelin lipid 
deposition in demyelinating diseases, and this is significant in the development of a 
remyelination therapy for patients suffering from MS. 
 GD1a ganglioside levels significantly decreased due to the EAE injury compared 
to control levels.  Acetate supplementation significantly increased spinal cord GD1a 
ganglioside levels in EAE compared to control-treated EAE mice, but treatment was 
unable to completely return levels to control levels.  GD1a within the CNS is a ligand for 
MAG whose interaction promotes myelin stability and inhibits nerve regeneration by 
reducing nerve sprouting (Schmitt et al. 2015, Schnaar 2010) both of which are important 
in maintaining normal function within the CNS (Pan et al. 2005, Vyas et al. 2002, Vyas 
& Schnaar 2001, Yang et al. 1996, Chiavegatto et al. 2000, McKerracher et al. 1994, 
Mukhopadhyay et al. 1994, Schachner & Bartsch 2000, Schnaar et al. 2014).  EAE injury 
may potentially decrease myelin stability due to a decrease in GD1a/MAG interactions.  
Treatment may change the level of GD1a/MAG interactions to promote myelin stability, 
but this interaction may not be to the same extent as controls.  This potential reduction in 
the interaction of GD1a and MAG in glyceryl-triacetate EAE mice compared to control 
mice is possibly due to an increase in the inflammatory response that may limit 
GD1a/MAG interactions with an anti-ganglioside antibody attack to ganglioside content 
altering myelin stability (Mata et al. 1999, Sadatipour et al. 1998, Acarin et al. 1996).  
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Treatment increased spinal cord GD1a levels in EAE compared to control-treated EAE 
mice to suggest treatment may promote myelin stability through MAG-GD1a interactions 
but not to the same extent as compared to controls. 
 Acetate supplementation significantly increased total spinal cord and brain GD3 
ganglioside levels in EAE mice compared to control-treated EAE mice.  Thus the 
dramatic loss of lipid due to the EAE injury may result in the metabolic need to increase 
GD3 content compared to GM1 similar to a developing brain (Kracun et al. 1991, Rosner 
et al. 1985).  Showing changes in GD3 levels in EAE and treatment is significant because 
in young mice, we may be promoting the continuation of myelination.   
 Acetate supplementation slightly increased FluoroMyelinTM intensity in EAE 
mice compared to control-treated EAE mice, but the intensity did not reach the same 
level as control mice.  FluoroMyelin™ binds to myelin via lipophilic affiliation 
indicating that an increase in intensity correlates with an increase in myelin lipid.  We 
showed acetate supplementation prevented the loss of spinal cord phospholipid and 
cholesterol in mice subjected to EAE, but treatment was unable to completely return 
GD1a ganglioside levels back to control.  Between the FluoroMyelinTM staining and 
spinal cord lipid data, treatment may increase myelin lipid and myelin stability in EAE 
mice compared to control-treated EAE mice but not to the same extent as controls. 
 Cytosolic PLA2 promotes the release of arachidonic acid from membrane 
phospholipid to promote the production of inflammatory eicosanoids (Shimizu 2009, 
Benjamins et al. 2012). EAE injury results in a significant increase in cPLA2 levels 
contributing to immune-mediated demyelination (Kalyvas & David 2004).  We also 
showed that the EAE injury resulted in a significant increase in cPLA2 protein levels 
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compared to control mice, and treatment returned levels back to control levels.  These 
data suggest treatment may modulate pro-inflammatory lipid signaling to down regulate 
the immune-mediated demyelination.  Treatment may decrease the amount of lipid 
broken down and potentially normalizing the lipid turnover rate in EAE mice. 
 EAE resulted in a significant increase in OMgp, a protein found within myelin 
that inhibits remyelination and axonal growth.  OMgp is suggested to act similar to 
NogoA binding to NgR1, p75NTR, or LINGO-1 to activate RhoA/ROCK to inhibit 
remyelination and axonal growth (Cafferty et al. 2010, Huang et al. 2005, Kan et al. 
2016, Mikol et al. 1993, Vourc'h & Andres 2004, Wang et al. 2002).  Interestingly, 
treatment returned levels back to control levels in mice subjected to EAE indicating a 
change in myelin structure with EAE and treatment.  Acetate supplementation may 
promote myelin lipid deposition by down-regulating pathways involved in remyelination 
inhibition and up-regulating pathways involved in myelination.  Treatment may alter 
myelin composition, structure, and stability between control-treated and glyceryl 
triacetate-treated EAE groups. 
 
The Importance to Develop Therapies that Promote Lipid Synthesis and/or Reduce 
Lipid Breakdown to Treat Multiple Sclerosis  
 
 Acetate supplementation administered through glyceryl triacetate may potentially 
promote lipid synthesis and/or reduce lipid breakdown based on results shown in these 
studies.  Treatment with glyceryl triacetate prevented the loss of spinal cord lipid 
components in mice subjected to EAE suggesting treatment may stimulate lipid 
deposition and/or prevent lipid breakdown.  In addition, we showed treatment with 
glyceryl triacetate returned cPLA2 levels back to control levels in mice subjected to EAE 
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to suggest treatment may prevent lipid breakdown through the cPLA2-arachidonic acid 
pathway.  We showed treatment significantly decreased p-ACC protein levels in mice 
subjected to EAE to suggest acetate may shift this enzyme from the inactive to active 
form to promote fatty acid synthesis.  Acetate supplementation is one potential lipid 
target, but there are other lipid supplementations that could potentially promote lipid 
synthesis and/or reduce lipid breakdown. 
 Previously, the therapeutic benefits of oleic acid supplementation in 
adrenoleukodystrophy (Moser et al. 1987), DHA supplementation in Zellweger syndrome 
(Martinez 1996, Martinez 2001, Martinez & Mougan 1999, Martinez et al. 1993, 
Martinez & Vazquez 1998, Martinez et al. 2000), and Lorenzo’s oil in 
adrenoleukodystrophy (Moser et al. 1999, Moser et al. 2007) were presented.  There are 
additional lipid supplementation therapies to provide evidence that normalizing lipid 
turnover may relate to changes in clinical outcomes and pathology in various diseases.  
Hydrocortisone, a steroid, significantly increases radiolabeled acetate incorporation into 
fatty acid and cholesterol in primary oligodendrocytes (Warringa et al. 1987).  This 
suggests cholesterol synthesis is important for myelination in oligodendrocytes.  In a 
mouse model for traumatic brain injury, a diet consisting of omega-3 fatty acids, DHA 
and eicosapentaenoic (EPA, 20:5n-3), improves clinical outcomes in wire hanging, grid 
walking, foot fault, and platform locating tests to suggest a high omega-3 fatty acid diet 
compared to normal diet may promote an improvement in sensorimotor and cognition 
function.  A high omega-3 fatty acid diet is anti-inflammatory decreasing mRNA pro-
inflammatory markers such as IL-1α, IL-1β, TNFα, and COX-2. This treatment may 
promote myelination increasing MBP (Pu et al. 2013).  A high omega-3 fatty acid diet is 
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clinically beneficial in patients with depression increasing brain white matter fatty acids 
as shown in MRI scans of patients (Chhetry et al. 2016).  All these data suggest fatty 
acids are important in promoting myelin lipid production in the CNS, and acetate, being 
the simplest fatty acid, may also do the same.  Supplementation of linolenic acid, an 
essential fatty acid, contributes to axonal survival in an animal model of sciatic nerve 
injury through regeneration and myelination.  As well, treatment improves function 
which is shown through the toe spreading reflex test in this model (Ramli et al. 2017).  
Fatty acid supplementation may promote myelination and axonal survival to show 
clinically improvements in animal behaviors in disease processes. 
 In cuprizone and lyso-lecithin animal models, cholesterol supplementation may 
promote remyelination and oligodendrocyte differentiation.  In the chronic cuprizone 
model, cholesterol decreases axonal damage, increases remyelination, and increases the 
number of OPCs and mature oligodendrocytes.  Cholesterol can alter these conditions by 
gaining access to CNS due to the decreased permeability of the BBB.  When cuprizone 
was removed from the diet, cholesterol increases OPC proliferation, the number of OPCs 
and mature oligodendrocytes, myelin content, and decreases axonal damage.  In the lyso-
lecithin model, cholesterol also increases remyelination and number of oligodendrocytes.  
All these data indicate cholesterol promotes remyelination and oligodendrocyte function 
in MS pathology (Berghoff et al. 2017).  Lipids have a role in myelin stability and in turn 
promote cognitive function.  All these data provide a potential therapeutic strategy, 
supplying the CNS with lipid, which promotes lipid synthesis and/or reduces lipid 




 A case study tested the effectiveness of a ketogenic diet with a child showing a 
dysfunction in the mitochondrial aspartate-glutamate carrier isoform 1, and this 
dysfunction results in the inability to release aspartate into the cytosol from the 
mitochondria through the malate-aspartate shuttle.  The child shows symptoms of 
hypotonia, deficits in psychomotor development, seizures, and hypomyelination.  
Hypomyelination is due to the inability of aspartate to form NAA and for NAA, to 
transport into oligodendrocytes to metabolize into acetate and aspartate.  After the child 
was administered a ketogenic diet consisting of a high fat and low carbohydrate count, 
the child improves clinical symptoms and white matter volume.  Improving white matter 
volume suggests treatment may promote myelination (Dahlin et al. 2015).  GLUT1 
deficiency syndrome results in a decrease in glucose uptake, and patients with this 
deficiency show mental impairment and motor dysfunction.  Ketogenic diet given to a 3.5 
year old boy with this deficiency shows clinical improvements in alertness and cognitive 
performance, and in addition, MRI scans indicate myelination as a result of the ketogenic 
diet (Klepper et al. 2007).  A high fat diet may be beneficial in treating demyelinating 
diseases. 
 Recently, it is suggested a ketogenic diet may be therapeutically beneficial for 
patients suffering with progressive MS.  Current MS therapies are immunomodulatory 
but do not decrease the progression of the disease leading to axonal loss and 
neurodegeneration.  There is a change in mitochondrial function in MS pathology, a 
metabolic dysfunction related to neurodegeneration progression in MS.  A dysfunction in 
mitochondrial function and a decrease in energy production through ATP is correlated 
with an increase in axonal loss and demyelination.  In the EAE model, there is the 
92 
 
presence of mitochondrial injury to associate with an increase in inflammation and 
neurodegeneration.  Administering an antioxidant shows to be neuroprotective in this 
model by decreasing inflammation, neuronal cell loss, and disease progression.  Patients 
suffering with MS may also have glucose hypometabolism due to a dysfunction in 
mitochondrial function and energy production, which gives rise to the hypothesis that 
ketogenic diet may be beneficial in MS patients.  In a MS animal model, the treatment 
with a ketogenic diet results in a decrease in inflammation and in clinical improvements 
related to learning, memory, and motor function.  In a clinical trial with Alzheimer’s 
patients, treatment with a ketogenic diet resulted in better cognition function (Storoni & 
Plant 2015).  Supplying the CNS with lipid seems to be a potential therapeutic strategy to 
promote lipid synthesis and/or reduce lipid breakdown to maintain the normal lipid 
turnover rate and normal cognitive function in demyelinating and metabolic disorders. 
 There are two mechanisms by which demyelination occurs: immune-mediated 
and oligodendrocyte-deficient demyelination (Lucchinetti et al. 2000, Nakahara et al. 
2012).  Currently available MS therapies target the autoimmune aspect of the disease 
(Lim & Constantinescu 2010).  However because it only targets one aspect of the disease 
process, it does not offer a complete treatment.  Therapies need to be developed to 
promote lipid synthesis and/or reduce lipid breakdown to treat demyelinating diseases 
like MS.  A combinational remyelination and immunomodulatory therapy would target 
both the oligodendrocyte-deficient and immune-mediated demyelination aspects of the 





 We will determine the effectiveness of glyceryl triacetate in other MS animal 
models like the cuprizone and relapse-remitting EAE models.  The cuprizone model 
mimics oligodendrocyte-deficient demyelination (Palumbo & Bosetti 2013, Procaccini et 
al. 2015, Ransohoff 2012, Simmons et al. 2013), and relapse-remitting EAE will 
determine therapeutic potential in the treatment of this particular type of MS, which is 
present in the majority of patients (Delbue et al. 2017, McQualter & Bernard 2007).  
Regarding the cuprizone model, we can measure the width of the corpus callosum 
(Wergeland et al. 2012) to determine the extent of demyelination as a result of injury and 
how glyceryl triacetate recovers that width.  As the amount of demyelination increases, 
the width of the corpus callosum decreases (Wergeland et al. 2012).  We expect 
prophylactic treatment with glyceryl triacetate recovers that width back to control 
animals to suggest acetate has a role in myelination and oligodendrocyte differentiation.  
Discussed in the introduction, cuprizone directly affects mature oligodendrocytes but has 
no effect on OPCs (Benardais et al. 2013).  If we show a change in the width of the 
corpus callosum with cuprizone and treatment, this suggests acetate may promote 
oligodendrocyte differentiation and function that in turn increases myelin lipid.  
Regarding the relapse-remitting EAE model, we will determine whether prophylactic 
treatment with glyceryl triacetate attenuates the onset of clinical symptoms similar to the 
progressive EAE model and reduces the number of relapses.   
 Once we perform the behavioral analyses, we will determine changes in brain 
lipid content with the cuprizone model and spinal cord lipid content in the relapse-
remitting EAE model compared to control animals.  We expect to show in both models, 
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treatment with glyceryl triacetate will significantly increase CNS lipid content compared 
to control-treated injury animals, but similar to controls.  All data will suggest treatment 
is clinically beneficial in MS and potentially treats the entire disease.  Also, the data will 
suggest that treatment recovers myelin lipid lost due inury to treat all forms of 
demyelination, both immune-mediated and oligodendrocyte-deficient demyelination. 
 The above analysis will, in addition, provide insight into the type of stimulus 
necessary to show changes in lipid content.  For example, a stimulus, in general like 
oligodendrocyte death, in the cuprizone model is required for glyceryl triacetate to 
promote the production of lipid, or an inflammatory stimulus, like EAE, is required for 
treatment to promote the production of lipid.  If treatment with glyceryl triacetate only 
significantly increases lipid levels in the relapse-remitting EAE compared to control-
treated EAE animals but no difference in the cuprizone model, an inflammatory stimulus, 
in particular, is essential for treatment to show changes in lipid content.  On the other 
hand, if treatment significantly increases lipid content in both the cuprizone and EAE 
model compared to control-treated injury animals, a stimulus, in general, is required for 
treatment to show changes in CNS lipid content.  This is significant regarding the 
treatment of both immune-mediated and oligodendrocyte-deficient demyelination in MS. 
 We will determine the effectiveness of using interventional treatments in the 
progressive EAE, relapse-remitting EAE, and cuprizone models.  An interventional 
treatment being effective in MS animal models is significant in the treatment of MS 
because patients are only prescribed medications when symptoms develop.  In the 
progressive EAE model, we can administer glyceryl triacetate when animals exhibit 
flaccid tail and hind limb paralysis.  We expect glyceryl triacetate will either reverse or 
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not worsen the clinical score in these animals.  In the relapse-remitting EAE, we can 
administer glyceryl triacetate after the first relapse and determine if treatment reduces the 
number of relapses from that point.  We expect interventional treatment reduces the 
number of relapses to show therapeutic benefits for the treatment of the majority of MS 
patients (Delbue et al. 2017, McQualter & Bernard 2007).  In the cuprizone model, we 
can administer glyceryl triacetate 3, 7, or 14 days after cuprizone diet and determine how 
the width of the corpus callosum changes over time with cuprizone and treatment. 
 Regarding the cuprizone model, we can determine how continuing glyceryl 
triacetate treatment after withdrawal promotes remyelination.  We can give cuprizone diet 
and glyceryl triacetate treatment for 30 days to mice, and after 30 days, we can remove 
the cuprizone diet and continue glyceryl triacetate treatment for 0, 7, 14, or 21 days.  
There will be nine groups: one control group, four non-treated cuprizone groups, and four 
treated cuprizone groups.  The control group will be healthy mice euthanized on the day 
of the cuprizone withdrawal to determine a normal baseline for the width of the corpus 
callosum.  The non-treated cuprizone groups will be mice given cuprizone but no 
glyceryl triacetate for 30 days and have cuprizone withdrawn for 0, 7, 14, or 21 days.  
These animals will give us the width of the corpus callosum over the traditional 
remyelination period.  The treated cuprizone groups will be mice given both cuprizone 
and glyceryl triacetate and receive glyceryl triacetate for 0, 7, 14, or 21 days after 
withdrawal of cuprizone.  Determine the width of the corpus callosum in this group will 
determine if treatment accelerates remyelination (Wergeland et al. 2012).  We expect 
acetate supplementation accelerates the rate of remyelination by returning the width of 
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corpus callosum to control levels much earlier compared to non-treated cuprizone 
animals.   
 We want to determine protein levels of enzymes involved in lipid synthesis.  We 
looked at AGPS, AceCS1/2, and p-ACC.  AGPS is the enzyme involved in ether 
phospholipid biosynthesis (Braverman & Moser 2012, Rosenberger et al. 2002, Schmitt 
et al. 2015), and AceCS1/2 catalyzes the conversion of acetate to acetyl-CoA (Jaworski et 
al. 2016, Shimazu et al. 2010).  We found there was no significant difference in these 
enzyme protein levels between control and EAE groups.  We suspect that we are looking 
at protein levels too late in the injury, 40 days post inoculation and treatment.  We need 
to understand how injury and treatment alter protein levels of these enzymes much earlier 
in the injury, a week or two post inoculation and treatment.  In addition, at this time 
point, we can also determine protein levels of an enzyme involved in cholesterol 
synthesis, HMG-CoA reductase (Jaworski et al. 2016).  We looked at the inactive 
phosphorylated ACC enzyme, important in fatty acid synthesis, (Baenke et al. 2013), and 
next, we need to determine protein levels of the non-phosphorylated form in EAE mice 
treated with either water or glyceryl triacetate.  We found in these studies treatment with 
glyceryl triacetate significantly decreased p-ACC protein levels in EAE mice compared 
to control-treated EAE mice suggesting that acetate may shift ACC from an inactive to 
active form to promote fatty acid synthesis.  We expect that acetate supplementation 
results in a significant increase in non-phosphorylated ACC protein levels in EAE mice 
compared to control-treated EAE mice. 
 In addition to understanding protein levels of these enzymes, we also want to 
determine how activity of these enzymes are altered due to EAE and administration with 
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glyceryl triacetate.  With an end point of a week or two post inoculation and treatment, 
we expect treatment with glyceryl triacetate significantly increases protein and activity 
levels of these enzymes in EAE compared to control-treated EAE mice.  In addition, we 
will determine how treatment alters histone acetylation in EAE to correlate with changes 
in enzyme protein, mRNA, and activity levels.  We expect acetate supplementation 
results in an increase in histone acetylation similar to previous literature (Soliman & 
Rosenberger 2011, Soliman et al. 2012b) to correlate with a significant increase in 
enzyme protein, mRNA, and activity levels in EAE compared to control-treated EAE 
mice.  All these data will test the hypothesis that acetate supplementation alters CNS lipid 
metabolism and promotes myelin lipid deposition in mice subjected to EAE. 
 We can further understand how treatment alters lipid breakdown through the 
cPLA2 pathway.  Again, we found acetate supplementation returned cPLA2 back to 
control levels to suggest treatment may modulate pro-inflammatory lipid signaling.  We 
can determine spinal cord and brain protein levels of enzymes and metabolites involved 
in this pathway, and this includes cyclooxygenases (COX-1 and COX-2), lipoxygenases 
(5-lipooxgenase), leukotrienes, thromboxanes, and prostaglandins in control and EAE 
mice treated with either water or glyceryl triacetate.  We expect to find no significant 
difference in protein levels between the two control groups because there is no 
inflammatory stimulus present, but in control-treated EAE mice, we expect all protein 
levels will significantly increase due to the presence of chronic CNS inflammation.  
Acetate supplementation will then return levels back to control to support the idea that 
treatment modulates pro-inflammatory lipid signaling through the cPLA2 pathway.  In 
addition, we can determine CNS enzymatic activity of cPLA2, COX, and lipoxygenases 
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in control and EAE mice treated with either water or glyceryl triacetate.  We expect 
treatment decreases activity of cPLA2, COX, and lipoxygenase enzymes compared to 
control-treated EAE mice.  Treatment will return the EAE-induced cPLA2-mediated 
inflammation to control levels.  All these data will suggest treatment modulates pro-
inflammatory signaling and alters CNS lipid metabolism by reducing lipid breakdown. 
 Instead of using an in vivo model, it may be simpler and more cost effective to 
move into an in vitro model to determine how acetate alters lipid synthesis and 
breakdown to correlate with changes in lipid.  We can use BV2 microglia, for example, 
because we know acetate increases fatty acid content in LPS-stimulated BV2 microglia 
(Bhatt & Rosenberger 2014).  To continue the BV2 story, we can determine how acetate 
treatment alters phospholipid, cholesterol, and ganglioside content in LPS-stimulated 
cells.  We can also determine how treatment alters cPLA2 and PLC pathways looking at 
mRNA, protein, and activity of these enzymes.  In addition, we can determine mRNA 
and protein levels of downstream effects within these two pathways.  For example, in 
cPLA2-arachondic acid pathway, we can determine mRNA, protein, and activity levels of 
COX and 5-lipooxygenase, and we can determine mRNA and protein levels of 
inflammatory eicosanoids and leukotrienes.  We expect acetate will decrease cPLA2, 
COX, and 5-lipooxygenase mRNA, protein, and activity levels in LPS-stimulated BV2 
microglia.  This will correlate with a decrease in inflammatory eicosanoids and 
leukotrienes due to treatment in these cells to suggest that acetate reduces lipid 
breakdown.  As well, we can determine mRNA, protein, and activity levels of enzymes 
involved in lipid synthesis.  Enzymes of interest include the ones analyzed in Figure 11, 
HMG-CoA reductase, and fatty acid synthase.  Fatty acid synthase, in addition to ACC, 
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promotes the production of fatty acid (Jaworski et al. 2016).  We need to do a time 
dependent experiment to determine the appropriate time to analyze these enzymes.  We 
will have the following groups control BV2 cells treated with either sodium chloride or 
sodium acetate and LPS-stimulated BV2 cells treated with either sodium chloride or 
sodium acetate.  We will collect cells 10 minutes, 15 minutes, 20 minutes, 30 minutes, 1 
hour, 1.5 hours, and 2 hours post LPS and acetate treatment for protein analysis of these 
enzymes.  The reason we will end at 2 hours is that Bhatt and Rosenberger showed 
acetate treatment increases fatty acid content in LPS-stimulated BV2 cells 2 hours post 
treatment (Bhatt & Rosenberger 2014).  We need to determine at which time point we 
show a significant decrease in protein levels due to LPS, and acetate treatment returns 
levels back to control levels.  Once that time point is determined, we will treat cells for 
that length of time with LPS and acetate and collect for mRNA, protein, and enzymatic 
analysis to determine whether acetate alters lipid synthesis.  We can extend all these 
experiments in primary oligodendrocytes, and this is significant regarding promoting 
myelin lipid synthesis and/or reducing myelin lipid breakdown. 
 Also using in vitro BV2 microglia and oligodendrocyte models, we can determine 
if an inflammatory stimulus is necessary for glyceryl triacetate to alter lipid content or a 
stimulus, in general like myelin debris, is sufficient.  We can treat cells with various 
levels of LPS or MOG peptide and determine lipid content.  From that, if cells treated 
with LPS only show decreases in lipid content, this suggests an inflammatory stimulus is 
essential to show changes in lipid.  Or, if cells treated with LPS or MOG show decreases 
in lipid content, this suggests any injury stimulus is essential to show changes in lipid.  
Understanding this concept is important in understanding MS pathology and therapeutic 
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development.  If inflammation needs to be present to show demyelination, then a 
combinational therapy of current immunomodulatory therapy with a therapy promoting 
lipid synthesis and/or reducing lipid breakdown is where therapeutic research needs to 
focus.  If an injury stimulus, in general, is necessary, then, therapeutic research needs to 
focus on a remyelination therapy that may potentially replace immunomodulatory 
therapies.  In addition, if MOG results in a significant decrease in lipid content in LPS-
stimulated glia, we can treat cells with acetate to show the recovery of lipid and 
determine its role in promoting myelin lipid synthesis. 
 We hypothesized that treatment promotes lipid synthesis in EAE mice and that in 
turn stimulates myelin lipid deposition.  This can be tested using a radiotracer method 
previously described (Rosenberger et al. 2002).  C57BL/6 mice will undergo EAE 
inoculation induced by MOG peptide and pertussis toxin as described (Chevalier & 
Rosenberger 2017), and these animals will be administered prophylactic glyceryl 
triacetate treatment for 40 days as described (Chevalier & Rosenberger 2017).  Before 
animals are anesthetized and euthanized, these animals will be intravenously infused with 
radiolabeled hexadecanol ([1,1-3H]hexadecanol) using an infusion pump for 5 minutes at 
a rate of 0.4mL/min (Rosenberger et al. 2002).  Hexadecanol is a fatty alcohol and is 
incorporated into the ether phospholipid biosynthesis (Figure 13).  This fatty alcohol can 
cross the BBB and replace the acyl group on DHAP catalyzed by AGPS.  Then through a 
series of reactions described in Figure 13, PakEtn, PakCho, PlsEtn, and PlsCho are 
formed.  We can determine radioactivity and phospholipid content of these ether 
phospholipids by using thin layer chromatography with the 2D phospholipid separation 




Figure 13: Ether phospholipid biosynthesis (Rosenberger et al. 2002, Figure reproduced 
with permission).  Abbreviations include DHAP (dihydroxyacetonephosphate), 2-lyso-
PakOH (1-O-alkyl-2-lyso-sn-glycero-3-phosphate), PakOH (1-O-alkyl-2-acyl-sn-glycero-
3-phosphate), PakCho (1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine or 
plasmanylcholine), PakEtn (1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine or 
plasmanylethanolamine), PlsEtn (ethanolamine plasmalogen), and PlsCho (choline 
plasmalogen).  Enzymes involved include the following: 1) glyceronephosphate O-
acyltransferase (GNPAT), 2) alkylglycerone phosphate synthase (AGPS), 3) alkyl-DHAP 
reductase, 4) 1-O-alkyl-2-acyl-sn-glycerol-3-phosphate acyltransferase, 5) 1-O-alkyl-2-
acyl-sn-glycerol-3-phosphate phosphohydrolase, 6)1-O-alkyl-2-acyl-sn-glycerol choline 
phosphotransferase, and 7)1-O-alkyl-2-acyl-sn-glycerol ethanolamine 
phosphotransferase.  Line indicates where in the synthesis that it transports from the 
peroxisome to the endoplasmic reticulum (ER).
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addition, part of the sample separated on thin layer chromatography can be used to 
determine radioactivity of each ether phospholipid.  We expect acetate supplementation 
significantly increases radiolabeled hexadecanol into PakEtn and PakCho content in EAE 
mice compared to control-treated EAE mice but similar to controls.  In these studies, 
treatment altered PtdEtn + PakEtn and PtdCho + PakCho fractions in the EtnGpl and 
ChoGpl phospholipid groups in EAE mice.  All these data will suggest treatment 
incorporates into the ether phospholipid biosynthesis to promote myelin lipid deposition. 
 In addition, we can determine the expression and activity of enzymes involved in 
the ether phospholipid biosynthesis (Figure 13).  Enzymes of interest include 
glyceronephosphate O-acyltransferase (GNPAT), AGPS, alkyl-DHAP reductase, 1-O-
alkyl-2-acyl-sn-glycerol-3-phosphate acyltransferase, 1-O-alkyl-2-acyl-sn-glycerol-3-
phosphate phosphohydrolase, 1-O-alkyl-2-acyl-sn-glycerol choline phosphotransferase, 
and 1-O-alkyl-2-acyl-sn-glycerol ethanolamine phosphotransferase.  These enzymes are 
involved in the production of PakEtn and PakCho, and the particular reaction of each 
enzyme is shown in Figure 13.  GNPAT catalyzes the addition on an acyl group on 
DHAP and then, the acyl group is replaced with a fatty alcohol catalyzed by AGPS 
(Braverman & Moser 2012).  The remaining enzymes are involved in the final steps 
leading to the production of plasmanyl ether phospholipids (Rosenberger et al. 2002).  
We expect acetate supplementation results in a significant increase in protein and activity 
of these enzymes involved in ether phospholipid biosynthesis in EAE mice compared to 
control-treated EAE mice but similar to controls. 
 After the above experiments, we can move into an in vitro model to determine 
how treatment directly affects the ether phospholipid biosynthesis.  First, we can repeat 
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the above experiments in BV2 microglia and oligodendrocytes and determine 
radioactivity and ether phospholipid content of PakEtn, PakCho, PlsEtn, and PlsCho.  In 
addition, we can use enzyme inhibitors and determine how treatment alters ether 
phospholipid content when particular enzymes are inhibited.  We can determine if acetate 
alters the expression and activity of particular enzymes involved in this pathway or alters 
all enzymes.  We expect that treatment in particular alters the rate limiting step in ether 
phospholipid biosynthesis, AGPS (Braverman & Moser 2012, Rosenberger et al. 2002). 
These suggest that treatment promotes myelin lipid deposition by showing changes in 
ether phospholipid content and altering expression and activity of enzymes involved in 
this pathway. 
 In the EAE model, we can determine how acetate supplementation alters the 
peripheral and central nervous system immune responses.  We know that acetate 
supplementation is anti-inflammatory in rat models of neuroinflammation and 
neuroborreliosis as well as in in vitro neuroglia (Brissette et al. 2012, Reisenauer et al. 
2011, Soliman et al. 2012b, Soliman et al. 2013a, Soliman et al. 2013b, Soliman et al. 
2012a).  We can determine the anti-inflammatory effects of glyceryl triacetate in the EAE 
model as well as in BV2 microglia and oligodendrocytes by using flow cytometry and 
ELISA to determine immune cell count and cytokine levels.  Using flow cytometry, we 
can determine CD4 T-cell, CD8 T-cell, and macrophage populations in blood, spinal 
cord, and brain of control and EAE mice treated with either water or glyceryl triacetate.  
We expect the populations of these cells are lower in glyceryl triacetate-treated EAE 
mice compared control-treated EAE mice but similar to controls.  In vitro, we can also 
use flow cytometry to determine the populations of these cells.  We will treat BV2 
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microglia and primary oligodendrocytes with LPS and acetate and collect samples for 
flow cytometry analysis to count immune cell populations.  Using ELISA, we can 
determine cytokine levels in blood, spinal cord, and brain in control and EAE mice 
treated with either water or glyceryl triacetate.  We expect acetate supplementation 
decreases pro-inflammatory cytokines in EAE mice compared to control-treated EAE 
mice but similar to non-EAE controls.  If ELISA is unable to detect cytokine levels in the 
blood and CNS of these animals, we can also use flow cytometry to determine cytokine 
populations by targeting particular cytokines to separate from the rest of the population.  
The same experiments can be extrapolated to in vitro BV2 microglia and 
oligodendrocytes. 
 Acetate may promote myelination and oligodendrocyte differentiation.  In 
primary oligodendrocytes, we expect acetate treatment increases lipid content in LPS-
stimulated cells to correlate with changes in mRNA of markers associated with 
oligodendrocyte differentiation.  These markers will include Tcf4 for immature 
oligodendrocytes, Mytl for mature oligodendrocytes, and Olig1 for oligodendrocytes in 
general (Emery 2010, Woodruff et al. 2001, Arnett et al. 2004).  Furthermore, we can use 
different markers to determine the number of OPC, immature oligodendrocytes, and 
mature oligodendrocytes.  OPC markers will include A2B5, a polysialoganglioside, NG2, 
PDGFRα, Sox5, Sox6, Sox 9, Hes 5, Id2, Id2, Id4, and E2A, and immature 
oligodendrocyte markers will include O1 antigen, galactosylcerebroside, and Tcf4.  
Mature oligodendrocyte markers will include MBP, PLP, YY1, Mytl, ZPF191, and MRF 






 Multiple sclerosis (MS) is an inflammatory demyelinating neurodegenerative 
disorder (Cusick et al. 2013, Lassmann & van Horssen 2011, McQualter & Bernard 
2007).  There are two mechanisms by which demyelination and the loss of myelin lipid 
can occur, immune-mediated and oligodendrocyte-deficient demyelination (Lucchinetti et 
al. 2000, Nakahara et al. 2012).  Immune-mediated demyelination, presented in MS 
lesion patterns I and II (Lucchinetti et al. 2000), result from a self-antigen attack on the 
central nervous system (CNS) (Cusick et al. 2013).  There is the presence of autoreactive 
T-cells, activated microglia and macrophages, and pro-inflammatory cytokines to result 
in chronic CNS inflammation that contribute to demyelination (Cusick et al. 2013, 
Lassmann & van Horssen 2011, McQualter & Bernard 2007).  Oligodendrocyte-deficient 
demyelination, presented in MS lesion patterns III and IV (Lucchinetti et al. 2000), 
results from a dysfunction in oligodendrocyte survival, maturation, and function 
(Lucchinetti et al. 2000).  Oligodendrocytes are myelinating CNS glia cells (Boulanger & 
Messier 2014, Mitew et al. 2014), so a dysfunction in oligodendrocyte survival, 
maturation, and function also contributes to demyelination.  Current MS available 
therapies only modulate the immune response of the disease (Lim & Constantinescu 
2010) but do not treat the oligodendrocyte-deficient demyelination.  Developing a 
therapy to stimulate lipid deposition and/or reduce lipid breakdown within the CNS may 
be a mechanism to treat MS in addition to current available therapies.
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 We hypothesized that acetate supplementation, administered as glyceryl triacetate, 
alters CNS lipid metabolism in mice subjected to experimental autoimmune 
encephalomyelitis (EAE), an autoimmune model for MS.  We determined the effect of 
this treatment on disease progression, CNS lipid content, and CNS protein levels in mice 
subjected to EAE.  We found acetate supplementation attenuated the onset of clinical 
symptoms in these animals shown by a daily clinical score and hang time test.  In 
addition, treatment prevented the loss of spinal cord phospholipid, fatty acid, and 
cholesterol content in mice subjected to EAE.  Treatment significantly increased spinal 
cord GD3 and GD1a ganglioside levels in EAE mice compared to control-treated EAE 
mice.  Regarding total brain and myelin brain lipid content, acetate supplementation 
increased phospholipid and ganglioside content in EAE mice compared to control-treated 
EAE mice.  We also determined protein levels of enzymes involved in lipid metabolism, 
cytoskeletal structure, and myelin structure.  We found acetate supplementation returned 
cPLA2 to control levels to suggest treatment modulates pro-inflammatory lipid 
breakdown.  Treatment did not return the cytoskeletal proteins, β-actin and merlin, back 
to control levels in EAE mice suggesting that treatment does not alter all EAE pathology.  
Interestingly, acetate supplementation returned oligodendrocyte myelin glycoprotein 
(OMgp) to control levels in EAE mice suggesting that treatment may promote 
remyelination and axonal growth because OMgp is known to inhibit both (Cafferty et al. 
2010, Huang et al. 2005, Kan et al. 2016, Mikol et al. 1993, Vourc'h & Andres 2004, 
Wang et al. 2002).  Furthermore, treatment significantly decreased phosphorylated 
acetyl-CoA carboxylase (p-ACC) levels in EAE compared to control-treated EAE mice 
indicating acetate may shift this enzyme from the inactive phosphorylated to an active 
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non-phosphorylated form to promote fatty acid synthesis.  Acetate supplementation 
attenuated disease progression, altered CNS and myelin lipid content, and influenced 
CNS and myelin protein content in mice subjected to EAE. 
 Future studies will address whether acetate supplementation stimulates myelin 
lipid deposition, reduces lipid breakdown, or combination of both.  Using different MS 
animal models and LPS-stimulated neuroglia models, we will determine how treatment 
alters mechanisms involved in lipid synthesis and breakdown by determining protein 
expression, mRNA expression, and enzymatic activities of enzymes and proteins 
involved in these pathways.  Furthermore, we will determine the effectiveness of 
prophylactic glyceryl triacetate treatment in other MS animal models like cuprizone and 
relapse-remitting EAE models.  We will also determine the effectiveness of 
interventional glyceryl triacetate treatments in the cuprizone, relapse-remitting EAE, and 
progressive EAE models to determine the clinical benefits in the treatment of MS, since 
patients are only prescribed medications when symptoms develop.  Future studies will 
determine whether acetate supplementation promotes myelin lipid deposition and/or 
reduces the breakdown to show that recovery of CNS lipid lost due to demyelination.   
 If acetate supplementation alters CNS lipid metabolism in MS animal models, this 
may start the conversation on whether MS may be a metabolic disorder (Corthals 2011).  
MS is considered an autoimmune disorder, but there may be an underlying dysfunction in 
lipid metabolism (Corthals 2011). As well, these studies provide insight into the potential 
mechanisms of action regarding glyceryl triacetate in mice subjected to EAE.  In a 
healthy normal state, there is a natural lipid turnover (Ando et al. 2003, Rosenberger et al. 
2002, Moser et al. 1999), but treatment may have a greater effect on energy production 
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and histone acetylation (Bhatt et al. 2013, Soliman & Rosenberger 2011, Soliman et al. 
2012b).  Regarding the EAE injury, lipid lost is significantly higher compared to lipid 
produced, where glyceryl triacetate-treated EAE mice show a normal lipid turnover rate 
either by promoting lipid synthesis, reducing lipid breakdown, or a combination of both.  







List of Abbreviations 
16:0: palmitic acid 
18:0: stearic acid 
18:1n-9: oleic acid 
18:1n-7: vaccenic acid 
18:2n-6: linoleic acid 
18:3n3: alpha-linolenic acid 
20:1n-9: eicosenoic acid 
20:4n-6: arachidonic acid 
22:4n-6: adrenic acid 
22:6n-3: docosahexaenoic acid or DHA 
24:0: lignoceric acid 
24:1n-9: nervonic acid 
2D: two-dimensional 
2-lyso-PakOH: 1-O-alkyl-2-lyso-sn-glycero-3-phosphate 
AceCS1/2: acyl-CoA synthetase 
AGPS: alkylglycerone phosphate synthase 
ASPA: aspartoacylase 




BBB: blood brain barrier  
BV2: immortalized murine cell line 
CD: cluster of differentiation 
CerPCho: sphingomyelin 
ChoGpl: choline glycerophospholipid 
CNS: central nervous system 
CoA: coenzyme A 
COX: cyclooxygenase 
cPLA2: cytosolic phospholipase A2 
DAG: diacylglycerol 
DHAP: dihydroxyacetone phosphate 
DHEA: dehydroepiandrosterone 
DMT: disease-modifying therapy 
DNA: deoxyribonucleic acid 
EAE: experimental autoimmune encephalomyelitis 
EPA: eicosapentaenoic acid 
ER: endoplasmic reticulum 
EtnGpl: ethanolamine glycerophospholipid 
FDA: food and drug administration 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GLUT1: glucose transporter 
GNPAT: glyceronephosphate O-acyltransferase 




HDAC: histone deacetylase 
HMG: β-hydroxy-β-methylglutaryl 




IGF-1: insulin-like growth factor 1 
IL: interleukin 
JNK: jun N-terminal kinase 
LPS: lipopolysaccharide 
MAG: myelin-associated glycoprotein 
MAPK: mitogen-activated protein kinase 
MBP: myelin basic protein 
Merlin: moesin-, ezrin-, radixin-like protein 
MHC: major histocompatibility complex 
MK-801: drug induces hypoacetylation 
MOG: myelin oligodendrocyte glycoprotein 
MRI: magnetic resonance imaging 
MS: multiple sclerosis 
NAA: N-acetylaspartate 
NANA: N-acetyl-neuraminic acid (sialic acid) 
NF-κB: nuclear factor kappa B 
113 
 
OMgp: oligodendrocyte myelin glycoprotein 
OPC: oligodendrocyte progenitor cell 
p-ACC: phosphorylated acetyl-CoA carboxylase 
PAF: platelet-activating factor 
pcPLA2: phosphorylated cytosolic PLA2 
PDGF: platelet-derived growth factor 
PDGFRα: platelet-derived growth factor receptor A 
PLC: phospholipase C 
PLP: proteolipid protein 
PlsCho: 1-O-alkenyl-2-acyl-sn-glycero-3-phosphocholine or plasmenylcholine or choline  
 plasmalogen 
PlsEtn: 1-O-alkenyl-2-acyl-sn-glycero-3-phosphoethanolamine or  
 plasmenylethanolamine or ethanolamine plasmalogen 
PtdCho: 1,2-diacyl-sn-glycero-3-phosphocholine or phosphatidylcholine 
PakCho: 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine or plasmanylcholine 
PtdEtn: 1,2-diacyl-sn-glycero-3-phosphoethanolamine or phosphatidylethanolamine 
PakEtn: 1-O-alkyl-2-acyl-sn-glycero-3-phosphoethanoline or plasmanylethanolamine 
PakOH: 1-O-alkyl-2-acyl-sn-glycero-3-phosphate 
PtdIns: 1,2-diacyl-sn-glycero-3-phosphoinositol or phosphatidylinositol 
PtdIns(4,5)P2: 1,2-Diacyl-sn-glycero-3-phospho-(1-D-myo-inositol 4,5-bisphosphate) or  
 phosphatidylinositol-4,5-bisphosphate 
PtdOH: 1,2-diacyl-sn-glycero-3-phosphate or phosphatidic acid 
PtdSer: 1,2-diacyl-sn-glycero-3-phosphoserine or phosphatidylserine 
114 
 
SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
TCA cycle: tricarboxylic acid cycle  
TGF-β: transforming growth factor beta 
Th1/Th17: T helper cell 1/17 
TMEV: theiler’s murine encephalomyelitis 
TNF-α: tumor necrosis factor alpha 
VCAM-1: vascular cell adhesion molecule-1 





 Study I of this dissertation is derived almost entirely from publication where 
Amber Chevalier is listed as the primary author.  Copyright clearance was obtained from 
the publishers of John Wiley and Sons for Study I to reproduce text, figures, and legends 
for this dissertation.  The published manuscript for the study is listed below.  
Chevalier, A. C. and Rosenberger, T. A. (2017) Increasing acetyl-CoA metabolism 
attenuates injury and alters spinal cord lipid content in mice subjected to 





Acarin, N., Rio, J., Fernandez, A. L., Tintore, M., Duran, I., Galan, I. and Montalban, X. 
(1996) Different antiganglioside antibody pattern between relapsing-remitting and 
progressive multiple sclerosis. Acta Neurol Scand, 93, 99-103. 
Aggarwal, S., Yurlova, L. and Simons, M. (2011) Central nervous system myelin: 
structure, synthesis and assembly. Trends Cell Biol, 21, 585-593. 
Al-Izki, S., Pryce, G., Jackson, S. J., Giovannoni, G. and Baker, D. (2011) 
Immunosuppression with FTY720 is insufficient to prevent secondary progressive 
neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler, 
17, 939-948. 
Alling, C., Vanier, M. T. and Svennerholm, L. (1971) Lipid alterations in apparently 
normal white matter in multiple sclerosis. Brain Res, 35, 325-336. 
Amaral, A., Hadera, M. G., Kotter, M. and Sonnewald, U. (2017) Oligodendrocytes Do 
Not Export NAA-Derived Aspartate In Vitro. Neurochem Res, 42, 827-837. 
Amaral, A. I., Hadera, M. G., Tavares, J. M., Kotter, M. R. and Sonnewald, U. (2016) 
Characterization of glucose-related metabolic pathways in differentiated rat 
oligodendrocyte lineage cells. Glia, 64, 21-34. 
Ando, S., Tanaka, Y., Toyoda, Y. and Kon, K. (2003) Turnover of myelin lipids in aging 
brain. Neurochem Res, 28, 5-13. 
Arnett, H. A., Fancy, S. P., Alberta, J. A. et al. (2004) bHLH transcription factor Olig1 is 
required to repair demyelinated lesions in the CNS. Science, 306, 2111-2115. 
Arun, P., Ariyannur, P. S., Moffett, J. R., Xing, G., Hamilton, K., Grunberg, N. E., Ives, 
J. A. and Namboodiri, A. M. (2010a) Metabolic acetate therapy for the treatment 
of traumatic brain injury. J Neurotrauma, 27, 293-298.
117 
 
Arun, P., Madhavarao, C. N., Moffett, J. R. et al. (2010b) Metabolic acetate therapy 
improves phenotype in the tremor rat model of Canavan disease. J Inherit Metab 
Dis, 33, 195-210. 
Autilio, L. A., Norton, W. T. and Terry, R. D. (1964) The Preparation and Some 
Properties of Purified Myelin from the Central Nervous System. J Neurochem, 11, 
17-27. 
Baenke, F., Peck, B., Miess, H. and Schulze, A. (2013) Hooked on fat: the role of lipid 
synthesis in cancer metabolism and tumour development. Dis Model Mech, 6, 
1353-1363. 
Bansal, R., Warrington, A. E., Gard, A. L., Ranscht, B. and Pfeiffer, S. E. (1989) 
Multiple and novel specificities of monoclonal antibodies O1, O4, and R-mAb 
used in the analysis of oligodendrocyte development. J Neurosci Res, 24, 548-
557. 
Barcelo-Coblijn, G. and Murphy, E. J. (2009) Alpha-linolenic acid and its conversion to 
longer chain n-3 fatty acids: benefits for human health and a role in maintaining 
tissue n-3 fatty acid levels. Prog Lipid Res, 48, 355-374. 
Baslow, M. H., Suckow, R. F., Sapirstein, V. and Hungund, B. L. (1999) Expression of 
aspartoacylase activity in cultured rat macroglial cells is limited to 
oligodendrocytes. J Mol Neurosci, 13, 47-53. 
Basso, A. S., Frenkel, D., Quintana, F. J. et al. (2008) Reversal of axonal loss and 
disability in a mouse model of progressive multiple sclerosis. J Clin Invest, 118, 
1532-1543. 
Batoulis, H., Recks, M. S., Addicks, K. and Kuerten, S. (2011) Experimental 
autoimmune encephalomyelitis--achievements and prospective advances. APMIS, 
119, 819-830. 
Bauer, M., Brakebusch, C., Coisne, C., Sixt, M., Wekerle, H., Engelhardt, B. and Fassler, 
R. (2009) Beta1 integrins differentially control extravasation of inflammatory cell 




Benardais, K., Kotsiari, A., Skuljec, J., Koutsoudaki, P. N., Gudi, V., Singh, V., 
Vulinovic, F., Skripuletz, T. and Stangel, M. (2013) Cuprizone 
[bis(cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes. 
Neurotox Res, 24, 244-250. 
Benjamins, J. A., Murphy, E. J. and Seyfried, T. N. (2012) Lipids: Basic  neurochemistry 
principles of molecular, cellular, and medical neurobiology. Elsevier Academic 
Press, Amsterdam. 
Berard, J., Wolak, K., Fournier, S. and David, S. (2010) Characterization of relapsing-
remitting and chronic forms of experimental auotimmune encephalomyelitis in 
C57BL/6 mice. Glia, 58, 434-445. 
Berghoff, S. A., Gerndt, N., Winchenbach, J. et al. (2017) Dietary cholesterol promotes 
repair of demyelinated lesions in the adult brain. Nat Commun, 8, 14241. 
Berti, R., Brennan, M. B., Soldan, S. S., Ohayon, J. M., Casareto, L., McFarland, H. F. 
and Jacobson, S. (2002) Increased detection of serum HHV-6 DNA sequences 
during multiple sclerosis (MS) exacerbations and correlation with parameters of 
MS disease progression. J Neurovirol, 8, 250-256. 
Bhakoo, K. K., Craig, T. J. and Styles, P. (2001) Developmental and regional distribution 
of aspartoacylase in rat brain tissue. J Neurochem, 79, 211-220. 
Bhatt, D. P., Houdek, H. M., Watt, J. A. and Rosenberger, T. A. (2013) Acetate 
supplementation increases brain phosphocreatine and reduces AMP levels with no 
effect on mitochondrial biogenesis. Neurochem Int, 62, 296-305. 
Bhatt, D. P. and Rosenberger, T. A. (2014) Acetate treatment increases fatty acid content 
in LPS-stimulated BV2 microglia. Lipids, 49, 621-631. 
Boghozian, R., McKenzie, B. A., Saito, L. B., Mehta, N., Branton, W. G., Lu, J., Baker, 
G. B., Noorbakhsh, F. and Power, C. (2017) Suppressed oligodendrocyte 
steroidogenesis in multiple sclerosis: Implications for regulation of 
neuroinflammation. Glia, 65, 1590-1606. 
Boulanger, J. J. and Messier, C. (2014) From precursors to myelinating oligodendrocytes: 
contribution of intrinsic and extrinsic factors to white matter plasticity in the adult 
brain. Neuroscience, 269, 343-366. 
119 
 
Bowman, R. E. and Wolf, R. C. (1962) A rapid and specific ultramicro method for total 
serum cholesterol. Clin Chem, 8, 302-309. 
Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 
72, 248-254. 
Braverman, N. E. and Moser, A. B. (2012) Functions of plasmalogen lipids in health and 
disease. Biochim Biophys Acta, 1822, 1442-1452. 
Breckenridge, W. C. and Kuksis, A. (1968) Specific distribution of short-chain fatty acids 
in molecular distillates of bovine milk fat. J Lipid Res, 9, 388-393. 
Brissette, C. A., Houdek, H. M., Floden, A. M. and Rosenberger, T. A. (2012) Acetate 
supplementation reduces microglia activation and brain interleukin-1beta levels in 
a rat model of Lyme neuroborreliosis. J Neuroinflammation, 9, 249. 
Brites, P., Waterham, H. R. and Wanders, R. J. (2004) Functions and biosynthesis of 
plasmalogens in health and disease. Biochim Biophys Acta, 1636, 219-231. 
Burgisser, P., Althaus, H. H., Rohmann, A. and Neuhoff, V. (1988) Lipid synthesis by 
oligodendrocytes from adult pig brain maintained in long-term culture. 
Neurochem Int, 13, 111-118. 
Cafferty, W. B., Duffy, P., Huebner, E. and Strittmatter, S. M. (2010) MAG and OMgp 
synergize with Nogo-A to restrict axonal growth and neurological recovery after 
spinal cord trauma. J Neurosci, 30, 6825-6837. 
Cahoy, J. D., Emery, B., Kaushal, A. et al. (2008) A transcriptome database for 
astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain 
development and function. J Neurosci, 28, 264-278. 
Campagnoni, A. T. and Campagnoni, C. W. (2004) Myelin basic protein gene: Myelin 
biology and disorders. Elsevier Academic Press, San Diego. 
Cermelli, C., Berti, R., Soldan, S. S., Mayne, M., D'Ambrosia J, M., Ludwin, S. K. and 
Jacobson, S. (2003) High frequency of human herpesvirus 6 DNA in multiple 
sclerosis plaques isolated by laser microdissection. J Infect Dis, 187, 1377-1387. 
120 
 
Chakraborty, G., Mekala, P., Yahya, D., Wu, G. and Ledeen, R. W. (2001) Intraneuronal 
N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for 
myelin-associated aspartoacylase. J Neurochem, 78, 736-745. 
Challoner, P. B., Smith, K. T., Parker, J. D. et al. (1995) Plaque-associated expression of 
human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A, 92, 7440-
7444. 
Chan, Y. M., Merkens, L. S., Connor, W. E., Roullet, J. B., Penfield, J. A., Jordan, J. M., 
Steiner, R. D. and Jones, P. J. (2009) Effects of dietary cholesterol and 
simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res, 
65, 681-685. 
Chapenko, S., Millers, A., Nora, Z., Logina, I., Kukaine, R. and Murovska, M. (2003) 
Correlation between HHV-6 reactivation and multiple sclerosis disease activity.  
J Med Virol, 69, 111-117. 
Chevalier, A. C. and Rosenberger, T. A. (2017) Increasing acetyl-CoA metabolism 
attenuates injury and alters spinal cord lipid content in mice subjected to 
experimental autoimmune encephalomyelitis. J Neurochem, 141, 721-737. 
Chhetry, B. T., Hezghia, A., Miller, J. M., Lee, S., Rubin-Falcone, H., Cooper, T. B., 
Oquendo, M. A., Mann, J. J. and Sublette, M. E. (2016) Omega-3 polyunsaturated 
fatty acid supplementation and white matter changes in major depression.  
J Psychiatr Res, 75, 65-74. 
Chiavegatto, S., Sun, J., Nelson, R. J. and Schnaar, R. L. (2000) A functional role for 
complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice.  
Exp Neurol, 166, 227-234. 
Chrast, R., Saher, G., Nave, K. A. and Verheijen, M. H. (2011) Lipid metabolism in 
myelinating glial cells: lessons from human inherited disorders and mouse 
models. J Lipid Res, 52, 419-434. 
Cinti, D. L., Cook, L., Nagi, M. N. and Suneja, S. K. (1992) The fatty acid chain 




Constantinescu, C. S., Farooqi, N., O'Brien, K. and Gran, B. (2011) Experimental 
autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).  
Br J Pharmacol, 164, 1079-1106. 
Corthals, A. P. (2011) Multiple sclerosis is not a disease of the immune system.  
Q Rev Biol, 86, 287-321. 
Cumings, J. N. (1953) The cerebral lipids in disseminated sclerosis and in amaurotic 
family idiocy. Brain, 76, 551-562. 
Cumings, J. N. (1969) The lipid composition of pure myelin in some demyelinating 
disorders. Neuropatol Pol, 7, 255-260. 
Cumings, J. N. and Goodwin, H. (1968) Sphingolopids and phospholipids of myelin in 
multiple sclerosis. Lancet, 2, 664-665. 
Cusick, M. F., Libbey, J. E. and Fujinami, R. S. (2013) Multiple sclerosis: autoimmunity 
and viruses. Curr Opin Rheumatol, 25, 496-501. 
D'Adamo, A. F., Jr. and Yatsu, F. M. (1966) Acetate metabolism in the nervous system. 
N-acetyl-L-aspartic acid and the biosynthesis of brain lipids. J Neurochem, 13, 
961-965. 
Dahlin, M., Martin, D. A., Hedlund, Z., Jonsson, M., von Dobeln, U. and Wedell, A. 
(2015) The ketogenic diet compensates for AGC1 deficiency and improves 
myelination. Epilepsia, 56, e176-181. 
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M. E., de Courten, M., Matsoukas, J. 
and Apostolopoulos, V. (2017) Multiple Sclerosis: Immunopathology and 
Treatment Update. Brain Sci, 7. 
Davison, A. N. and Wajda, M. (1962) Cerebral lipids in multiple sclerosis. J Neurochem, 
9, 427-432. 
de Castro, F., Bribian, A. and Ortega, M. C. (2013) Regulation of oligodendrocyte 
precursor migration during development, in adulthood and in pathology.  
Cell Mol Life Sci, 70, 4355-4368. 
122 
 
Delbue, S., Comar, M. and Ferrante, P. (2017) Natalizumab treatment of multiple 
sclerosis: new insights. Immunotherapy, 9, 157-171. 
Della-Flora Nunes, G., Mueller, L., Silvestri, N., Patel, M. S., Wrabetz, L., Feltri, M. L. 
and Poitelon, Y. (2017) Acetyl-CoA production from pyruvate is not necessary 
for preservation of myelin. Glia, 65, 1626-1639. 
Denic, A., Johnson, A. J., Bieber, A. J., Warrington, A. E., Rodriguez, M. and Pirko, I. 
(2011) The relevance of animal models in multiple sclerosis research. 
Pathophysiology, 18, 21-29. 
Deon, M., Garcia, M. P., Sitta, A. et al. (2008) Hexacosanoic and docosanoic acids 
plasma levels in patients with cerebral childhood and asymptomatic X-linked 
adrenoleukodystrophy: Lorenzo's oil effect. Metab Brain Dis, 23, 43-49. 
Eichberg, J. and Iyer, S. (1996) Phosphorylation of myelin protein: recent advances. 
Neurochem Res, 21, 527-535. 
Elias, E. R., Irons, M. B., Hurley, A. D., Tint, G. S. and Salen, G. (1997) Clinical effects 
of cholesterol supplementation in six patients with the Smith-Lemli-Opitz 
syndrome (SLOS). Am J Med Genet, 68, 305-310. 
Emery, B. (2010) Regulation of oligodendrocyte differentiation and myelination. Science, 
330, 779-782. 
Ferdinandusse, S., Denis, S., Mooijer, P. A., Zhang, Z., Reddy, J. K., Spector, A. A. and 
Wanders, R. J. (2001) Identification of the peroxisomal beta-oxidation enzymes 
involved in the biosynthesis of docosahexaenoic acid. J Lipid Res, 42, 1987-1995. 
Folch, J., Lees, M. and Sloane Stanley, G. H. (1957) A simple method for the isolation 
and purification of total lipides from animal tissues. J Biol Chem, 226, 497-509. 
Georgiou, J., Tropak, M. P. and Roder, J. C. (2004) Myelin-associated glycoprotein gene: 
Myelin biology and disorders. Elsevier Academic Press, San Diego. 
Gerstl, B., Eng, L. F., Tavaststjerna, M., Smith, J. K. and Kruse, S. L. (1970) Lipids and 
proteins in multiple sclerosis white matter. J Neurochem, 17, 677-689. 
123 
 
Gerstl, B., Kahnke, M. J., Smith, J. K., Tavaststjerna, M. G. and Hayman, R. B. (1961) 
Brain lipids in multiple sclerosis and other diseases. Brain, 84, 310-319. 
Glade, M. J. and Smith, K. (2015) Phosphatidylserine and the human brain. Nutrition, 31, 
781-786. 
Gordon, N. (2000) Canavan disease: a review of recent developments. European Journal 
of Paediatric Neurology, 5, 65-69. 
Greer, J. M. and Lees, M. B. (2002) Myelin proteolipid protein--the first 50 years.  
Int J Biochem Cell Biol, 34, 211-215. 
Haas, D., Garbade, S. F., Vohwinkel, C., Muschol, N., Trefz, F. K., Penzien, J. M., 
Zschocke, J., Hoffmann, G. F. and Burgard, P. (2007) Effects of cholesterol and 
simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS).  
J Inherit Metab Dis, 30, 375-387. 
Hajra, A. K. (1995) Glycerolipid biosynthesis in peroxisomes (microbodies). Prog Lipid 
Res, 34, 343-364. 
Hampton, D. W., Anderson, J., Pryce, G. et al. (2008) An experimental model of 
secondary progressive multiple sclerosis that shows regional variation in gliosis, 
remyelination, axonal and neuronal loss. J Neuroimmunol, 201-202, 200-211. 
Handel, A. E., Williamson, A. J., Disanto, G., Handunnetthi, L., Giovannoni, G. and 
Ramagopalan, S. V. (2010) An updated meta-analysis of risk of multiple sclerosis 
following infectious mononucleosis. PLoS One, 5. 
Hovens, C. M. and Kaye, A. H. (2001) The tumour suppressor protein NF2/merlin: the 
puzzle continues. J Clin Neurosci, 8, 4-7. 
Huang, J. K., Phillips, G. R., Roth, A. D. et al. (2005) Glial membranes at the node of 
Ranvier prevent neurite outgrowth. Science, 310, 1813-1817. 
Hudson, L. D. (2004) Proteolipid protein gene: Myelin biology and disorders. Elsvier 
Academic Press, San Diego. 
124 
 
Irons, M., Elias, E. R., Abuelo, D. et al. (1997) Treatment of Smith-Lemli-Opitz 
syndrome: results of a multicenter trial. Am J Med Genet, 68, 311-314. 
Jaworski, D. M., Namboodiri, A. M. and Moffett, J. R. (2016) Acetate as a Metabolic and 
Epigenetic Modifier of Cancer Therapy. J Cell Biochem, 117, 574-588. 
Jung, J., Cai, W., Lee, H. K. et al. (2011) Actin polymerization is essential for myelin 
sheath fragmentation during Wallerian degeneration. J Neurosci, 31, 2009-2015. 
Kakalacheva, K., Munz, C. and Lunemann, J. D. (2011) Viral triggers of multiple 
sclerosis. Biochim Biophys Acta, 1812, 132-140. 
Kalyvas, A. and David, S. (2004) Cytosolic phospholipase A2 plays a key role in the 
pathogenesis of multiple sclerosis-like disease. Neuron, 41, 323-335. 
Kan, Q. C., Zhang, H. J., Zhang, Y. et al. (2016) Matrine Treatment Blocks NogoA-
Induced Neural Inhibitory Signaling Pathway in Ongoing Experimental 
Autoimmune Encephalomyelitis. Mol Neurobiol. 
Kennedy, E. P. (1986) The biosynthesis of phospholipids: Lipids and membranes: past, 
present, and future. Elsevier, Amsterdam. 
Kihara, A. (2012) Very long-chain fatty acids: elongation, physiology and related 
disorders. J Biochem, 152, 387-395. 
Kim, H. Y., Huang, B. X. and Spector, A. A. (2014) Phosphatidylserine in the brain: 
metabolism and function. Prog Lipid Res, 56, 1-18. 
Kipp, M., Nyamoya, S., Hochstrasser, T. and Amor, S. (2017) Multiple sclerosis animal 
models: a clinical and histopathological perspective. Brain Pathol, 27, 123-137. 
Kirmani, B. F., Jacobowitz, D. M., Kallarakal, A. T. and Namboodiri, M. A. (2002) 
Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: 




Kirmani, B. F., Jacobowitz, D. M. and Namboodiri, M. A. (2003) Developmental 
increase of aspartoacylase in oligodendrocytes parallels CNS myelination.  
Brain Res Dev Brain Res, 140, 105-115. 
Kishimoto, Y., Radin, N. S., Tourtellotte, W. W., Parker, J. A. and Itabashi, H. H. (1967) 
Gangliosides and glycerophospholipids in multiple sclerosis white matter.  
Arch Neurol, 16, 41-54. 
Klepper, J., Engelbrecht, V., Scheffer, H., van der Knaap, M. S. and Fiedler, A. (2007) 
GLUT1 deficiency with delayed myelination responding to ketogenic diet. 
Pediatr Neurol, 37, 130-133. 
Knox, K. K., Brewer, J. H., Henry, J. M., Harrington, D. J. and Carrigan, D. R. (2000) 
Human herpesvirus 6 and multiple sclerosis: systemic active infections in patients 
with early disease. Clin Infect Dis, 31, 894-903. 
Kracun, I., Rosner, H., Drnovsek, V., Heffer-Lauc, M., Cosovic, C. and Lauc, G. (1991) 
Human brain gangliosides in development, aging and disease. Int J Dev Biol, 35, 
289-295. 
Kumar, S., Mattan, N. S. and de Vellis, J. (2006) Canavan disease: a white matter 
disorder. Ment Retard Dev Disabil Res Rev, 12, 157-165. 
Lassmann, H. and van Horssen, J. (2011) The molecular basis of neurodegeneration in 
multiple sclerosis. FEBS Lett, 585, 3715-3723. 
Li, M., Li, Y., Liu, X., Gao, X. and Wang, Y. (2012) IL-33 blockade suppresses the 
development of experimental autoimmune encephalomyelitis in C57BL/6 mice.  
J Neuroimmunol, 247, 25-31. 
Lim, S. Y. and Constantinescu, C. S. (2010) Current and future disease-modifying 
therapies in multiple sclerosis. Int J Clin Pract, 64, 637-650. 
Liu, C. Y., Guo, S. D., Yu, J. Z. et al. (2015) Fasudil mediates cell therapy of EAE by 




Long, P. M., Tighe, S. W., Driscoll, H. E., Fortner, K. A., Viapiano, M. S. and Jaworski, 
D. M. (2015) Acetate supplementation as a means of inducing glioblastoma stem-
like cell growth arrest. J Cell Physiol, 230, 1929-1943. 
Long, P. M., Tighe, S. W., Driscoll, H. E., Moffett, J. R., Namboodiri, A. M., Viapiano, 
M. S., Lawler, S. E. and Jaworski, D. M. (2013) Acetate supplementation induces 
growth arrest of NG2/PDGFRalpha-positive oligodendroglioma-derived tumor-
initiating cells. PLoS One, 8, e80714. 
Lublin, F. D. and Reingold, S. C. (1996) Defining the clinical course of multiple 
sclerosis: results of an international survey. National Multiple Sclerosis Society 
(USA) Advisory Committee on Clinical Trials of New Agents in Multiple 
Sclerosis. Neurology, 46, 907-911. 
Lublin, F. D., Reingold, S. C., Cohen, J. A. et al. (2014) Defining the clinical course of 
multiple sclerosis: the 2013 revisions. Neurology, 83, 278-286. 
Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H. 
(2000) Heterogeneity of multiple sclerosis lesions: implications for the 
pathogenesis of demyelination. Ann Neurol, 47, 707-717. 
Madhavarao, C. N., Arun, P., Anikster, Y., Mog, S. R., Staretz-Chacham, O., Moffett, J. 
R., Grunberg, N. E., Gahl, W. A. and Namboodiri, A. M. (2009) Glyceryl 
triacetate for Canavan disease: a low-dose trial in infants and evaluation of a 
higher dose for toxicity in the tremor rat model. J Inherit Metab Dis, 32, 640-650. 
Madhavarao, C. N., Hammer, J. A., Quarles, R. H. and Namboodiri, M. A. (2002) A 
radiometric assay for aspartoacylase activity in cultured oligodendrocytes.  
Anal Biochem, 308, 314-319. 
Maggio, B., Cumar, F. A. and Maccioni, H. J. (1972) Lipid content in brain and spinal 
cord during experimental allergic encephalomyelitis in rats. J Neurochem, 19, 
1031-1037. 
Magnusson, C. D. and Haraldsson, G. G. (2011) Ether lipids. Chem Phys Lipids, 164, 
315-340. 
Markoullis, K., Sargiannidou, I., Schiza, N., Hadjisavvas, A., Roncaroli, F., Reynolds, R. 
and Kleopa, K. A. (2012) Gap junction pathology in multiple sclerosis lesions and 
normal-appearing white matter. Acta Neuropathol, 123, 873-886. 
127 
 
Martinez, M. (1996) Docosahexaenoic acid therapy in docosahexaenoic acid-deficient 
patients with disorders of peroxisomal biogenesis. Lipids, 31 Suppl, S145-152. 
Martinez, M. (2001) Restoring the DHA levels in the brains of Zellweger patients.  
J Mol Neurosci, 16, 309-316; discussion 317-321. 
Martinez, M. and Mougan, I. (1999) Fatty acid composition of brain 
glycerophospholipids in peroxisomal disorders. Lipids, 34, 733-740. 
Martinez, M., Pineda, M., Vidal, R., Conill, J. and Martin, B. (1993) Docosahexaenoic 
acid--a new therapeutic approach to peroxisomal-disorder patients: experience 
with two cases. Neurology, 43, 1389-1397. 
Martinez, M. and Vazquez, E. (1998) MRI evidence that docosahexaenoic acid ethyl 
ester improves myelination in generalized peroxisomal disorders. Neurology, 51, 
26-32. 
Martinez, M., Vazquez, E., Garcia-Silva, M. T., Manzanares, J., Bertran, J. M., Castello, 
F. and Mougan, I. (2000) Therapeutic effects of docosahexaenoic acid ethyl ester 
in patients with generalized peroxisomal disorders. Am J Clin Nutr, 71, 376S-
385S. 
Mata, S., Lolli, F., Soderstrom, M., Pinto, F. and Link, H. (1999) Multiple sclerosis is 
associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler, 5, 
379-388. 
Mathew, R., Arun, P., Madhavarao, C. N., Moffett, J. R. and Namboodiri, M. A. (2005) 
Progress toward acetate supplementation therapy for Canavan disease: glyceryl 
triacetate administration increases acetate, but not N-acetylaspartate, levels in 
brain. J Pharmacol Exp Ther, 315, 297-303. 
Mayatepek, E., Lehmann, W. D., Fauler, J., Tsikas, D., Frolich, J. C., Schutgens, R. B., 
Wanders, R. J. and Keppler, D. (1993) Impaired degradation of leukotrienes in 
patients with peroxisome deficiency disorders. J Clin Invest, 91, 881-888. 
Mayatepek, E. and Tiepelmann, B. (1996) Defective degradation of leukotrienes in 




McKerracher, L., David, S., Jackson, D. L., Kottis, V., Dunn, R. J. and Braun, P. E. 
(1994) Identification of myelin-associated glycoprotein as a major myelin-derived 
inhibitor of neurite growth. Neuron, 13, 805-811. 
McQualter, J. L. and Bernard, C. C. (2007) Multiple sclerosis: a battle between 
destruction and repair. J Neurochem, 100, 295-306. 
Mehta, V. and Namboodiri, M. A. (1995) N-acetylaspartate as an acetyl source in the 
nervous system. Brain Res Mol Brain Res, 31, 151-157. 
Mikol, D. D., Rongnoparut, P., Allwardt, B. A., Marton, L. S. and Stefansson, K. (1993) 
The oligodendrocyte-myelin glycoprotein of mouse: primary structure and gene 
structure. Genomics, 17, 604-610. 
Mikol, D. D. and Stefansson, K. (1988) A phosphatidylinositol-linked peanut agglutinin-
binding glycoprotein in central nervous system myelin and on oligodendrocytes.  
J Cell Biol, 106, 1273-1279. 
Minagar, A. (2013) Current and future therapies for multiple sclerosis. Scientifica 
(Cairo), 2013, 249101. 
Mitew, S., Hay, C. M., Peckham, H., Xiao, J., Koenning, M. and Emery, B. (2014) 
Mechanisms regulating the development of oligodendrocytes and central nervous 
system myelin. Neuroscience, 276, 29-47. 
Moffett, J. R., Arun, P., Ariyannur, P. S., Garbern, J. Y., Jacobowitz, D. M. and 
Namboodiri, A. M. (2011) Extensive aspartoacylase expression in the rat central 
nervous system. Glia, 59, 1414-1434. 
Moffett, J. R., Arun, P., Ariyannur, P. S. and Namboodiri, A. M. (2013) N-
Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, 
lipid synthesis, and protein acetylation. Front Neuroenergetics, 5, 11. 
Morell, P. (1984) Myelin. Plenum Press, New York. 




Moser, A. B., Borel, J., Odone, A., Naidu, S., Cornblath, D., Sanders, D. B. and Moser, 
H. W. (1987) A new dietary therapy for adrenoleukodystrophy: biochemical and 
preliminary clinical results in 36 patients. Ann Neurol, 21, 240-249. 
Moser, A. B., Jones, D. S., Raymond, G. V. and Moser, H. W. (1999) Plasma and red 
blood cell fatty acids in peroxisomal disorders. Neurochem Res, 24, 187-197. 
Moser, H. W., Moser, A. B., Frayer, K. K., Chen, W., Schulman, J. D., O'Neill, B. P. and 
Kishimoto, Y. (1981) Adrenoleukodystrophy: increased plasma content of 
saturated very long chain fatty acids. Neurology, 31, 1241-1249. 
Moser, H. W., Moser, A. B., Hollandsworth, K., Brereton, N. H. and Raymond, G. V. 
(2007) "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and 
current assessment of efficacy. J Mol Neurosci, 33, 105-113. 
Mukhopadhyay, G., Doherty, P., Walsh, F. S., Crocker, P. R. and Filbin, M. T. (1994) A 
novel role for myelin-associated glycoprotein as an inhibitor of axonal 
regeneration. Neuron, 13, 757-767. 
Murphy, A. C., Lalor, S. J., Lynch, M. A. and Mills, K. H. (2010) Infiltration of Th1 and 
Th17 cells and activation of microglia in the CNS during the course of 
experimental autoimmune encephalomyelitis. Brain Behav Immun, 24, 641-651. 
Nakahara, J., Maeda, M., Aiso, S. and Suzuki, N. (2012) Current concepts in multiple 
sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol, 
42, 26-34. 
Namboodiri, A. M., Moffett, J. R., Arun, P. et al. (2006a) Defective myelin lipid 
synthesis as a pathogenic mechanism of Canavan disease. Adv Exp Med Biol, 576, 
145-163; discussion 361-143. 
Namboodiri, A. M., Peethambaran, A., Mathew, R., Sambhu, P. A., Hershfield, J., 
Moffett, J. R. and Madhavarao, C. N. (2006b) Canavan disease and the role of N-
acetylaspartate in myelin synthesis. Mol Cell Endocrinol, 252, 216-223. 
Neuhaus, O., Wiendl, H., Kieseier, B. C., Archelos, J. J., Hemmer, B., Stuve, O. and 
Hartung, H. P. (2005) Multiple sclerosis: Mitoxantrone promotes differential 
effects on immunocompetent cells in vitro. J Neuroimmunol, 168, 128-137. 
130 
 
Norton, W. T. and Poduslo, S. E. (1973) Myelination in rat brain: method of myelin 
isolation. J Neurochem, 21, 749-757. 
Oh, J. and O'Connor, P. W. (2015) Established disease-modifying treatments in 
relapsing-remitting multiple sclerosis. Curr Opin Neurol, 28, 220-229. 
Paintlia, A. S., Paintlia, M. K., Khan, M., Vollmer, T., Singh, A. K. and Singh, I. (2005) 
HMG-CoA reductase inhibitor augments survival and differentiation of 
oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J, 19, 
1407-1421. 
Palumbo, S. and Bosetti, F. (2013) Alterations of brain eicosanoid synthetic pathway in 
multiple sclerosis and in animal models of demyelination: role of 
cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids, 89, 273-278. 
Pan, B., Fromholt, S. E., Hess, E. J., Crawford, T. O., Griffin, J. W., Sheikh, K. A. and 
Schnaar, R. L. (2005) Myelin-associated glycoprotein and complementary axonal 
ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology 
and behavioral deficits in single- and double-null mice. Exp Neurol, 195, 208-
217. 
Pecina-Slaus, N. (2013) Merlin, the NF2 gene product. Pathol Oncol Res, 19, 365-373. 
Pham-Dinh, D., Dautigny, A. and Linington, C. (2004) Myelin oligodendrocyte 
glycoprotein gene: Myelin biology and disorders. Elsevier Academic Press, San 
Diego. 
Poll-The, B. T. and Gartner, J. (2012) Clinical diagnosis, biochemical findings and MRI 
spectrum of peroxisomal disorders. Biochim Biophys Acta, 1822, 1421-1429. 
Polman, C. H., O'Connor, P. W., Havrdova, E. et al. (2006) A randomized, placebo-
controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 
354, 899-910. 
Procaccini, C., De Rosa, V., Pucino, V., Formisano, L. and Matarese, G. (2015) Animal 
models of Multiple Sclerosis. Eur J Pharmacol, 759, 182-191. 
131 
 
Pu, H., Guo, Y., Zhang, W. et al. (2013) Omega-3 polyunsaturated fatty acid 
supplementation improves neurologic recovery and attenuates white matter injury 
after experimental traumatic brain injury. J Cereb Blood Flow Metab, 33, 1474-
1484. 
Radin, N. S. (1981) Extraction of tissue lipids with a solvent of low toxicity.  
Methods Enzymol, 72, 5-7. 
Ramli, D., Aziz, I., Mohamad, M., Abdulahi, D. and Sanusi, J. (2017) The Changes in 
Rats with Sciatic Nerve Crush Injury Supplemented with Evening Primrose Oil: 
Behavioural, Morphologic, and Morphometric Analysis. Evid Based Complement 
Alternat Med, 2017, 3476407. 
Ransohoff, R. M. (2012) Animal models of multiple sclerosis: the good, the bad and the 
bottom line. Nat Neurosci, 15, 1074-1077. 
Reisenauer, C. J., Bhatt, D. P., Mitteness, D. J., Slanczka, E. R., Gienger, H. M., Watt, J. 
A. and Rosenberger, T. A. (2011) Acetate supplementation attenuates 
lipopolysaccharide-induced neuroinflammation. J Neurochem, 117, 264-274. 
Revina, E. S., Gromova, N. V. and Timoshina, T. E. (2011) Changes in phospholipid 
composition of the spinal cord in rabbits with allergic encephalomyelitis as an 
experimental model of multiple sclerosis. Bull Exp Biol Med, 152, 224-227. 
Rice, G. P., Hartung, H. P. and Calabresi, P. A. (2005) Anti-alpha4 integrin therapy for 
multiple sclerosis: mechanisms and rationale. Neurology, 64, 1336-1342. 
Ridge, S. C., Sloboda, A. E., McReynolds, R. A., Levine, S., Oronsky, A. L. and Kerwar, 
S. S. (1985) Suppression of experimental allergic encephalomyelitis by 
mitoxantrone. Clin Immunol Immunopathol, 35, 35-42. 
Rizzo, W. B., Phillips, M. W., Dammann, A. L., Leshner, R. T., Jennings, S. S., Avigan, 
J. and Proud, V. K. (1987) Adrenoleukodystrophy: dietary oleic acid lowers 
hexacosanoate levels. Ann Neurol, 21, 232-239. 
Robinson, A. P., Harp, C. T., Noronha, A. and Miller, S. D. (2014) The experimental 
autoimmune encephalomyelitis (EAE) model of MS: utility for understanding 
disease pathophysiology and treatment. Handb Clin Neurol, 122, 173-189. 
132 
 
Rone, M. B., Cui, Q. L., Fang, J. et al. (2016) Oligodendrogliopathy in Multiple 
Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.  
J Neurosci, 36, 4698-4707. 
Rosenberger, T. A., Oki, J., Purdon, A. D., Rapoport, S. I. and Murphy, E. J. (2002) 
Rapid synthesis and turnover of brain microsomal ether phospholipids in the adult 
rat. J Lipid Res, 43, 59-68. 
Rosner, H., Al-Aqtum, M. and Henke-Fahle, S. (1985) Developmental expression of 
GD3 and polysialogangliosides in embryonic chicken nervous tissue reacting with 
monoclonal antiganglioside antibodies. Brain Res, 350, 85-95. 
Roth, G. A., Monferran, C. G., Maggio, B. and Cumar, F. A. (1982) Central nervous 
system lipid alterations in rats with experimental allergic encephalomyelitis and 
its suppression by immunosuppressive drugs. Life Sci, 30, 859-866. 
Rouser, G., Siakotos, A. and Fleischer, S. (1969) Quantitative analysis of phospholipids 
by thin-layer chromatography and phosphorus analysis of spots. Lipids, 1, 85-86. 
Sadatipour, B. T., Greer, J. M. and Pender, M. P. (1998) Increased circulating 
antiganglioside antibodies in primary and secondary progressive multiple 
sclerosis. Ann Neurol, 44, 980-983. 
Saher, G., Brugger, B., Lappe-Siefke, C., Mobius, W., Tozawa, R., Wehr, M. C., 
Wieland, F., Ishibashi, S. and Nave, K. A. (2005) High cholesterol level is 
essential for myelin membrane growth. Nat Neurosci, 8, 468-475. 
Saher, G., Quintes, S. and Nave, K. A. (2011) Cholesterol: a novel regulatory role in 
myelin formation. Neuroscientist, 17, 79-93. 
Salvati, S., Attorri, L., Confaloni, A. and Di Biase, A. (1990) Lipid changes in central 
nervous system membranes in experimental allergic encephalomyelitis (EAE). 
Neurochem Res, 15, 1051-1053. 
Sango, K., McDonald, M. P., Crawley, J. N. et al. (1996) Mice lacking both subunits of 
lysosomal beta-hexosaminidase display gangliosidosis and 
mucopolysaccharidosis. Nat Genet, 14, 348-352. 
133 
 
Sassa, T., Wakashima, T., Ohno, Y. and Kihara, A. (2014) Lorenzo's oil inhibits 
ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain 
fatty acid. J Lipid Res, 55, 524-530. 
Schachner, M. and Bartsch, U. (2000) Multiple functions of the myelin-associated 
glycoprotein MAG (siglec-4a) in formation and maintenance of myelin. Glia, 29, 
154-165. 
Schiffmann, S., Ferreiros, N., Birod, K. et al. (2012) Ceramide synthase 6 plays a critical 
role in the development of experimental autoimmune encephalomyelitis.  
J Immunol, 188, 5723-5733. 
Schmitt, S., Castelvetri, L. C. and Simons, M. (2015) Metabolism and functions of lipids 
in myelin. Biochim Biophys Acta, 1851, 999-1005. 
Schnaar, R. L. (2010) Brain gangliosides in axon-myelin stability and axon regeneration. 
FEBS Lett, 584, 1741-1747. 
Schnaar, R. L., Gerardy-Schahn, R. and Hildebrandt, H. (2014) Sialic acids in the brain: 
gangliosides and polysialic acid in nervous system development, stability, disease, 
and regeneration. Physiol Rev, 94, 461-518. 
Segel, R., Anikster, Y., Zevin, S., Steinberg, A., Gahl, W. A., Fisher, D., Staretz-
Chacham, O., Zimran, A. and Altarescu, G. (2011) A safety trial of high dose 
glyceryl triacetate for Canavan disease. Mol Genet Metab, 103, 203-206. 
Serafini, B., Rosicarelli, B., Franciotta, D. et al. (2007) Dysregulated Epstein-Barr virus 
infection in the multiple sclerosis brain. J Exp Med, 204, 2899-2912. 
Shimazu, T., Hirschey, M. D., Huang, J. Y., Ho, L. T. and Verdin, E. (2010) Acetate 
metabolism and aging: An emerging connection. Mech Ageing Dev, 131, 511-516. 
Shimizu, T. (2009) Lipid mediators in health and disease: enzymes and receptors as 
therapeutic targets for the regulation of immunity and inflammation.  
Annu Rev Pharmacol Toxicol, 49, 123-150. 
Simmons, S. B., Pierson, E. R., Lee, S. Y. and Goverman, J. M. (2013) Modeling the 
heterogeneity of multiple sclerosis in animals. Trends Immunol, 34, 410-422. 
134 
 
Singh, S., Choudhury, A., Gusain, P., Parvez, S., Palit, G., Shukla, S. and Ganguly, S. 
(2016) Oral acetate supplementation attenuates N-methyl D-aspartate receptor 
hypofunction-induced behavioral phenotypes accompanied by restoration of 
acetyl-histone homeostasis. Psychopharmacology (Berl), 233, 1257-1268. 
Singhal, N. K., Huang, H., Li, S. et al. (2017) The neuronal metabolite NAA regulates 
histone H3 methylation in oligodendrocytes and myelin lipid composition.  
Exp Brain Res, 235, 279-292. 
Smerjac, S. M. and Bizzozero, O. A. (2008) Cytoskeletal protein carbonylation and 
degradation in experimental autoimmune encephalomyelitis. J Neurochem, 105, 
763-772. 
Smith, M. D., Bhatt, D. P., Geiger, J. D. and Rosenberger, T. A. (2014) Acetate 
supplementation modulates brain adenosine metabolizing enzymes and adenosine 
A(2)A receptor levels in rats subjected to neuroinflammation.  
J Neuroinflammation, 11, 99. 
Smith, M. E. (1964) Lipid Biosynthesis in the Central Nervous System in Experimental 
Allergic Encephalomyelitis. J Neurochem, 11, 29-37. 
Soliman, M. L., Combs, C. K. and Rosenberger, T. A. (2013a) Modulation of 
inflammatory cytokines and mitogen-activated protein kinases by acetate in 
primary astrocytes. J Neuroimmune Pharmacol, 8, 287-300. 
Soliman, M. L., Ohm, J. E. and Rosenberger, T. A. (2013b) Acetate reduces PGE2 
release and modulates phospholipase and cyclooxygenase levels in neuroglia 
stimulated with lipopolysaccharide. Lipids, 48, 651-662. 
Soliman, M. L., Puig, K. L., Combs, C. K. and Rosenberger, T. A. (2012a) Acetate 
reduces microglia inflammatory signaling in vitro. J Neurochem, 123, 555-567. 
Soliman, M. L. and Rosenberger, T. A. (2011) Acetate supplementation increases brain 
histone acetylation and inhibits histone deacetylase activity and expression.  
Mol Cell Biochem, 352, 173-180. 
Soliman, M. L., Smith, M. D., Houdek, H. M. and Rosenberger, T. A. (2012b) Acetate 
supplementation modulates brain histone acetylation and decreases interleukin-




Steinberg, S., Chen, L., Wei, L., Moser, A., Moser, H., Cutting, G. and Braverman, N. 
(2004) The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis 
disorders in the Zellweger syndrome spectrum. Mol Genet Metab, 83, 252-263. 
Steinberg, S. J., Dodt, G., Raymond, G. V., Braverman, N. E., Moser, A. B. and Moser, 
H. W. (2006) Peroxisome biogenesis disorders. Biochim Biophys Acta, 1763, 
1733-1748. 
Storoni, M. and Plant, G. T. (2015) The Therapeutic Potential of the Ketogenic Diet in 
Treating Progressive Multiple Sclerosis. Mult Scler Int, 2015, 681289. 
Suh, P. G., Park, J. I., Manzoli, L. et al. (2008) Multiple roles of phosphoinositide-
specific phospholipase C isozymes. BMB Rep, 41, 415-434. 
Svennerholm, L. (1957) Quantitative estimation of sialic acids. II. A colorimetric 
resorcinol-hydrochloric acid method. Biochim Biophys Acta, 24, 604-611. 
Sztriha, L. S., Nork, M. P., Abdulrazzaq, Y. M., al-Gazali, L. I. and Bakalinova, D. B. 
(1997) Abnormal myelination in peroxisomal isolated 
dihydroxyacetonephosphate acyltransferase deficiency. Pediatr Neurol, 16, 232-
236. 
Taranova, N. P. (1985) Disturbance of lipid composition in spinal cord of rabbits with 
experimental allergic encephalomyelitis. Neurochem Res, 10, 1483-1497. 
Thacker, E. L., Mirzaei, F. and Ascherio, A. (2006) Infectious mononucleosis and risk for 
multiple sclerosis: a meta-analysis. Ann Neurol, 59, 499-503. 
Tilve, S., Difato, F. and Chieregatti, E. (2015) Cofilin 1 activation prevents the defects in 
axon elongation and guidance induced by extracellular alpha-synuclein. Sci Rep, 
5, 16524. 
Tsen, A. R., Long, P. M., Driscoll, H. E. et al. (2014) Triacetin-based acetate 
supplementation as a chemotherapeutic adjuvant therapy in glioma. Int J Cancer, 
134, 1300-1310. 
Turner, M. J., Pang, P. T., Chretien, N. et al. (2015) Reduction of inflammation and 
preservation of neurological function by anti-CD52 therapy in murine 
experimental autoimmune encephalomyelitis. J Neuroimmunol, 285, 4-12. 
136 
 
Ueno, K., Ando, S. and Yu, R. K. (1978) Gangliosides of human, cat, and rabbit spinal 
cords and cord myelin. J Lipid Res, 19, 863-871. 
Virtanen, J. O. and Jacobson, S. (2012) Viruses and multiple sclerosis.  
CNS Neurol Disord Drug Targets, 11, 528-544. 
Vourc'h, P. and Andres, C. (2004) Oligodendrocyte myelin glycoprotein (OMgp): 
evolution, structure and function. Brain Res Brain Res Rev, 45, 115-124. 
Vyas, A. A., Patel, H. V., Fromholt, S. E., Heffer-Lauc, M., Vyas, K. A., Dang, J., 
Schachner, M. and Schnaar, R. L. (2002) Gangliosides are functional nerve cell 
ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve 
regeneration. Proc Natl Acad Sci U S A, 99, 8412-8417. 
Vyas, A. A. and Schnaar, R. L. (2001) Brain gangliosides: functional ligands for myelin 
stability and the control of nerve regeneration. Biochimie, 83, 677-682. 
Wanders, R. J., Ferdinandusse, S., Brites, P. and Kemp, S. (2010) Peroxisomes, lipid 
metabolism and lipotoxicity. Biochim Biophys Acta, 1801, 272-280. 
Wanders, R. J. and Waterham, H. R. (2006) Peroxisomal disorders: the single 
peroxisomal enzyme deficiencies. Biochim Biophys Acta, 1763, 1707-1720. 
Wang, K. C., Koprivica, V., Kim, J. A., Sivasankaran, R., Guo, Y., Neve, R. L. and He, 
Z. (2002) Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that 
inhibits neurite outgrowth. Nature, 417, 941-944. 
Warringa, R. A., Hoeben, R. C., Koper, J. W., Sykes, J. E., van Golde, L. M. and Lopes-
Cardozo, M. (1987) Hydrocortisone stimulates the development of 
oligodendrocytes in primary glial cultures and affects glucose metabolism and 
lipid synthesis in these cultures. Brain Res, 431, 79-86. 
Weller, S., Gould, S. J. and Valle, D. (2003) Peroxisome biogenesis disorders.  
Annu Rev Genomics Hum Genet, 4, 165-211. 
Wergeland, S., Torkildsen, O., Myhr, K. M., Mork, S. J. and Bo, L. (2012) The cuprizone 
model: regional heterogeneity of pathology. APMIS, 120, 648-657. 
137 
 
Wolswijk, G. (2000) Oligodendrocyte survival, loss and birth in lesions of chronic-stage 
multiple sclerosis. Brain, 123 ( Pt 1), 105-115. 
Woodruff, R. H., Tekki-Kessaris, N., Stiles, C. D., Rowitch, D. H. and Richardson, W. D. 
(2001) Oligodendrocyte development in the spinal cord and telencephalon: 
common themes and new perspectives. Int J Dev Neurosci, 19, 379-385. 
Yang, L. J., Zeller, C. B., Shaper, N. L., Kiso, M., Hasegawa, A., Shapiro, R. E. and 
Schnaar, R. L. (1996) Gangliosides are neuronal ligands for myelin-associated 
glycoprotein. Proc Natl Acad Sci U S A, 93, 814-818. 
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L. and Karin, N. 
(1992) Prevention of experimental autoimmune encephalomyelitis by antibodies 
against alpha 4 beta 1 integrin. Nature, 356, 63-66. 
Yu, R. K., Tsai, Y. T., Ariga, T. and Yanagisawa, M. (2011) Structures, biosynthesis, and 
functions of gangliosides--an overview. J Oleo Sci, 60, 537-544. 
Zhang, J. and Liu, Q. (2015) Cholesterol metabolism and homeostasis in the brain. 
Protein Cell, 6, 254-264. 
Zindler, E. and Zipp, F. (2010) Neuronal injury in chronic CNS inflammation.  
Best Pract Res Clin Anaesthesiol, 24, 551-562. 
 
